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Part I 
INTRODUCTION 
1 

Chapter 1 
Introduction 
1.1 From health services planning to health 
planning 
In health policy making there has been a shift in recent years away from the 
pure planning of health services towards a comprehensive health planning, 
in which an attempt is made to apply the increasingly scarce resources in 
such a way as to achieve the "maximum" health for the population. This 
shift is exemplified by the WHO campaign for Health for All in the year 
2000 and by the use of targets in the European region (i). It has been 
noticeable in the Netherlands as well in the health policy statement of the 
Health 2000 Report (2) which was presented to parliament in 1986. 
There are two interesting features in this shift. One is the tendency 
to measure the effectiveness of a policy, an intervention or a technology in 
terms of health, the outcome rather than the input, output or process. The 
other is the acceptance that choices need to be made since, however large 
the budget for health is, it will always be limited. Of course this last con-
cern has received most of the attention in recent years politically, but both 
features have generated a demand for a different kind of information on 
which to base policy decisions. The orientation towards health has spurred 
the interest in the health benefits to be expected from interventions both 
at an individual level and at the level of a population, and the concern with 
the optimization of scarce resources has led to a vivid interest in cost effec-
tiveness, again for the individual patient as well as for policy making at a 
population level. New disciplines have emerged to supply this information: 
a renewed interest in clinical epidemiology to document the health effects 
of curative care and in population epidemiology to monitor the changes in 
3 
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health status of a population and to identify risk factors for which preven-
tive interventions could be devised, and on the other hand the emergence 
of among others medical decision making, health technology assessment 
and health economics to help the priority setting. The Dutch government 
has started several projects in this field, for instance the scenario studies in 
which the possible and probable future developments in certain disease cat-
egories or technologies are identified and analyzed for the specific purpose 
of supplying information on which to base policy decisions. 
In all these disciplines, estimates of the health effects of an intervention 
play a crucial role. These estimates are not easily provided for individual 
patients but the estimates of the effect of interventions at the population 
level, which is essential for health policy making, have proved to be par-
ticularly difficult. Epidemiology, the discipline best suited to supply this 
information, has only recently started to develop methodologies which allow 
for estimates into the future based on analysis of the past. The necessity 
for more detailed effect estimates is demonstrated by the cost effectiveness 
studies, which in recent years have made their cost estimates increasingly 
precise. In the absence of equally precise effect estimates, crude measures of 
attributable risk have been used to estimate health benefits of prevention. 
A discrepancy then evolves between the cost estimates and the measures of 
effect, which makes the value of the results debatable. 
In the competition for the limited resources, advocates of preventive 
interventions have had to support their claims with facts about the expected 
returns of such an investment. Not only do they have to explain that 
prevention now will not lead to visible health benefits tomorrow, on the 
contrary it will at best result in the non-occurrence of a specific disease in 
the (far) future, but furthermore they have to do so at a time when the 
major multi factorial intervention trials yield disappointing results, while 
new curative technologies are widely acclaimed. 
Some of that disappointment may be due to unrealistic expectations of 
the interventions and to limitations of the methodology used to estimate 
the effects of prevention. If prevention is to compete for the allocation of 
scarce resources, it will have to be able to apply existing knowledge about 
risk factors to realistically estimate the health benefits to be expected from 
an intervention on these risk factors. Although epidemiology has been good 
at identifying the risk factors on which to intervene, the application of this 
epidemiologic knowledge in health policy making is still very primitive. 
Furthermore changing prevalences of risk factors in a population, will 
affect the health needs of that population. Careful estimates of the effect of 
prevalence changes are therefore not only important to assess the impact of 
preventive interventions, but also to estimate the health needs upon which 
to base decisions about levels of health services. These changing health 
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needs can be the result of preventive interventions but also of past changes 
in risk factor prevalence or autonomous changes in the future. If one is 
serious about a public health policy based on health needs, the interest in 
effect estimates of changing risk factor prevalences will go beyond their use 
in priority setting for preventive interventions, and will extend to health 
policy making in general for instance through realistic target setting. 
1.2 From epidemiology to health policy 
In traditional epidemiology certain characteristics of population groups can 
be identified which correlate with elevated or lowered disease incidence 
rates in these groups when compared to a reference population. These 
characteristics may be the causative agent of the disease as is the case, 
for instance, in the chromosomal abnormality in the Down's Syndrome, 
whereby the characteristic is directly related to the etiology of the disease. 
It may also be a risk factor for the disease as for example, exposure 
to cigarette smoke is for lung cancer, in which case it is obvious that the 
characteristic in some way causes or helps to cause the disease, but the 
exact etiology is still unknown. Often several hypotheses exist about the 
biological reason for the effect of the risk factor and one can demonstrate 
that the occurrence of the disease varies with the prevalence and sever-
ity of exposure to the risk factor, and can be influenced by changing the 
distribution of the risk factor. 
But a characteristic may also be a risk indicator. An example would be 
the relationship between the presence of an abnormal ECG and the risk of 
ischemic heart disease. Such a risk indicator will identify the population 
with a higher risk of developing the disease without knowing whether the 
characteristic has anything to do with the causation of the disease, whether 
it is the result of the disease or even simply an identification means for a 
population in which a hitherto unsuspected risk factor is responsible for the 
elevated disease incidence. Risk indicators are also those characteristics of a 
population, which may very well be real risk factors but which cannot or will 
not be subject to preventive intervention. Sex and age but also for instance 
marital status are examples of such risk indicators. It does not mean that 
these characteristics should not be studied in epidemiology but merely that 
their main use is in assessing the overall risk of the population (for instance 
as a result of demographic changes) and in identifying high risk groups 
within the population rather than in providing clues for preventive action. 
Finally, of course, every correlation, for which no etiologic hypothesis has 
been proven, may turn out to be a spurious relationship. 
Awaiting definite proof of the etiology, it is the category of the risk 
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factors that is of particular interest for prevention since one can argue that 
a reduction in risk factor prevalence will result in a reduction of disease 
incidence, even if the exact pathway of causation has not yet been identified. 
For the important causes of death there has been an extensive search for risk 
factors in the hope of finding preventive measures for non communicable 
diseases that would be as effective and as acceptable, as vaccinations were 
for infectious diseases. 
The Framingham Study for Cardiovascular Disease (3) and the British 
Physicians Study for Lung cancer (4) are beyond any doubt the classics 
of early epidemiology of non communicable diseases. These large longi-
tudinal studies not only supplied data from which risk factors for major 
disease categories were identified, but they still supply the most thorough 
quantitative material about that relationship. While the model for lung 
cancer was relatively simple (smoking was found to be such an overwhelm-
ing risk factor that it eclipsed any other potential determinant), the model 
that emerged for ischemic heart disease was more complex. Three major 
risk factors (smoking, hypertension and hypercholesterolemia) proved to 
be heavily correlated with the incidence of different forms of ischemic heart 
disease. In the 1960's and 1970's, as the epidemic of ischemic heart disease 
reached its peak, first in the United States and later in the West European 
countries, the information about the relationship between these three risk 
factors and the incidence of the disease resulted in a number of intervention 
trials. 
Some of the smaller trials focussed on one or two risk factor interventions 
(Veterans study on hypertension, HDFP, LRC-CPPT etc.) but the inter 
relationship between the three major risk factors, observed in the Framing-
ham data occasioned a number of large multi factorial intervention trials. 
The best known of these are MRFIT (5), the WHO collaborative trial (6) 
and the North Karelia Project in Finland (7). While all of these, and several 
smaller trials as well (8-11) showed conclusively that risk factors could be 
intervened upon in the study population, all of them showed disappointing 
end results in terms of health benefits. Although in some subgroups there 
was a reduced mortality for some categories of ischemic heart disease, the 
overall mortality did not seem to be reduced by the interventions. 
Several hypotheses have been formulated by the study groups, for the 
apparent failure of prevention. One was that the overall down ward trend in 
the prevalence of risk factors in the open population may have masked the 
benefits in the intervention population. These might have been more ap-
parent, had one intervened in a different phase of the epidemic. One should 
keep in mind that the follow up period has been relatively short so far, espe-
cially considering the often very lengthy disease process of atherosclerosis. 
Also relatively little attention has been paid to trends in other causes of 
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death over that same period, that may well have influenced the total mor-
tality rates. However the final aftertaste of these experiments has been 
a severe disappointment and prevention in general has suffered a setback 
(12). 
While the Framingham Study and comparable studies, concentrated on 
the identification of risk factors for specific diseases, a concurrent interest 
developed in the influence of life styles and social determinants on more 
general indicators of health. These studies were the direct result of a redi-
rection of attention away from disease and towards health. Health was no 
longer measured purely in terms of life expectancy, mortality or absence of 
disease, but following the WHO definition of health, it measured subjective 
well being as well. The best known of these lifestyle studies is perhaps the 
Alameda county project (13-15). 
It showed a distinct relationship between health status and individual 
life styles, but also between health and more social determinants such as 
marital status and the presence of a "social network", the relationship be-
tween individuals in their direct community. These determinants of health 
were s.ummarized as the health practices which proved to be positively as-
sociated with health outcomes after 9 years, after controlling for the initial 
levels of health. The message to the population was clear: don't drink, 
don't smoke, eat breakfast, sleep eight hours a night and get enough ex-
ercise. The result of this interest in health was a boom in joggers, health 
foods and mineral waters. 
However since both the risk factors and the health outcomes measured 
were broadly defined, it has been difficult to formulate specific hypotheses 
concerning the underlying causal pathway and the more specific quantifi-
cation of the health benefits to expect from interventions in risk factors, 
has necessarily remained vague. Although the results have had a major 
impact on the populations concern about health and the possible means 
of personally influencing ones own health, the impact of these studies on 
the rationalization of preventive health policy measures has remained dis-
appointing. The fear is that the excessive interest in health, one could even 
say the fashion of healthism, may prove to be as short lived as all fashions 
and that the aftermath will be a disillusion with prevention in general (16). 
If decisions on prevention or interventions on the determinants of health 
are to be rational, it will be of major importance to have realistic expec-
tations of such policy measures. It is necessary that the extensive data 
that have emerged from epidemiologic research on non communicable dis-
eases are reassembled in such a way that they can provide insight into the 
quantitative benefits to be expected of preventive interventions. For ef-
fect estimates of preventive interventions to be realistic the three following 
points will be essential: 
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• The emphasis on single disease categories has brought to light the 
fact that many risk factors can be identified for one disease, but it 
has given less attention to the fact that several major diseases have 
risk factors in common. For health policy this is important infor-
mation since it means that an intervention on one risk factor will 
affect the incidence of several disease categories simultaneously. This 
may result in very different effect estimates when considering preven-
tive interventions from the risk factor rather than from the disease 
perspective. Recently, at a workshop organized by the Brookings 
Institute, the absence of an accepted multi factorial model for effect 
estimates has been identified as a major handicap in cost effectiveness 
studies of prevention (17). 
• The interest in the causation of disease has focussed research on the 
exposure to a risk factor and on the occurrence of disease. Often con-
siderable time elapses before exposure leads to incidence of disease. 
This means that once risk factors are identified, preventive interven-
tions will not only be directed towards preventing first exposure but 
also towards terminating existing exposure in the population. The 
traditional epidemiologic research has produced far less information 
about the effect of termination of exposure and the associated time 
lags before risk reduction is complete. The absence of sound time di-
mensions when calculating the expected effects may have been partly 
responsible for the disappointment of the multi factorial intervention 
trials, it may just not be realistic to expect visible results after such 
a short follow up period. 
• To be able to make changing patterns of disease in a population vis-
ible, epidemiologists have greatly relied on age specific incidence or 
mortality rates, or standardized statistics to compare the health of 
populations over time or over geographic locations. This was done 
because incidence rates differ for age groups and therefore a different 
demographic structure may obscure the relative importance of dis-
eases in different populations. For the same reasons effect measures 
are also often presented as proportional changes in age specific rates. 
However for policy purposes this can be very confusing, since in re-
ality demographic changes do occur and a reduction in age specific 
incidence rates may not be accompanied by a reduction in absolute 
incidence in the population. For policy purposes it is important to 
work with absolute numbers, since these represent the real number of 
patients for whom services need to be planned. In an aging popula-
tion with many chronic diseases in old age, this may mean that a very 
successful preventive intervention, causing a marked decline in the age 
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specific incidence rate, may still result in a higher number of cases in 
the population as the age group to which the reduced incidence rates 
apply increases in absolute numbers. This is often difficult to explain 
and makes it difficult to "sell" the intervention politically, since an 
appreciation of the health benefits requires an understanding of the 
dynamics underlying the effect estimates and a visualization of what 
would occur in the absence of the intervention. 
Estimates of effect will have to be based on the existing epidemiologic 
knowledge but will have to be presented in a way that can be of direct 
use to health policy makers. For this purpose the Prevent model was de-
veloped. The Prevent model presented in the following chapters does not 
pretend to predict reality, it calculates to the best of the current epidemi-
ologic knowledge what will happen to mortality in the population after an 
intervention on known risk factors. The final validation of such a model can 
only be made prospectively, its value now must lie primarily in its ability to 
perform complex calculations, and to present understandable conclusions. 
1.3 Objectives of the project 
The goal of the Prevent project was to devise a tool for policy makers to use 
epidemiologic data on the relationship between risk factors and diseases, 
to estimate the effect on the health of a population of changes in risk 
factor prevalence, either autonomous or through interventions. These effect 
estimates can either be used directly in policy making for instance to set 
realistic targets, or serve as input for formal priority setting exercises such 
as cost effectiveness analyses. 
From this goal three main objectives of the project can be derived: 
1. To adapt existent epidemiologic measures and techniques to devise a 
methodology that will allow an estimate of the effects of changes in 
risk factor prevalence in a population on a chosen measure of health. 
This methodology will have to be able to take into account the effect 
of one risk factor on several diseases and the effect of simultaneous 
interventions on several risk factors (the multi factorial nature of the 
model) and will have to incorporate a time dimension to allow for a 
slow risk reduction. The results must be presented both as propor-
tional changes in age specific disease incidence rates and as changes 
in absolute measures of health. 
2. To distill from existing epidemiologic studies the data necessary to 
apply the above tool to policy making in the Netherlands. There is a 
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vast body of literature on risk factors and intervention trials, and the 
purpose of the project was not to add to this pool but to see if the 
existing data could be used in a more effective way. Since most of the 
studies were done abroad the exercise would at the same time serve 
to see if data can be transferred from one population to another. 
3. To use the methodology and the data to construct a tool which could 
be used by policy makers. One of the major problems in using sci-
entific results in policy making is that very often the case presented 
in these results does not exactly correspond with the situation for 
which a policy decision needs to be made. The ability of the policy 
maker to experiment with the different circumstances or alternative 
interventions, may not lead to different conclusions but will greatly 
enhance the understanding of the dynamics underlying the effect es-
timates. This understanding in turn will lead to a more rational use 
of the effect estimates. 
The organization of this book reflects these three objectives. Part II 
deals with the methodology. It reviews the existing epidemiologic measures 
and techniques on which the methodology is based, it analyses the necessary 
changes to fit these for our purpose and finally shows how the methodology 
is applied in a computer simulation program Prevent. The third part is 
concerned with the data input necessary for Prevent. It briefly reviews 
the epidemiologic knowledge about risk factors and diseases relevant for 
the Dutch population and then assigns relative risks to the risk factor-
disease combinations for which there is sufficient evidence to accept the 
causal nature of the relationship, and for which prevalence data for the 
Dutch population exist. Finally, in part IV the results generated by the 
current version of the Prevent model are interpreted. The three sections 
are followed by two final chapters which contain a discussion of the possible 
uses of Prevent in Dutch health policy making and the conclusions of the 
project. 
Not every reader may be equally interested in all parts. Each is therefore 
preceded by a short summary in which the most important questions and 
conclusions of those chapters are reviewed. A reader may read only those 
introductions, skip a part and still be able to follow the discussion in the 
final chapters. The input data used in the basic runs are summarized in 
appendix C to allow for easy reference. 
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Introduction and 
summary 
In this first section we will discuss the methodology of Prevent, developed 
to achieve the first objective stated in chapter 1: "To adapt existent epi-
demiological measures and techniques in order to devise a methodology that 
will allow an estimate of the effects of changes in risk factor prevalence in a 
population on a chosen measure of health. This methodology will have to 
be able to take into account the effect of one risk factor on several diseases 
and the effect of simultaneous interventions on several risk factors and will 
have to incorporate a time dimension to allow for a slow risk reduction. 
The results must be presented both as proportional changes in age specific 
disease incidence rates and as changes in absolute measures of health." 
In chapter 2 some existing epidemiological techniques that are relevant 
to the Prevent project will be reviewed. In the following chapter we will 
discuss the methodological adjustments necessary to meet the conditions 
stated in the objective. In the final chapter the computer model will be 
presented, for although the concept of Prevent is simple, the calculations 
are cumbersome and they are performed in a computer simulation model. 
Existing epidemiologic measures in Prevent 
In epidemiology an analysis of the distribution of disease incidence and risk 
factor prevalence in different populations is used to confirm the hypothesis 
of a causal relationship between risk factor and disease. The strength of 
the relationship is often expressed as the ratio of incidence between ex-
posed and non exposed, the Incidence Density Ratio (IDR) or relative risk 
(2.2.1). The importance of a risk factor for the incidence of a certain dis-
ease in a population is usually expressed as the Etiologic Fraction (EF), 
the proportion of the total incidence of the disease that can be attributed 
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to the prevalence of that risk factor in the population (2.2.2). It also gives 
an indication of the proportion of incidence that could be prevented by the 
total elimination of that risk factor in the population. 
However, since most often prevention will not eliminate but merely re-
duce the prevalence of a risk factor, a measure was developed to estimate 
the impact of a change in prevalence of a risk factor on the incidence of 
a disease, the Potential Impact Fraction (PIF). It stands for the incidence 
that is avoided by a preventive intervention as a proportion of the incidence 
that would have occurred in that population without the intervention. Both 
the EF and the PIF can be calculated when P's, the prevalences of exposure 
to a risk factor, in the population, and the corresponding !DR's are known. 
The potential impact fraction in the traditional epidemiological literature 
assumes an immediate elimination of excess risk after the termination of 
exposure. The ex-exposed are returned to the category of non exposed 
with, by definition, an IDR of 1. 
The Prevent methodology 
Prevent is a model which estimates the effect of changes in risk factor 
prevalence in a population in terms of health benefit. It is based on the 
epidemiologic effect measure the Potential Impact Fraction. To achieve the 
objectives stated it has incorporated the following three requirements in 
the methodology: 
• the possibility that one risk factor affects several diseases, and that 
one disease is affected by several risk factors, 
• a time dimension to simulate the reduction in excess risk after cessa-
tion of exposure to the risk factor, 
• the interaction between the effect of the intervention and the demo-
graphic evolution in the population. 
In the current version of Prevent all measures of health benefit are based 
on mortality. There are two steps in the methodology, in the first PIF's are 
calculated, in the second step these proportional measures are expressed in 
absolute heaith benefits. The first two requirements of the methodology 
are incorporated in the first step of the model (3.2), the third one dictated 
the format of the second step (3.3). 
Step 1, the calculation of PIF's 
In the first step of the Prevent model several risk factors and several diseases 
are analyzed simultaneously. The prevalence of each risk factor is denoted 
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by P, the proportion of the (sub )population exposed in a certain exposure 
category. In order to use the information on the causal relationship between 
risk factor exposure and disease incidence as effectively as possible, the 
prevalence is stratified by age and sex category. Since one risk factor can 
affect several diseases, each exposure category is assigned several IDR's, 
each representing the strength of the relationship between the risk factor 
and one of the diseases. 
Knowing the existing distribution of a population over exposure cate-
gories (P) and the corresponding IDR's, we can estimate the proportional 
changes in incidence (PIF) for each disease affected by that risk factor, due 
to changes in P, for instance as a result of a preventive intervention. In 
a second step of the model these disease specific PIF's are applied to the 
disease specific mortality quotients and then to a population, so that the 
proportional PIF's are translated into absolute measures of health benefit. 
Interventions on a risk factor will result in a shift of a proportion of the 
population from exposed to ex-exposed. These shifts cause proportional 
changes in incidence rates for all the diseases affected by that risk factor. 
In other words, it will result in several PIF's, age, sex and disease specific. 
The second condition of the methodology was the introduction of a time 
dimension. For each risk factor and disease combination a time period 
in years is assumed between the moment of cessation of exposure and the 
moment the lowest relative risk for ex-exposed, the remnant IDR is reached. 
This time period is called LAG. The introduction of this time dimension 
necessitates an adjustment of the equation used for the calculation of PIF 
as well as an additional dimension of the input data on prevalence and 
IDR. It means that the ultimate PIF is not reached immediately after 
the intervention but only after LAG years. It may take years before the 
intervention has its maximum effect. 
The time dimension also means however, that past changes in risk factor 
prevalence, whatever their cause, may continue to affect disease incidence in 
the future. This change in disease specific incidence should not be ascribed 
to the intervention. To incorporate the proportional effect of such past (and 
possibly also of future) "autonomous trends" in risk factor prevalences, 
Prevent calculates Trend Impact Fractions TIF 's, in a manner similar to 
the PIF's. 
Step 2, the calculations of health benefits 
By the end of LAG years the maximum PIF is reached, the effect of the 
intervention in proportional terms. The effect in absolute numbers, the 
health benefit, will of course also depend three other factors: on the pro-
portional changes in disease specific incidence over that same period caused 
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by autonomous trend (the TIF's), the relative contribution of the diseases, 
influenced by that specific risk factor, on total mortality and the demo-
graphic changes in the population over those LAG years. 
It is the time dimension in the first step of the model and the fact that 
it may vary for different diseases, which makes the interaction between 
the PIF's and the demographic changes interesting. In Prevent the second 
step of the model consists of a population model in one year age groups 
to which disease specific mortality quotients (M) are applied, to simulate 
the evolution of the population over time. The assumption is that the 
proportional changes in incidence from the first part of the model, the PIF's 
and TIF's, are translated into the same proportional changes in disease 
specific mortality after a certain latency period, LAT. 
If the TIF's only are applied, the resulting new disease specific mortality 
quotients and the evolution of the population represent the so called ref-
erence or trend scenario, the developments expected when no intervention 
takes place. If however both TIF's and PIF's are applied to the mortality 
quotients, the population evolves as is expected as a result of the interven-
tion. Note that prevalence changes in one risk factor may generate changes 
in disease specific mortality quotients for several diseases, and that risk fac-
tors for which no intervention is simulated nevertheless may cause changes 
in mortality quotients through TIF's as a result of autonomous trends in 
risk factor prevalences. The differences between the reference and the in-
tervention population represent the effect of the intervention and can be 
expressed in several measures of health benefit: differences in mortality, 
potential years of life gaiu'ed (PYLG) etc. To see the full effect of an inter-
vention on such a measure of health benefit the model should simulate for 
at least LAG+LAT years. 
In summary this means that an intervention on risk factor prevalence P 
at time t=O will result in a proportional reduction in incidence, PIF spread 
over LAG years, from t=O to LAG. These PIF's are applied to mortality 
quotients, M, after LAT years, from t=LAT to LAG+LAT. The result-
ing new disease specific mortality quotients are applied to the population 
together with the other mortality quotients over at least LAG+LAT years. 
The Prevent model 
The stratification and the time dimensions necessary for the methodology, 
make it imperative that the calculations of health benefits are done in a 
computer simulation model (4). One of the objectives of the project was 
that the tool developed should be useful for policy makers. We decided at 
the start of the model development that it should be an interactive model 
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which could run on an IBM compatible micro computer and which could 
be operated without prior knowledge of the epidemiologic techniques used 
in the model. 
The files containing the array of data on P and IDR's, the time dimen-
sions, the existing mortality quotients and the population data, can be ad-
justed for any population, but can not be changed directly by the user. The 
user. can specify changes in risk factor prevalence as a result of autonomous 
trends or interventions, the time period over which the intervention occurs, 
the length of the simulation period and whether the first, proportional part 
of the model will take a cohort factor into account. Prevent will present the 
results in graphical or tabular output, for the intermediate output variables 
of EF, TIF and PIF and for the outcome variables: disease specific mor-
tality, total mortality, (disease specific) mortality difference, PYLG, actual 
life years gained, survival curves and life expectancy at birth. 
20 
Chapter 2 
Theoretical background 
2.1 Summary and definitions 
In this chapter some existing epidemiological measures will be reviewed 
that were developed to estimate effects of risk factor interventions, and 
their applications in preventive policy making. In this summary we will 
first present the definitions and, if relevant, the detailed equations of the 
epidemiologic variables referred to in this chapter. In the text they are then 
only presented in a simplified version. 
P is the proportion of the population exposed to a certain risk factor, pos-
sibly including a proportion that was never exposed. P is always age, 
sex and risk factor specific. It can be stratified further by exposure 
category and ex-exposure level. Within one age, sex specific subpop-
ulation :LP=l. 
Exposure category is a stratification by severity of exposure. 
Ex-exposure level is a stratification by the remaining effect of exposure 
after cessation of exposure. 
IDR is the incidence density ratio, the ratio of the incidence rate among 
exposed over the incidence rate among never exposed. In the text 
it is used interchangeably with RR or relative risk. The IDR is age, 
sex, risk factor, exposure category and disease specific. The IDR of 
the never exposed is always 1 by definition, the IDR of the exposed 
is always ;::: 1. 
EF is the etiologic fraction, the proportion of incident cases attributable 
to the prevalence of a risk factor in a population at a certain moment 
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in time. It is the equivalent of what has been called attributable risk 
(percentage) by other authors. 
EF = Pex(IDR- 1) 
Pex(IDR-1) + 1 
where: 
- Pex :proportion of the population exposed to a risk factor. 
PIF is the potential impact fraction, the incident cases prevented at a cer-
tain moment in time, by an intervention to reduce risk factor preva-
lence, as a proportion of the incident cases that are expected to occur 
at that time in the absence of the intervention. 
where: 
- Pex: proportion of the population exposed. 
- P:x: the remaining proportion of the population exposed after in-
tervention. 
M is a mortality quotient, the number of deaths per 100.000 of the pop-
ulation. It is age and sex specific, time dependent and can also be 
disease specific. 
PYLG are the potential years of life gained by a death avoided. The total 
number of deaths at a point in time are each multiplied by the current 
life expectancy at the age of death. It is the mirror image of PYLL 
the potential years of life lost. 
QALY is quality adjusted life years, a measure of health benefit based on 
the PYLG times the quality measure assigned to the health status 
during the PYLG. 
2.2 Calculating the Potential Impact Frac-
tion 
2.2.1 The use of relative risks 
The effect of exposure to a risk factor on disease incidence is often quantified 
as the relative risk or incidence density ratio IDR, the ratio of the incidence 
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among exposed over the incidence among the non exposed. Relative risks 
can be derived from cohort studies and are identical to incidence density 
ratio's when very short time spans are concerned (1). For some risk factors 
only data from case control studies are available, the resulting odds ratio's 
can be equated to relative risks under certain conditions (2). 
Estimates of incidence density ratio's and estimates of the prevalence 
of risk factors in the Dutch population, will be necessary for the effect 
estimates of risk factor interventions. The prevalence of risk factors in a 
population is often known, but incidence density ratio's will have to be esti-
mated from relative risk ratio's or odds ratio's, from previous epidemiologic 
studies (3-9). Ideally, they can be transferred to another population if the 
following conditions are met: 
• Relative risks need to be controlled for the influence of other known 
or suspected etiological agents which overlap in distribution with the 
exposure of the risk factor of interest (confounders). 
• Relative risks have to apply to the general population. If the controls 
are stratified to match cases they may not be representative of the 
general population. 
The utilization of relative risk estimates from other populations involves 
the risk that populations differ on an important characteristic which makes 
it impossible to compare them. The most obvious variables for which one 
would wish to control are age, sex and race. The influence of different age 
structures in populations on total mortality has been extensively discussed 
and several methods for the standardization suggested (10-12). 
Walter in 1978 (13) puts forward the hypothesis that a relative risk if 
properly standardized should perhaps be viewed as a biological constant 
and thus can easily be transferred from one population to another. This 
hypothesis seems to be corroborated by empirical data such as those pre-
sented by Mcintosh on the relative risk of smoking and pregnancy (14). 
2.2.2 Attributable risk and impact measures 
In epidemiology the fraction of the incidence that can be attributed to 
the prevalence of a certain risk factor in a population has been referred to 
as the attributable risk in that population. Over the years this measure 
was refined by several authors (15-17) and some dispute over the termi-
nology evolved. To avoid further misunderstanding we shall refer to the 
"Etiological Fraction" (EF) as suggested by Miettinen, and defined as "the 
proportion of incident cases attributable to the prevalence of a risk factor" 
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or the difference in the number of cases in a population with exposure and 
without exposure as a fraction of the number of cases in the population with 
exposure, or 
P(IDR-1) 
EF= P(IDR-1)+1 
The etiological fraction in fact represents the incidence that could be 
avoided in a population if there was no exposure to that risk factor. As 
such it has been used to set priorities for preventive action. 
B. Ouellet et al in 1979 (18) made an attempt to determine the per-
centage of premature mortality and of potential years of life lost (PYLL) 
in Canada attributable to smoking and alcohol. Mortality causes were 
screened for those believed to be related to smoking and drinking. Using 
relative risks from epidemiologic studies elsewhere, a calculation of the at-
tributable fraction (as they call the EF) was made, based on the known dis-
tribution of risk factors in the Canadian population. The approach demon-
strates how, using the EF, the ranking of causes of premature mortality can 
be transformed into a ranking of risk factors and used to establish preven-
tive policy priorities. A couple of problems were identified but not solved 
in this exercise: 
• the problem of the lead time between exposure and the increased 
risk of disease (no mention was made of its complement the lag time 
between preventive action and maximal reduction of relative risk). 
• the problem of the interaction between risk factors and the impor-
tance of possible dependency in the distribution of risk factors. 
On both issues the authors concluded that insufficient data exist to be able 
to take them into account. 
Miettinen had already alluded to the possible use of the etiologic fraction 
as a measure of the fraction of disease prevented. He pointed out that this 
prevented fraction is not merely a negative etiologic fraction: it is the 
proportion of cases prevented by the factor, among the total number of 
cases that would have developed in the absence of the protective factor 
(hypothetical totality of cases both prevented and unprevented). 
Walter (13) proposed that this prevented fraction may serve as a ratio-
nal foundation for the choice between alternative preventive strategies for 
health planners. And Morgenstern and Bursic (19) argued that epidemio-
logical research on risk factors should be implemented and used by health 
planners to estimate the potential impact of a preventive intervention. The 
proposed Potential Impact Fraction (PIF) is defined as "the proportional 
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reduction in the total number of new (incident) cases of a certain disease, 
resulting from a specific change in the distribution of a risk factor in the 
population at risk", or the difference between the number of cases that 
would have occurred without risk factor intervention and the number of 
cases that occurred with risk factor intervention as a fraction of the number 
of cases that would have occurred without risk factor intervention, or 
PIF = (Pex- P;,)(IDR- 1) 
Pez(IDR -1) + 1 
where Pex is the estimated proportion of the candidate population ex-
posed before the planned intervention, P;, is the estimated proportion of 
the candidate population exposed after the intervention and IDR is the 
relative risk. 
However, Morgenstern introduces certain assumptions which he con-
siders necessary but which seriously hamper the use of his methodology by 
health planners. The first two have to do with the lack of a time dimension, 
the others with the limitation to a single disease/risk factor combination. 
• Post intervention risk must be identical to non exposed risk. 
• No significant secular trends in age specific risks of disease may exist. 
These assumptions by Morgenstern severely limit the possible use of 
the measure and illustrate the necessity of a time dimension and of a 
category of ex-exposed in effect estimates. 
We know from several studies that, for instance, the relative risk of 
lung cancer for ex-smokers falls rapidly after smoking cessation but 
that it never really seems to attain the non smoker level. If a reduction 
in relative risk over time, is to be taken into account the PIF can not 
remain a static measure. 
Furthermore risk factor prevalences change in a population over time, 
for instance as a result of previous interventions. This is illustrated 
by R.P. Ouellet in 1979 (20), who uses a community impact measure-
ment of preventive interventions, adjusted for program acceptance 
and drug efficiency, to assess the impact of a new detection and treat-
ment program, over and above the regular medical care sector. The 
example is worked out for hypertension and stroke in a black urban 
community in Baltimore. The importance of Ouellets paper lies pri-
marily in the fact that the trends in incidence as a result of earlier 
preventive actions, are taken into account when estimating the impact 
attributable to the proposed intervention. 
• No significant secular trends may exist in the distribution of other 
risk factors. 
26 CHAPTER 2. THEORETICAL BACKGROUND 
• No allowance can be made for the fact that one risk factor may affect 
several diseases. 
It has been argued before that from a policy perspective the multi-
factorial approach in the estimation of the effect of risk factor inter-
ventions is essential and the PIF will need to be adjusted to take this 
into account. 
The necessity of looking at several relevant risk factors for one disease was 
already illustrated in the multi factorial intervention trials. Sturmans et al 
in 1977 (21), tried to calculate the impact of preventive interventions on 
hypertension, hypercholesterolemia and smoking on CHD mortality. They 
compared the maximum number of prevented deaths calculated with the 
traditional expressions for EF (without correction for possible interaction 
between risk factors) with the same estimates derived from the multi fac-
torial approach. 
Another example of a multi factorial approach in the sense that not 
only several risk factors for one disease but also several diseases are con-
sidered simultaneously, is the work on Health Risk Appraisal, HRA (22). 
The health risk appraisal method is basically a computer program in which 
risk characterizations of an individual are translated into a measure of life 
expectancy. Its main purpose is to aid health education as it provides a 
quantification of health benefits to be derived from specific behavior mod-
ification. The theory is that the reduction of life expectancy as shown by 
the computer will shock and thus the health education message will be 
more readily accepted. Although the quantification uses the same basis of 
relative risks for its calculation of the health benefits of risk reduction, it 
concentrates on individuals rather than populations. The micro approach 
resembles the macro approach but by its nature does not address the prob-
lems of a dynamic population with secular trends in risk factor prevalence, 
demographic trends etc. 
2.2.3 Conclusions 
The literature shows that epidemiology has produced some useful expres-
sions: the Etiologic Fraction and the Potential Impact Fraction, with which 
the effects of changes in risk factor prevalence on changes in disease specific 
incidence can be estimated. 
If relative risk ratio's were corrected for confounding influences they 
could be used. Age, sex and race are important determinants of incidence 
rates, and since we are not only interested in proportional but also in ab-
solute measures of effect for the Dutch population, it is preferable not to 
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work with a "standard" population, but to use age, sex and race specific 
relative risks. 
However the following adjustments will have to be made: 
• Since age, sex and exposure levels all apparently greatly influence the 
relative risk found in epidemiology, the EF and PIF calculations will 
have to be stratified to take those into account. This is also necessary 
to be able to transfer relative risks from one population to another. 
• Although mention is made of the "lead time", no time dimension is 
used in these traditional epidemiologic calculations. The introduction 
of a time dimension will not only allow for a lead time, and its comple-
ment the lag time, but will also make it possible to take secular trends 
in risk factor prevalence (possibly the result of earlier interventions) 
into account. 
• The effect measures used until now have been restricted to one disease 
with one risk factor. The EF and PIF, as presented here, may not 
necessarily be correct even for a single risk factor intervention if we 
know that other risk factors simultaneously influence the incidence of 
the same disease. 
2.3 Calculating health benefits 
The proportional reductions in incidence are of limited interest as estimates 
of effect, when comparing interventions. In order to rank priorities for a 
specific population these PIF's will have to be expressed in absolute mea-
sures of health benefit and aggregated over several diseases. There are two 
main categories of health measures that could be used for this purpose: 
mortality measures and measures based on morbidity. These will be briefly 
reviewed and the special problems of the aggregation over several disease 
categories discussed. 
2.3.1 Mortality measures 
The most fundamental of all measures of health benefit is a reduction in the 
number of deaths. The evaluation of a health intervention is often expressed 
in terms of the number of deaths avoided. In order to make comparisons 
between populations of a different size, either between different populations 
or the same population at different points in time, the mortality benefit is 
sometimes expressed as a change in age and sex specific mortality rates. In 
developing countries, infant mortality rates are still a very useful measure 
of both health and available health care. 
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As populations age and causes of death are more concentrated in older 
age groups, a certain cause of death avoided sometimes results in a substi-
tution by another cause of death. This created a need to express the benefit 
not in the number of deaths avoided but in the amount of life gained. Mea-
sures like life expectancy for populations and potential years of life gained 
(PYLG or potential years of life lost, PYLL, as its counterpart) for individ-
uals evolved. An increase of life expectancy for a population indicates that 
an intervention does not merely substitute one cause of death for another, 
and PYLG allows to weigh causes of death according to the age at which 
death was avoided. 
This concept of potential years of life lost has gained attention as a way 
of evaluating the impact of a cause of death (23). Each death is multiplied 
by the number of years the individual, considering his age, could have 
expected to live. The choice of the age specific life expectancy as the upper 
limit has been extensively discussed since especially in the older age groups, 
mortality rates are rapidly changing and the life expectancy measures may 
underestimate the true survival period. Some authors (24, 25) have settled 
this problem by choosing a rather arbitrary cutoff point and comparing the 
years of life gained from the avoided moment of death until that end point 
age, for instance 70 years. An additional argument for eliminating the very 
old from this analysis comes from the fact that the causes of death are 
much more difficult to ascertain with any degree of certainty in the oldest 
age group, and some suggest that the possibility of influencing mortality 
among the elderly by changing personal health habits may be limited (26).1 
The implicit assumption in such an arbitrary end point is that death 
before that age is premature and deserves to be avoided, while prolongation 
of life beyond that age is not a political objective (27). Some authors even 
define health benefits as years of "productive" life gained (28). 
All of these measures have in common, however, that they are static. 
They look at a population at a certain point in time and do not allow for 
the dynamics of an aging population. If a time dimension is introduced in 
the first part of the model we will have to develop a dynamic population 
model in which the above measures of mortality benefit are expressed over 
time. 
1 For similar practical reasons the very yonng (i.e. under 1 year of age) are often 
eliminated from the analysis. The argument is that the infant death rate is determined 
by very special risk factors, and compared to mortality in later years infancy is a relatively 
"dangerous" period of life. Therefore causes of death in that age group tend to be of a 
different nature than those in later life. But they are accorded a very heavy weight since 
they add so many years of life gained. . 
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2.3.2 Morbidity measures 
In a population with a large share of chronic-degenerative diseases mor-
tality measures may not be a very satisfactory measure of benefit. Some 
indication of the load of morbidity or invalidity avoided through an inter-
vention may be required. The most fundamental measures of morbidity are 
incidence and prevalence. Although PIF's will give a proportional change 
in incidence, the translation into absolute measures of incidence and from 
there of prevalence are difficult because reliable data on disease incidence 
in a population are often not available. As a proxy for the number of cases, 
morbidity is sometimes measured through the utilization of health services, 
the "burden of disease". Each case of a certain disease is weighed with the 
average costs, not only financial but also in terms of health care utiliza-
tion, or maybe even "suffering", associated with that disease. Although 
this type of measure was primarily developed to weigh the different disease 
categories as to the claim they placed on health services, it could also be 
adjusted to express more specifically the burden of disease for the indi-
vidual. In most countries health services utilization statistics are available 
and some composite though often crude measure of the burden of disease 
by disease category could be developed. This should be specified by age 
and sex category, since the course of a disease may vary according to these 
characteristics. 
Similarly in countries where life expectancy is high and most individuals 
lead long healthy lives before being struck by illness, the importance of 
an intervention should perhaps not be expressed in terms of increased life 
expectancy or PYLG, but more in terms of potential years of active life 
gained (29-33). Manton (34) showed that an addition of years of active life 
can either be achieved through a parallel shift in incidence and mortality 
(PYLG is identical to the potential years of active life gained) or through 
a compression in morbidity without a concurrent shift in mortality. With 
a benefit measure based solely on mortality the second type of benefit will 
not even become visible. 
Several authors have come up with solutions for this dilemma. Katz (35) 
constructed an "invalidity" table comparable to a life table in which the 
(partial) elimination of a cause of death was shown in terms of increase in 
years of active life. Such a table can only be constructed for a population for 
which detailed information on invalidity rates is available, not only for each 
disease category but also age and sex specific. That type of information 
exists for few populations. 
In line with the above measures, all of which basically weigh disease 
cases according to the resulting consequences for the individual, would be 
some subjective valuation of the different burdens of disease, some mea-
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sure of quality of life. Although different diseases may entail the same 
objective burden of disease in terms of, for instance, hospitalization, the 
ultimate health status of those hospitalized and of survivors may differ by 
disease. Furthermore they may be experienced differently by the individual. 
This is exemplified by the emotional reactions to cancer and AIDS. Health 
economists have also felt this need to weigh states of health not only by 
their quantitative characteristics but also by their appreciation, and have 
developed the concept of the QALY, the quality adjusted life years. There 
is now a vast literature on this subject (for instance 36-39) and although 
authors may disagree on the best methodology to estimate the weighing 
factor to be assigned to different states of health, the QALY is defined as 
a measure of potential years of life gained corrected for their quality. 
However QALY research as it has been developed in health economics, 
primarily to compare technologies and health services, has concentrated 
on the valuation of health states, not diseases. There is little information 
available on health status by diagnosis and of the different valuations of 
health states by age group or sex, or by diagnosis. A further problem with 
both the objective and the subjective measures of morbidity is that they 
can vary considerably over time. Over long simulation periods they will be 
less reliable than mortality measures. 
2.3.3 Aggregation of mortality benefits 
If one risk factor affects several diseases, the ultimate benefit of an in-
tervention will be the health benefits aggregated over the relevant disease 
categories. In the case of mortality benefits this may be expressed as to-
tal mortality reduction or parallel to the potential years of life gained, an 
actual growth in the population. 
When analyzing the effect of a disease specific mortality reduction on 
total mortality "competing death risks" or the "independency of causes of 
death" have to be addressed {40-44). The conceptual problem of competing 
death risks was first brought to light by the demographers. In the lifetable 
techniques one can calculate the effect of a reduction of age specific mor-
tality due to the elimination of a specific cause of death. The problem is 
whether one can assume that the population "saved" by the elimination 
of a cause of death can simply be returned to the pool of survivors and 
therefore runs the same risks of dying from the other causes of death. The 
same problem obviously occurs with partial elimination of a cause of death. 
In most life tables including the recent ones for the Netherlands by 
van Ginneken ( 45) the choice was made to assume independence of causes 
of death and therefore indeed subject survivors to the same age specific 
mortality risks from other causes. However many authors have argued 
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that an interdependency between causes of death and a transition between 
them must exist (46, 47). The demographers have responded by developing 
different models to allow for such "competing death risks". 
Manton et al developed the model of an underlying "lethal defect" ( 48, 
49) resulting in Patterns of Failure rather than causes of death. Wong 
proposed a competing risk model in which a susceptibility ratio is taken into 
account (50) which links causes of death by assuming "saved individuals" 
to have a higher or lower susceptibility to the remaining causes of death 
than the general population. 
All of the above models have in common that they approach the prob-
lem primarily from a demographicalfmathematical point of view without a 
clear medical-biological hypothesis to explain this "susceptibility" or under-
lying "lethal defect". This can result in a hypothesis about the association 
between tuberculosis and cancer in general, based solely on a stable per-
centage of total mortality attributable to these joint causes of death ( 47). 
For prevention it is of vital importance to know whether elimination of 
one cause of death will merely result in a replacement by another cause of 
death, as is suggested by Keyfitz and Fries (29, 51) or that one may truly 
expect an increase in life expectancy as defended by Schatzkin and Manton 
(42, 52). 
A possible common disease process for the major diseases may bear 
with a closer look. If there is a relationship between the susceptibility 
for different causes of death this may either be genetically determined or 
influenced by an external risk factor. The first hypothesis would basically 
only allow for substitution of causes of death assuming a predetermined 
limit to life expectancy, and is supported by the multiple cause morbidity 
and mortality in the oldest age groups. The latter possibility assumes 
that because of the joint risk factors between different causes of death, 
an elimination of such a risk factor will result in a mortality reduction 
for several major diseases and therefore result in a sizeable increase in life 
expectancy ( 44). 
In the Prevent model the causes of death will be clustered by their joint 
risk factors. The assumption will therefore be that those causes of death 
that are interrelated, will be influenced simultaneously by their joint risk 
factor, and other causes of death will be assumed to be independent. 
2.3.4 Conclusions 
Estimates of the simultaneous proportional reduction in the incidence of 
several diseases, as a result of a reduction in risk factor prevalence, will 
have to be translated into "health benefits". 
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What the ultimate effect of a proportional reduction in incidence will 
be, depends on the measure chosen as indicator of health. Theoretically 
there are three possible effects on the health indicator. 
The changes in incidence of that particular disease have no effect on 
the chosen health indicator. This may sound paradoxical but this is for 
instance the case when one chooses mortality as the health indicator and 
one considers the effect of changes in the incidence of a non lethal disease. 
Changes in incidence will not affect the health indicator in question. Sim-
ilarly acute diseases that are either cured or cause death, will not greatly 
influence measures of invalidity. 
A change in incidence is identical to a change in health indicator, for 
instance in a disease for which the case fatality rate is 100%: the incidence 
is identical to the disease specific mortality and changes in disease incidence 
will be directly translated into changes in mortality. 
Some cases result in changes in the relevant health indicator, in the case 
of mortality, when for instance the case fatality rate is less than 100%. The 
absolute number of incident cases prevented will not be equal to the number 
of deaths avoided. But not only will a mortality shift be but a partial 
reflection of the total health benefit gained by the incidence reduction, the 
case fatality rate may also be influenced by curative care, necessitating 
a clear distinction between benefits resulting from preventive action and 
those resulting from therapeutic progress. 
Most diseases will affect most health indicators as described in the third 
situation, a reduction in incidence will be partially reflected in a reduction 
of the indicator. 
The choice of health indicator will clearly determine the effect on health 
of the disease specific incidence reduction resulting from the risk factor 
intervention. The choice will thus also influence the priority setting. 
In summary, the second step in the model will have to take the following 
points into account: 
• Since the outcome of the first step is theoretically a proportional re-
duction in incidence, a measure of health benefit will have to be chosen 
that evolves parallel to incidence changes. For example proportional 
changes in incidence are identical to proportional changes in mortality 
as long as there is no difference in case fatality rates between avoided 
cases and the observed cases. The latency period between incidence 
and health outcome, and possible changes in case fatality rate over 
time will have to be addressed. 
• Since the proportional incidence changes are at least disease, age and 
sex specific, the health benefit measure chosen will also have to be 
stratified by disease, age and sex. 
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• With the introduction of a time dimension in the first part of the 
model, it is impossible to have a static measure of health benefit if 
we want to go beyond proportional changes, and express the health 
benefit in absolute terms for a real population. A dynamic population 
model, that takes the aging of the population and the competing death 
risks into account will have to be constructed. 
• Finally with a dynamic population model, a health benefit compared 
to the current level of the chosen health indicator will not be sufficient. 
The very fact that the population ages and that secular trends in risk 
factor prevalence are taken into account in step one, means that we 
will have to develop a reference scenario in which the evolution of 
the health indicator is simulated as it would have occurred had there 
been no intervention. 
These points, together with the requirements for step 1 as formulated in 
the conclusions of the first section (2.2.3), will determine the methodology 
for the Prevent model. They will be discussed in the next chapter. 
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Chapter 3 
Methodology of Prevent 
3.1 Summary and definitions 
In the previous chapter the epidemiological measure of Potential Impact 
Fraction, as developed by Morgenstern, was explored as a basis on which 
to estimate the proportional effect of a reduction in prevalence of a certain 
risk factor, on the disease specific incidence. It was subsequently argued 
that this proportional reduction in incidence calculated in the first step 
would have to be applied to a dynamic population model in the second 
step to allow for a translation into health benefits in absolute terms and 
an aggregation over several disease categories. For both steps a number of 
conditions were identified that are important for the Prevent model. 
In this chapter we will explain how the methodology for the Prevent 
model evolved. The time dimension necessitated some adjustment of the 
equation used for the calculation of PIF, as well as additional stratification 
of the input data, on prevalence and IDR. It also dictated the dynamic 
population of step 2 and the two parallel scenario's, trend and intervention. 
All outcome measures will be based on differences in mortality between both 
scenario's. 
Figure 3.1 shows a simplified version of the model, for only one time 
interval. This process is reiterative for all the years of the simulation period. 
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Figure 3.1: The basic version of the Prevent model 
Trend (0) 
c, = Health 
Benefit 
In the text the following abbreviations and equations will be used. The 
definitions and the equations will be presented here with all the necessary 
subscripts. Simplified versions will be used in the text. The equations used 
in the previous chapter will not be defined again unless they have been 
changed. 
Remnant IDR is the lowest Incidence Density Ratio that can be achieved 
after cessation of exposure. It is risk factor and disease specific but 
is equal for all exposure categories. 
LAG is the time it takes (in years) after cessation of exposure, for the 
Incidence Density Ratio associated with a certain exposure category, 
to reach the remnant IDR level, through linear reduction. Each year 
of LAG represents an ex-exposure level as defined earlier. LAG is risk 
factor and disease specific but is assumed to be equal for all age, sex 
and exposure categories. 
Lead time is the time it takes (in years) after first exposure to a risk factor 
to reach the full relative risk associated with that exposure category. 
It is not used in the Prevent model. 
LAT is the latency period, the time (in years) between incidence and mor-
tality. It is disease and risk factor specific but assumed to be equal 
for all age, and sex categories, and to remain equal over time for each 
disease/risk factor combination. 
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PIDR is a intermediate variable, used to calculate EF's, TIF's and PIF's. 
It is risk factor, disease, sex, and age specific, it is time dependent, 
and there is a set ofPIDR's for both the reference and the intervention 
population. 
en ID 
PIDRr,j,z,3,A = '""""'"""" pr,j,3,A,n,i IDRr,z,3,A,n,i 
t L....J L....J t-LAT•·• (3.1) 
n=l i=O 
Where: 
- P: proportion of the population 
- IDR: Incidence Density Ratio 
- en: total number of exposure categories; 
- n: index for exposure category; 
- r: index for risk factor; 
- ID: total number of ex-exposure levels; 
- i: index for ex-exposure level; 
- j=0,1: index for reference (0) or intervention population (1). 
- A: index for age; 
- s: index for sex; 
- z: index for disease; 
- t: index for time. 
EF the etiologic fraction is the proportion of incident cases attributable to 
the prevalence of a risk factor in a population at a certain moment in 
time. It is always age, sex, risk factor and disease specific, and time 
dependent. 
(3.2) 
Where: 
- r: index for risk factor; 
- j=0,1: index for reference (0) or intervention population (1). 
- A: index for age; 
- s: index for sex; 
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- z: index for disease. 
- t: index for time. 
TIF is the trend impact fraction, the incident cases prevented at a certain 
moment in time, by an autonomous change in risk factor prevalence, 
as a proportion of the incident cases that would have occurred at that 
time in the absence of change. TIF is initially always age, sex, risk 
factor and disease specific and time dependent. In a second stage 
TIF's are aggregated over risk factors. 
PIDRr,O,z,•,A- PIDRr,O,z,.,A 
TIF[·z,•,A = o t 
pI DRr,O,z,•,A 
0 
(3.3) 
Where: 
- r: index for risk factor; 
- j=O: index for reference population; 
- A: index for age; 
- s: index for sex; 
- z: index for disease. 
- t: index for time. 
PIF is the potential impact fraction, the incident cases prevented at a cer-
tain moment in time, by an intervention to reduce risk factor preva-
lence, as a proportion of the incident cases that would have occurred 
at that time in the absence of the intervention. PIF is initially always 
age, sex, risk factor and disease specific and time dependent. In a 
second stage PIF's are aggregated over risk factors. 
PIDpr,O,z,•,A _ PIDpr,l,z,•,A 
pI F;·z·• ,A = ---~"~-=----~~:-~--=-"~--
p IDR';•o,z,•,A 
Where: 
- r: index for risk factor; 
- j=O,l: index for reference (0) or intervention population (1). 
- A: index for age; 
- s: index for sex; 
- z: index for disease. 
(3.4) 
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- t: index for time. 
Disease specific mortality is the absolute number of deaths due to a 
specific disease at each point in time. This can be differentiated by 
sex. 
Total mortality is the absolute number of deaths at each point in time. 
This can be differentiated by sex. 
(Disease specific) Mortality difference is the difference in the total 
number of deaths between the intervention and the reference pop-
ulation, at each point in time. This can be differentiated by sex. 
PYLG are the potential years of life gained, the absolute number of deaths 
avoided by an intervention, at a point in time, multiplied by the 
current life expectancy associated with the age at death. 
AYLG are the actual years of life gained, the difference between the total 
population in the intervention and in the reference scenario, at a point 
in time. 
The methodology remains simple. What makes the model complicated 
are the multiple dimensions of exposure, the many consecutive steps due to 
the time variables that vary for each risk factor-disease combination and the 
multi factorial nature of the model. The time dimension and the interaction 
with demography are the reason why the outcomes can be unexpected and 
therefore interesting. The only way to process such a large number of 
basically simple calculations is in a computer model. The formal structure 
~f the model will be the subject of the next chapter. 
3.2 Calculating the potential impact frac-
tion 
In the first step of the model PIF stands for the incidence prevented by 
the intervention, as a proportion of the incidence that would have occurred 
had there been no intervention. 
In the previous chapter we identified three adjustments to be made to 
use the PIF in the Prevent model: a stratification, a time dimension and 
an adjustment for the multi factorial nature of the model. 
3.2.1 Stratification 
The expression of PIF relies on data on prevalence P of a risk factor in 
a population and on data on relative risk ratio's as an approximation of 
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incidence density ratio's, IDR. To transfer relative risks from one population 
to another, either geographically or over time, the estimates need to be as 
"clean" as possible. This means that IDR's have to be corrected for possible 
other factors in the population which may influence the relative risk value 
found. Such factors are only important if they interact with both the risk 
factor and the disease studied and thereby affect the relative risk found. 
Some factors are known and generally accounted for in epidemiologic 
literature. The most obvious examples are sex and age. When possible 
IDR's will be stratified into age and sex specific values. With the corre-
sponding prevalence data, PIF's can then be calculated, which will be age 
and sex specific. 
There are other population characteristics that influence certain disease 
incidences but for which at present there is no adequate quantification. Ex-
amples are race and social stratification of the population. It is well docu-
mented that socioeconomic status (SES) is correlated with disease specific 
mortality (for a recent overview see Marmot and Mackenbach 53, 54). It 
may be important to stratify PIF's for social class since there is evidence to 
suspect a considerable cumulation of risk factors in the lower socioeconomic 
groups and also evidence that the effectiveness of preventive interventions 
varies according to socioeconomic group. 
Unfortunately when stratification of the exposure to a risk factor is 
available by socioeconomic status, it is seldom an extra dimension. Thus 
when using the SES data, the age and sex stratification has to be given 
up. We have chosen for the age and sex stratification, because there are 
also corresponding IDR values. An additional analysis by SES at a later 
stage may prove interesting, since the cumulation of risk factors may partly 
explain for the SES gradient in mortality and the Prevent model would allow 
for a hypothetical quantification of this effect. 
Joint exposure to several risk factors will also affect the relative risks. If 
there is no interaction, we will assume that relative risks are multiplicative. 
In that case risk factors need not be considered jointly as long as they are 
distributed independently (see appendix A). 
Other confounders, factors that interact with the risk factor under con-
sideration and will therefore confound the relative risk values found, are 
not so easily dealt with. If it concerns known confounders, they are of-
ten corrected for in the relative risk estimates. However the possibility of 
unknown confounders remains, that may both influence the relative risk 
estimates and the effect of the risk factor in our population. 
Finally the stratification within the risk factor under consideration needs 
to be addressed. For most risk factors there is a dose-effect relationship, in 
fact this is one of the conditions for a causal relationship. In the original 
PIF expression there is a dichotomy in the population between the exposed 
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proportion P of the population and the non exposed (1-P). In reality how-
ever we will want to specify the amount of exposure, when it influences the 
IDR value. 
In summary, the availability of data on IDR and P will determine the 
detail of stratification of the PIF. For each risk factor considered, a separate 
PIF will be calculated for each disease. This PIF will be age and sex specific. 
The stratification by exposure categories, is aggregated in the PIF equation. 
3.2.2 A time dimension 
The original PIF expression by Morgenstern is static, the reference inci-
dence is calculated from the original prevalence and the intervention is as-
sumed to have an instantaneous effect on prevalence, so that PIF is a direct 
result of the difference between these two. Adding a time dimension simply 
means that P is indexed for time. However as soon as a time dimension 
is introduced, the reference incidence which by definition is the incidence 
as it would have been without the intervention may change autonomously 
over time. 
The time index is important because it allows for the expression of the 
following time variables: LAG, LAT and time spread of an intervention. 
Lag time 
The lag time (LAG) is the time it takes for the excess risk associated with 
the risk factor to disappear when exposure ceases. In the case of alcohol 
and driving it usually is a matter of hours, but in the case of smoking and 
lung cancer it takes approximately ten years for an ex-smoker to reach the 
lowest possible risk level, and that level is not even the same as that of a 
lifelong non smoker. There is always a remnant relative risk for ex-smokers. 
We assume that the IDR diminishes over time after a cessation of expo-
sure. The "ex" population, after the successful intervention, can therefore 
not be added to the non exposed population in the PIF expression since 
they will not have the same IDR. Their IDR will depend on how long ago 
the intervention took place and on the ultimate IDR level an "ex" can 
achieve. In Prevent we will assume that the reduction in risk is linear over 
LAG years, between the IDR of the exposed and the remnant IDR of the 
"ex" exposed after LAG years. The prevalence P and IDR will thus be 
further stratified by the time dimension, ex-exposure level. 
The introduction of this variable has certain consequences for the model. 
If there is a slow reduction of risk over time interventions now will only 
attain their full effect in the future but also prevalences in the past will 
determine incidence in the present. Prevent will thus have to take past 
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changes in exposure prevalence into account to estimate their influence on 
current incidence. 
Changes in risk factor prevalence in the past are considered to be au-
tonomous trends, even if they are due to past interventions. Because of the 
length of the LAG time for some risk factor-disease combinations, these 
past trends may even influence the incidence of the disease in the future, a 
change of disease incidence which should not be assigned to the intervention 
currently evaluated. Similarly there may be an autonomous trend in risk 
factor prevalence that will continue in the future, independent of an inter-
vention. The effects of these trends in risk factor prevalence on incidence 
are calculated with the trend impact fraction TIF, which is derived with 
the following expression, almost identical to the PIF expression: 
TIF = PIDR0 - PIDRt 
t PIDRo (3.5) 
where PI DR0 is the PIDR at time 0, PI DRt the PIDR at time t taking 
the trends into account. 
A PIF by definition, calculates the incidence reduction as a fraction of 
the incidence that would have occurred had there been no intervention. 
This "reference" incidence can no longer be the PIDR at time 0, but will 
evolve over time as a result of (past or future) risk factor prevalence trends. 
The mathematical expression for PIF will therefore be adjusted as follows: 
PIF = PIDRt- PIDR~ 
t PIDRt (3.6) 
where PIDRt takes only the trends into account, and PID~ takes both 
the trends and the intervention into account. 
TIFt and PI Ft represent the proportional changes in incidence at time 
t. When this proportional change is applied to the mortality quotient at 
the start of the simulation, time 0, it will yield the mortality quotient at 
timet. 
Lead time 
As a complement to the lag time, which stands for the slow reduction in risk 
after cessation of exposure, there should be a time variable to indicate the 
slow increase in risk when first exposed, until the full relative risk ratio's 
apply. This lead time should apply if there is a positive trend in risk factor 
prevalence. From epidemiology we know relatively little about this variable, 
more commonly the length of exposure is given and an increase in relative 
risk assumed related to that length of exposure. Few empirical studies 
have considered the lead time specifically. A complicating factor is that first 
3.2. CALCULATING THE POTENTIAL IMPACT FRACTION 43 
exposure often occurs at an early age and subsequent incidence or mortality 
only occurs at a much older age. This is a reason why the lead time is not 
very important ·for the risk factors considered in Prevent. Theoretically it 
could be incorporated but in the current version it is omitted. 
Latency period 
A reduction in incidence is seldom reflected in an immediate change in the 
health indicator chosen to measure effect. If we consider mortality as the 
effect measure this means that there is a time between the incidence of the 
disease and subsequent death. In the Prevent model this time variable is 
called LAT for latency period. LAT simply stands for the number of years 
before a change in incidence will be reflected in a change in disease specific 
mortality. 
Theoretically this time variable does not apply until the second step of 
the model since it denotes time between the PIF and its expression in mor-
tality reduction. However, in the implementation of the model, LAT occurs 
in step 1. When reconstructing the past Prevent will go back LAG+LAT 
years and although the effect of an intervention will start to become appar-
ent after LAT years, it will not reach its full potential until after LAG+LAT 
years. 
In Prevent incidence as such is not calculated, only proportional changes 
in incidence. A proportional reduction in incidence is assumed to be iden-
tical to a proportional reduction in mortality as long as the case fatality 
rates between the population before and after intervention do not differ. In 
this condition lies the essence of the LAT period. First of all it is obvious 
that case fatality rates implicitly assume a time interval: incidence seldom 
causes instantaneous death as in the case of fatal motor vehicle accidents or 
sudden cardiac death. The introduction of the latency period LAT allows 
for a more realistic estimate of the effect of incidence reduction. 
Secondly LAT stands for all that occurs between incidence and death: 
the moment of diagnosis, the level of curative care and the therapeutic 
success rate. In the condition as formulated above, Prevent assumes that 
these remain unchanged over time. In reality this will seldom occur. By 
introducing the LAT variable the model shows at which point assumptions 
about changing therapeutic care would have to be introduced. 
In the present version of Prevent these changes are not taken into ac-
count and LAT is considered to be a constant that can take different values 
for each risk factor-disease combination. Obviously this is a simplification 
since it is but an average of the real survival period and will not show the 
distribution of the mortality reduction over time. 
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Time spread of an intervention 
A reduction in risk factor prevalence will seldom be achieved immediately. 
With a time dimension, it is possible to spread prevalence changes over a 
number of years. This does not affect the methodology, it will just deter-
mine the rate of change of prevalence as a result of the intervention. It does 
mean that the full effect of an intervention will not be seen until LAG+LAT 
years after the completion of the intervention. 
In summary, by adding a time dimension to the calculation of PIF, some 
changes in the methodology occur that go beyond the simple indexing of 
variables for time. Of the time variables introduced, LAG and LAT are 
the most important ones. LAG and LAT together determine which time 
span, both retrospectively and prospectively, has to be taken into account 
to see the full effect of an intervention. LAG determines the rate at which 
the IDR is reduced to the remnant IDR of the ultimate ex-exposed. It also 
means that historical developments in prevalence of exposure are taken into 
account. The incorporation of LAG thus adds an extra dimension to both 
prevalence and IDR. The time variable LAG necessitated adjustment ofthe 
PIF in order to take autonomous trends in risk factor prevalence from the 
past into account. As a consequence the variable TIF was introduced and 
the mathematical expression used to calculate PIF had to be adjusted. 
3.2.3 A multi factorial model 
In the objective of the project it was stated that the methodology should 
allow for the fact that one risk factor may affect several disease categories 
and one disease may be influenced by several risk factors. This is the multi 
factorial aspect of the model. 
The fact that one risk factor affects several disease categories is not 
important in the first step of the model. The outcome PIF is still disease 
specific and only in the second step of the model will these disease specific 
incidence changes be aggregated into one health benefit measure. 
The multi factorial character of certain diseases however, needs to be 
considered in the methodology for step 1. If several risk factors influence the 
incidence of a certain disease, all of these risk factors need to be considered 
to determine the ultimate changes in disease incidence. The resulting PIF 
needs to be disease specific but not risk factor specific. 
Before applying the methodology to several overlapping risk factor-
disease combinations two questions need to be addressed: 
• Can the PIF equation designed for a single risk factor, be applied 
when several risk factors are known to be present? 
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• How can the interaction between risk factors be incorporated? 
These questions need to be addressed because, except for rare exceptions, 
the lack of data on the joint exposure to several risk factors and on the 
relative risk of joint exposure, necessitate that each risk factor for a disease 
is considered separately. 
In appendix A the mathematical derivation of the expressions for the 
etiological fraction and the potential impact fraction are given for a situa-
tion where more than one risk factor is present. It is shown there that the 
expressions remain the same if relative risk ratio's are assumed to be multi-
plicative and the distribution of risk factors in the population independent. 
This assumption of an independent distribution is not necessary when rela-
tive risk ratio's are assumed to be additive but then the expressions for EF 
and PIF need to be adjusted. This alternative is of interest if Prevent were 
to be used to estimate the cumulative effect of an unequal distribution of 
risk factors over socioeconomic strata. 
Interaction between two risk factors is said to occur when joint expo-
sure results in a relative risk that is either higher or lower than what would 
be expected from the relative risks of each risk factor separately. In some 
cases such interaction is well documented as in esophageal cancer where 
alcohol and cigarette smoking jointly result in a relative risk that is far 
more elevated than would be expected (55). For other disease categories 
such as IHD that are also affected by several risk factors, interaction would 
have a much greater effect if it was shown to exist. There is a considerable 
body of literature on the assessment of the influence of one risk factor in 
the presence of other (confounding) variables. The methodology to prove 
the existence of interaction hinges on the definition of the effect of two risk 
factors without interaction. In other words, interaction is present when 
the observed relative risk of joint exposure differs from the expected. The 
expected relative risk of joint exposure depends on what theoretical model 
is applied to the relative risks when two risk factors are present simultane-
ously. 
In such an analysis a choice has to be made whether two relative risks 
are considered to be additive or multiplicative. Kleinbaum, Kupper and 
Morgenstern (1) argue that although the additive hypothesis is very useful 
to show the public health effects of the joint presence of two risk factors, 
the multiplicative theory better suits the pathobiological process of disease. 
This is corroborated by the multistage models developed for cancers (56). 
From the empirical data on the effect of joint risk factors, it is ob-
vious that for instance the IHD disease incidence greatly increases when 
more than one known risk factor is present, but there is still no consensus 
whether the ultimate effect is additive, multiplicative or whether interaction 
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is present (57-63). 
Because of the absence of clear evidence on interaction we shall assume 
that no interaction exists for the risk factors considered. We will assume 
that relative risk ratio's are multiplicative, and that risk factors are dis-
tributed independently in the population. Risk factor- and disease specific 
PIF's and TIF's can then be calculated as if no other risk factors were 
present. 
Because of the possibility of autonomous trends and of simultaneous 
interventions, all risk factors influencing one disease need to be considered. 
The effect of the different PIF's and TIF's are assumed to be multiplicative, 
and are calculated with the following equations: 
rj 
PJFf = 1- II [1- PIFtz,r] (3.7) 
r=l 
The same procedure is also applied to the TIF's: 
rf 
TIFf= 1- II [1- TIFt•r] (3.8) 
r=l 
Where: 
- rf: total number of risk factors influencing disease z; 
- r: index for risk factor; 
- P(T)I Ft'r, P(T)IF for a single risk factor disease combination. 
3.3 Calculating health benefits 
Given the methodology of step 1 the requirements for the methodology in 
step 2 were set. In the current version of Prevent the effect measures are 
all expressed as changes in mortality. As was discussed previously, other 
measures could easily be substituted if they are related to age and sex 
specific disease incidences. The incorporation of such a measure will not 
necessitate major changes in methodology. 
In the following chapters all measures of health benefit are based on 
mortality changes. The advantage of mortality data is that they are reliable, 
even if the causes of death are not always correctly coded (64). There is 
little risk of double counting as often happens in morbidity data. Finally 
the assumption that all other circumstances will remain unchanged (the 
assumption of ceteris paribus) is slightly less unrealistic for mortality than 
for a measure of morbidity. 
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The PIF's, proportional changes in disease specific incidence, are con-
sidered to be identical to proportional changes in disease specific mortality 
after LAT years. To translate these proportional changes in disease spe-
cific mortality into deaths avoided, the PIF's are applied to disease specific 
mortality quotients and these to a population. 
The consequence of the choice of a time dimension in step 1 is that 
step 2 needs to be a dynamic population model, in which the population 
changes over time as a result of changing age group sizes (demography) and 
changing age and sex specific mortality quotients (M). In Prevent disease 
specific mortality quotients M change only as a result of changing risk factor 
prevalences, either through trends or interventions (TIF's or PIF's). 
As a logical result of the decision to have two parallel scenario's in step 
1, the reference scenario based on TIF's and the intervention scenario based 
on TIF's and PIF's, step 2 works with two parallel populations, one of which 
evolves due to age and sex specific mortality changes caused by TIF and 
the other as a result of mortality changes caused by TIF and PIF together. 
• Reference population is TIF x M x population 
• Intervention population is PIF x TIF x M x population 
The following available measures of health benefit are alternative ways of 
presenting the differences between these two populations: 
Mortality Prevent will show the evolution over time of disease specific 
and total mortality in both the reference and the intervention popu-
lation. This evolution is not only the result of changes of risk factor 
prevalence but also of demography. After LAG+LAT years the effect 
of the intervention wears off and that of trend and demography take 
over again. 
Mortality reduction As deaths from a certain disease are prevented, the 
absolute number of deaths from a competing cause of death may actu-
ally increase. The mere substitution of one cause of death for another 
is a debatable health benefit. One is therefore not only interested in 
disease specific mortality reduction but also in the total mortality re-
duction over time. Prevent will show the difference in total mortality 
over time by subtracting total mortality in the intervention popula-
tion from total mortality in the reference population for each year of 
the simulation period. Since everyone must ultimately die, there may 
eventually develop a slight surplus mortality, as all those "saved" die 
of another cause of death. 
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PYLG As was discussed in the previous chapter it is sometimes of interest 
to weigh deaths according to the age at which they occur. The tradi-
tional Potential Years of Life Gained PYLG will simply multiply each 
death prevented by the current life expectancy at the age of death. 
Since of course the added benefit of the expected years of survival 
gained, should in reality not all be assigned at the time of the death 
avoided, PYLG should really be interpreted as a measure of mortality 
reduction weighed by age at death. 
A YLG Since we are nevertheless interested in some measure of the sur-
vival gained over time, due to an intervention, the health benefit 
measure Actual Years of Life Gained was introduced. AYLG shows 
the cumulative difference between the two populations. In AYLG the 
individuals saved are returned to the total population and will remain 
part of that population until they die. By subtracting the total in-
tervention population from the total trend population, AYLG shows 
how the deaths prevented lead to a real increase in the surviving pop-
ulation. This is probably the best cumulative measure of the benefit 
derived from an intervention since it takes the competing death risks 
and the remaining survival period into account. 
Survival curves In this outcome measure the new mortality quotients as 
a result of the intervention, are applied to an imaginary cohort of 
100,000 newborns. The resulting survival curve is shown alongside 
the one produced without the intervention. It is specific to a certain 
year. 
Life expectancy at birth The increased survival will also affect the life 
expectancy at birth. For a certain year, Prevent will show the life 
expectancy in the starting year of the simulation, the life expectancy 
as a result of trends and the life expectancy in the population with 
an intervention. 
EF, PIF, TIF There are also intermediate outcome variables. Prevent 
will offer the option of EF's, PIF's and TIF's as effect measurements. 
Chapter 4 
Computer model Prevent 1 
In this chapter we will describe the actual Prevent computer model. The 
general class of models Prevent fits into is that of simulation models. Math-
ematically the model is a set of difference equations, that cannot be solved 
analytically. Thus numerical methods are used. The 'simulation step is one 
year. 
The model consists of two main parts: a proportions model (step 1), 
in which P's and IDR's are transformed into PIF's, TIF's and EF's, and a 
population model (step 2), in which the TIF's and PIF's are used to cal-
culate new disease specific mortality rates, and the trend and intervention 
populations. 
Two new elements were added to the computer model which were not 
discussed previously in the methodological chapter: the "cohort" or "age 
group" calculations in step 1 and the IDRfac. 
With the introduction of the time dimension and the stratification of 
exposure P by age, the problem arose what to do with the prevalence of 
risk factors in different age groups as the population ages. Prevalences of 
exposure or changes in prevalence can either be considered specific to an 
age group or to a birth cohort. If one assumes that the prevalence of a risk 
factor is specific to an age group, an aging birth cohort will take on the 
exposure values of the next age group. If however, risk factor prevalence is 
assumed to be cohort specific, prevalences in age groups will change over 
time as different birth cohorts move into that age group. Since both models 
can be used for different risk factors in Prevent, both computation methods 
will be discussed. 
IDRfac is a variable with which an IDR of a certain exposure group can 
1 By Jan Barendregt and Louise Gunning-Sdtepers. 
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be multiplied and which may change over time. It was used in the historical 
testing (see chapter 8) to simulate the effect of changing exposure intensities 
over time. In the basic Prevent runs it is set to 1 but we will briefly show 
how it is incorporated in the calculations. 
4.1 The proportions model 
P, the proportions of the population exposed to a risk factor in different 
exposure categories, are considered by age group, and by sex. The propor-
tions non exposed (defined as never exposed), exposed and ex-exposed, are 
three stock variables connected by two flows: one from the non-exposed to 
the exposed,the inflow2 , and one from the exposed to the ex-exposed, the 
outflow (see figure 4.1 and 4.2). Both can be the result of an autonomous 
trend or an intervention. There are always (LAG + 1) levels of risk: one 
for the exposed and LAG for the ex-exposed. 
Figure 4.1: Simple flows between stocks 
non- inflow outflow ex-
exposed r----. exposed exposed 
Figure 4.2: Flow from exposed to ex-exposed in discrete steps 
non-
exposed 
inflow 
ex-exposed 
out- r---, r---, 
flow I I _I LAG-1 I 
1 year 1· • · ~ year L __ ..J L __ ..J 
Two additional remarks need to be made: 
;::LAG 
year 
2 This flow from non-exposed to exposed is calculated as a percentage of the exposed. 
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• There is no lead time in the model. Any proportion shifting from non 
exposed to exposed gets the exposed IDR in the following year. 
• There is no flow back from the ex-exposed to exposed. Once a pro-
portion has shifted to 1 year old ex-exposed, that proportion will 
inevitably end up as (LAG and over) year old ex-exposed. 
As explained earlier, exposure is stratified into categories. Each expo-
sure category has it's own IDR, possibly it's own remnant IDR and it's own 
set of associated proportions over ex-exposure levels. However all categories 
share the same pool of non-exposed (figure 4.3). 
Figure 4.3: Flows with more than one exposure category 
ex·exposed 
out- r---. r---,~ 
category 1 flow I I I LAG·1 '2: LAG 
exposed 1 year 1 · · · · · · 1 year year 
1
.._ _ __, L __ _j L __ _j 
non-
exposed 
\..----, out- r----, r--.., 
flow I I I LAG·1 
1 year I ...... I year I 
L __ _, L __ __J 
category 2 exposed 
Within the model: 
'2:LAG 
year 
• Each category has it's own inflow and outflow trends. 
• The simplifying assumption is made that in each category the ex-
exposed need the same LAG number of years to arrive at the remnant 
IDR. 
• The sum over all levels and categories of the proportions exposed plus 
the proportion non exposed always equals 1. 
4.1.1 Shift in proportions due to trends 
In the cohort version we assume that risk factor prevalence or changes in 
risk factor prevalence are not age dependent, but are characteristic of a 
cohort. The prevalences in age groups change as cohorts move in and out, 
with the aging ofthe population. With each year's simulation step not only 
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Figure 4.4: Shift of proportions at each time step 
non· 
exposed 
non-
t+l exposed 
exposed 
exposed 
ex·exposed 
r---, r--, 
I I I LAG·1 I 
11year 1 ...... 1 year I 
L'\_~ L- _j 
·. 
---, \.---, 
I I LAG·1 I I 1 year I ...... I year I 
L __ ..J L __ _j 
;::LAG 
year 
;::LAG 
year 
trends are applied and proportions shifted, but the age index is increased 
by 1 (figure 4.4). 
Two points need to be decided on: what to do with the youngest and 
the oldest (95 and over) age groups. The youngest age group will take on 
the prevalences of exposure of the previous cohort in that age group, after 
that years trends have been applied. Moreover, it is assumed that there are 
no ex-exposed in the youngest age group, so the proportion non exposed 
equals (!-proportion exposed). The oldest age group, of 95 and over, each 
year is assigned the exposition of the 94 years old of the previous year, 
again after applying trends. 
The available input data are not as detailed as is required here. At 
time 0 the proportions non-, ex- and currently exposed have an age group 
stratification. In the cohort version of the model those proportions will be 
applied to as many 1 year groups as will fit into that particular age group. 
Trends in prevalence continue to be specified by age group. 
Let: 
- A: 1 year age index, A = Amin, ... , 95. 
- Amin: lowest age at risk. 
- t: index for time. 
- i: index for time since cessation of exposure. 
PAID • d - t ' : proportiOn expose . 
- P/•0 : proportion non exposed. 
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- Pi'•1 : proportion ex-exposed after LAG years or more. 
- P/·;, i = 2, ... , I D - 1: proportion ex-exposed less than LAG years. 
- I D = LAG+ 1, i.e. the number of levels of ex-exposure. 
- rp1usf: inflow trend in exposure. 
- rminf: outflow trend in exposure. 
PA+l,ID pA,ID(1 · A 1 A) t+1 = t - rmznt + rp ust 
PA+1,ID-1 pA,ID · A t+1 = t rmznt 
PA+1,0 _ pA,O pA,ID 1 A t+1 - t - t rp USt 
P A+1,i - pA,i+1 . - 2 ID - 2 t+1 - t , z- ... 
pA+1,1 _ pA,1 + pA,2 
t+1 - t t 
pAmin,ID _ pAmin+1,ID 
t+1 - t+1 
P Amin,i - 0 . - 1 JD 1 t+1 - , z- . . . -
pAmin,O _ 1 _ pAmin,ID t+1 - t+1 
Remarks: 
• indices for category and sex are suppressed. 
• P/• 0 and P/•ID are constrained to be 2: 0. 
( 4.1) 
(4.2) 
(4.3) 
( 4.4) 
(4.5) 
(4.6) 
(4.7) 
(4.8) 
• the trends are not specified in 1 year age groups, but in the same age 
groups as in the age group version. 
In the age group version of the model the proportions are shifted over 
time as follows: Let, 
- A: index for age group. 
P A,ID pA,ID(1 · A 1 A) t+l = t - rmznt + rp ust 
PA,ID-1 _ pA,ID m · A t+l - t r znt 
P A,O _ pA,O pA,ID 1 A t+1 - t - t rp USt 
(4.9) 
(4.10) 
(4.11) 
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PA,i - pA,i+l . - 2 ID 2 t+l- t 'l- . . . - (4.12) 
pA,l _ pA,l + pA,2 
t+l - t t (4.13) 
Remarks: 
• indices for category and sex are suppressed. 
• P/• 0 and P/,ID are constrained to be ;::: 0. 
4.1.2 Proportions and !DR's, or PIDR's 
For further calculations the PIDR's are needed, the sum product of P and 
IDR, for all exposure categories and ex-exposure levels within one age, sex 
group. 
The model's database contains IDR's by disease and risk factor for the 
currently exposed. It also specifies the remnant IDR and the LAG. By way 
of a linear interpolation the intermediate ex-exposure levels are assigned an 
IDR. 
(4.14) 
Where: 
- z: index for disease; 
- ID=LAG+1; 
- i: index for time since cessation, from 0 (i=ID) to ;:::LAG years (i=l); 
- indices for risk factor, exposure category, age and sex are suppressed. 
Because the model includes a LAT time dimension, proportions exposed 
('P') and IDR's cannot simply be multiplied to arrive at the right PIDR. 
When proportions at time t are multiplied with the IDR's, we will get 
PIDR's at timet+ LAT. To get PIDR's at t = 0, we need proportions at 
t =-LAT. 
Prevent calculates past proportions, using past trends and current pro-
portions non-, ex-and currently exposed. The proportions at t = -LAT 
are used to calculate PIDR's at t=O, proportions at t = -LAT + 1 give 
PIDR's at t = 1, etc.3 
3 The ex-exposed are as a rule not differentiated by the number of years since exposure 
ceased, so we need past trends. We reconstruct past prevalences by putting equations 
(4.1) and (4.3) in reverse, each year subtracting rmint X PfD from the pool of ex-
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All proportions P are now multiplied with the associated IDR's, sum-
ming over exposure categories and levels and thus producing PIDR's. Then 
the proportions are shifted, trends applied, time updated one year and once 
more proportions and IDR's are multiplied etc. 
If the IDRfac is used, the PIDR becomes: 
en ID 
PIDR~·j,z,•,A = LLP;!£A.1r~~iiDRr,z,•,A,n,iiDRfac: (4.15) 
n=l i=O 
Where: 
- en: number of exposure categories; 
- n: index for exposure category; 
- r: index for risk factor; 
- ID: number of years since cessation ; 
- i: index for ex-exposure level; 
- j=O,l: index for reference (0) or intervention population (1). 
- A: index for age; 
- s: index for sex; 
- z: index for disease; 
- t: index for time. 
Three remarks must be made here: 
• In the basic runs presented in the following chapters the time depen-
dent variable IDRfac is always 1. It has been used only when testing 
the model (see chapter 8). 
• One risk factor may influence several diseases each of which may have 
a different LAT. Prevent always starts at t = -LAT with the disease 
with the longest LAT. 
exposed. If there are at t=-LAT still ex-exposed left, these are assigned to there proper 
place by calculating the proportions exposed from t=-LAT to t=-(LAT+LAG), again 
subtracting rmin1 X P{D from the ex-exposed and putting it in P!f1~AT-t. If at 
t = -(LAT +LAG- 1) the pool of ex-exposed is not exhausted, then the remaining 
proportion is assigned to P_!. LAT' or the ~ LAG year old ex-exposed. 
56 CHAPTER 4. COMPUTER MODEL PREVENT 
• PIDR's (and TIF's, PIF's and EF's as well) are aggregated to 20 
5-year age groups (0-4,5-9, ... 90-94, 95 and over), since the disease 
specific mortality rates, that are used in the population model, are 
for 5 year age groups. In the cohort model, PIDR's are calculated 
as the mean of 5 one-year cohorts, in the age group model the PIDR 
calculated for one age group will be assigned to each 5-year age group 
within that age group. PIDR's for those age groups that are consid-
ered not to be at risk, are set to 1. 
PIDR's thus calculated concern the reference populations and can be used 
to calculate TIF's. For the intervention population the cycle is reiterated 
to take the intervention's shift in P into account. 
4.1.3 Shift in proportions due to interventions 
Interventions in the Prevent model are defined as changes in the prevalence 
of one or more risk factors. Usually these will be reductions in risk factor 
prevalence, although it is of course also possible to simulate an increase in 
risk factor prevalence. Only the cohort model allows for a direct definition 
of prevalence in the birth cohort entering the model at a certain time. 
General intervention With a general intervention, the user can specify 
new proportions of currently exposed by category, sex and age group. 
If the intervention is a reduction in prevalence, i.e. if the new pro-
portion is lower, then some the currently exposed become next years 
one year old ex-exposed. If positive, some non exposed will shift to 
next years proportion exposed.4 There are three characteristics of a 
general intervention which can be defined: 
1. All exposure groups (age, sex and exposure categories) can be 
given the same percentage change, or new prevalence proportions 
can be specified by group. 
2. The year of intervention can be specified, default is 1985. 
3. The intervention can be spread over more than one year (one year 
is default). If this option is chosen, then the proportion currently 
exposed will decrease (or increase) with the same percentage 
each year, so every year a diminishing (or increasing) proportion 
will shift into the 1 year old ex-exposed (or currently exposed). 
Prevalence for the youngest one-year age group The second inter-
vention possibility, in the cohort version of the model only, is to 
iJnterventions are supposed to happen end of period, i.e. an intervention in 1985 is 
supposed to happen at the very end of that year and will take effect in 1986. 
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specify the prevalence of the risk factor for the youngest cohort at 
risk, by exposure category, sex and year. The default is that the 
youngest cohort at risk gets the same proportion currently exposed 
as the one year older cohort. This option allows the user to specify a 
proportion currently exposed between (and including) 0 and 1. 
Unless the user decides to do no intervention at all, in which case the PIDR's 
of the 'intervention' population are identical to those of the reference pop-
ulation, Prevent starts the proportions model again, applying the same 
trends on the new proportions (resulting from the specified intervention) 
and calculating a second set of PIDR's. 
With the two sets of PIDR's the next step is taken. 
4.1.4 From PIDR's to TIF's, PIF's and EF's 
As mentioned before, Prevent allows interventions on more than one risk 
factor simultaneously. PIF's and TIF's need to be disease specific but not 
risk factor specific. When calculating them from the two sets of PIDR's, 
Prevent will sequentially consider all the risk factors that affect a certain 
disease even if no intervention took place. Prevent aggregates all the risk 
factor disease specific PIF's into one disease specific PIF using equation 
3.7. The same procedure is also applied to the TIF's using equation 3.8. 
The EF's, on the other hand, are not aggregated, they are stored to 
disk, disease and risk factor specific, and are only used as output measures. 
They are calculated by equation 3.2. The PIF's and TIF's thus calculated, 
for the complete simulation period will be applied to the age, sex specific 
disease mortality quotients in the population model. 
4.2 The population model 
The population model is always a cohort model, the option 'cohort or age 
group' only exists in the proportions model. The population model consists 
of two parallel populations: one the reference, the other the intervention 
population. Each is divided into two sexes and 96 age groups (0-95). 
In the basic runs, that are discussed in chapters 8-11, the populations 
at t = 0 (=1985) are both set equal to the population of the Netherlands on 
January 1, 1986, assuming that population to be equal to that of December 
31, 1985 (65). For the general mortality, the mortality quotients as calcu-
lated over the period 1980-1984 (66), and the associated life expectancies 
from the same source are used. All these are in 1 year age groups. 
The CBS prognosis for future mortality rates are not used, since the 
expected decrease in mortality depends, among other things, on expecta-
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tions of decreasing risk factor exposition. In Prevent the user can specify 
his own expectations on future risk factor prevalence, and mortality will be 
adjusted accordingly. 
For the number of births the CBS prognosis (medium variant) is used 
until 2000, thereafter the number of births is kept constant at the 2000 
level. 
The disease specific mortality quotients are calculated from the numbers 
of deaths from these diseases5 . These figures are in 5 year groups, by 
primary cause of death in 1985 (67). 
For the reference population the TIF's are applied to adjust disease 
specific mortality quotients, while for the intervention population both the 
TIF's and the PIF's are applied (see equations 4.16 and 4.17). 
zt 
M2••,A = M'•A- LTIFt••,A Mz,•,A (4.16) 
z=l 
zt 
Mtl,•,A = M'·A- L [1- ( 1- TIFt·•,A) X 
z=l 
(4.17) 
Where: 
- A = 0, ... , 95 : one year age index. 
- s = 1, 2 : index for sex. 
- z = 1, ... , zt : index for disease. 
- zt : total number of diseases involved. 
- j = 0,1 : index for reference (0) or intervention population (1). 
- M•,A : constant overall mortality quotient. 
- M{·•,A : adjusted overall mortality quotient. 
- Mz,•,A: disease specific mortality quotient. 
5 We have used the following classification (ICD ninth revision): lung cancer, ICD 162; 
breast cancer, ICD 174~schemic heart disease, lCD 410-414; cerebrovascular accident, 
ICD 430-438; COLD, lCD 490-496; cirrhosis of the liver, lCD 57l;traffic accidents, lCD 
E810-E819; accidental fall, lCD E880-E888. 
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The overall mortality quotient is in one year age groups, and the disease 
specific quotients, TIF's and PIF's in five year age- groups. 
The resulting two sets of mortality quotients are used to calculate next 
year's reference and intervention population by the following equations: 
POP/+1J. 0 = 0.515Bt(1 - M/•1•0 ) 
POP/+2J. 0 = 0.485Bt(1 - M/·2•0) 
POPj,&,A - -POPj,&,A- 1(1- Mj,&,A- 1) 
t+1 - t t 
(4.18) 
(4.19) 
(4.20) 
POPi' 8 "95 - POPi' 8 ' 95(1- Mi' 8 ' 95 ) + POPi' 8 ' 94(1- Mi' 8 ' 94 ) (4.21) t+1 - t t t t 
Where: 
- A= 1, ... , 94: one year age index. 
- s = 1, 2 : index for sex. 
- j = 0,1 : index for reference (0) and intervention population (1). 
- Bt : number of births. 
- M{' 8 'A ,j = 0,1 : adjusted overall mortality quotient. 
Remarks: 
• Births are divided into male (.515) and female (.485), (cf. eq. 4.18 
and 4.19). 
• Eq. 4.21 describes the age group of 95 and over. 
• Migration is assumed not to occur. 
In the population model several output measures (as defined in the previous 
chapter) are calculated, all based on mortality. 
• Disease specific mortality: calculated for both the reference and the 
intervention population by multiplying disease, age and sex specific 
mortality quotients with the one year age groups and summing over 
age. 
• Disease specific mortality difference: calculated by subtracting the 
disease specific mortality of the intervention population from the ref-
erence population. 
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• Overall mortality: calculated for reference and intervention popula-
tion and summed over age. 
• Mortality difference: calculated by subtracting overall mortality of 
the intervention population from that of the reference population. 
• Potential years of life gained: calculated by multiplying age specific 
mortality difference with the current life expectancy of that particular 
one-year age group, and then summing over age. 
• Actual years of life gained: this is calculated by each year, subtracting 
the intervention population from the reference population. 
• Survival curve. This is simulation year specific and is calculated by 
applying the adjusted total mortality quotients of the specified year 
to an initial population of 100,000 newborns. 
• Life expectancy at birth. This is simulation year specific and is cal-
culated by applying the adjusted total mortality quotients to an ini-
tial population of 100,000 newborns, and dividing the resulting total 
number of years lived by 100,000. The value for 1985 comes from the 
Central Bureau of Statistics (CBS). 
Apart from these output measures the PIF's, TIF's and EF's are avail-
able for output as well. 
4.3 Some general remarks on the implemen-
tation 
One of the objectives of the project was that Prevent could be used directly 
by policy makers. Special care was taken to make the model easy to use: 
Prevent is interactive, menu driven, the user is asked to input as few data 
as possible, and usually default values are available. Output is available in 
both graphic and tabular form. It runs on most IBM PC compatibles. 
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Introduction and 
summary 
During the work on the Dutch health policy paper "The Health 2000 Re-
port" a health model was developed with major emphasis on the determi-
nants of health, paving the way for more interest in policy measures in the 
preventive and intersectoral field. During this exercise an attempt was made 
to estimate the relative contribution of each of the health determinants, to 
the health status of the Dutch population. The problems encountered dur-
ing this quantification effort have been reported elsewhere (1,2). A direct 
result of these quantification problems was the research proposal on which 
this project has been based. This entailed that the methodology that would 
be developed should also be applied to Dutch data. 
In the previous section the main emphasis has been on the conceptual 
and methodological aspects of this project. In this section we shall look at 
the data collection necessary to apply the Prevent model to policy making 
for the Dutch population in order to achieve the second objective stated in 
chapter 1: "To distill from existing epidemiologic studies the data necessary 
to apply the Prevent tool to policy making in the Netherlands." 
Since the results are primarily intended for policy making the choice of 
the disease categories to include in the project was determined by criteria, 
relevant to public health policies: 
1. the disease had to contribute significantly to the ill health of the 
Dutch population, 
2. the disease should have known risk factors upon which interventions 
can reasonably be applied. 
The research proposal specified that the project should concentrate on 
three main categories of disease that contribute significantly to premature 
mortality, morbidity and invalidity in the Netherlands. These three main 
groups were: cardiovascular disease, cancers and accidents. 
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Together they represent: 
• 76% of total mortality (average '76-'80) 
• 72% of potential years oflife lost (average '76-'80) 
• 25.7% of hospital admissions (1982) 
• 17.1%ofinvaliditypensions (1983) 
Within these three main categories the following eight diagnostic entities 
(ICD, ninth revision) were specified: 
-Ischemic Heart Disease (IHD) 
-Cerebrovascular Diseases (CVA) 
-Cancer of the lung (Lungca.) 
-Cancer of the breast (Brstca.) 
-Cancer of the colon (Colon ca.) 
-Cancer of the stomach (Stomachca.) 
-Traffic accidents (Tr. ace.) 
-Other accidents (Oth. ace.) 
(except suicide and homicide) 
(ICD 410-414) 
(ICD 430-438) 
(ICD 162) 
(ICD 174) 
(ICD 153) 
(ICD 151) 
(ICDE800-E848) 
(ICDE849-E999 except 
E950-E969) 
Table 5.1 shows the burden of ill health occasioned by these eight disease 
categories in more detail. They are a logical starting point for a risk factor 
intervention study. 
First the risk factors, generally accepted and well documented, for 
each of these disease categories were identified. In the following phase we 
searched in the opposite direction and tried to identify the most important 
diseases known to be (partly) influenced by the risk factors identified in the 
first phase. Both steps will be summarized in the chapter 5. The necessary 
quantification of these relationships will be made explicit in chapter 6. 
In the search for the risk factor-disease combinations to include in the 
current version of the Prevent model, preference was given to those for 
which there is sufficient evidence of the causality of the relationship. Not 
only in the sense that exposure to the risk factor influences disease incidence 
but also the fact that that influence is reversed once exposure ceases. This 
meant that for certain diseases spch as stomach cancer the evidence on 
the etiology was as yet insufficient to include the disease in the model. For 
other diseases such as colon cancer there appears to be a causal relationship 
with exposure to certain risk factors but there is not yet a consensus about 
the quantification of the relationship is still uncertain. In that case the 
particular risk factor-disease combination was not included in the current 
version of the model. 
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Table 5.1: Burden of disease in 1985 for major diagnoses 
Incidence Mortality Hospital Adm. Hospital 
per100,000 per 100,000 per 100,000 days 
M F M F M F M F 
Cardiovascular Disease 
- -
391 340 1474 1010 14.8 18.2 
myocardial infarct 370 390 171 107 280 113 16.0 17.2 
ischem. heart disease 
- -
39 27 322 139 9.7 12.8 
cerebrovasc.acc. 
- -
71 93 178 161 23.5 29.5 
Cancers 335 329 266 187 821 996 17.5 16.6 
larynx, lung 95 11 105 12 196 24 18.9 21.5 
breast 1 97 - 40 1 144 19.0 18.7 
cervix - 30 - 4 - 47 - 11.5 
colon 22 27 18 21 29 34 26.5 30.9 
stomach 23 13 22 13 35 18 23.1 28.3 
liver, gallbladder 4 8 5 8 
- - - -
Accidents 
- -
35 24 847 628 14.0 20.6 
occupational 908 73 1 - 39 2 - -
traffic 489 266 18 7 212 110 17.2 18.9 
other 2210 2340 16 17 
- - - -
Source: 234 
For the calculations in Prevent three types of data are needed: data on 
IDR for all exposure categories, data on the prevalence of risk factors in 
the Dutch population and data on the time dimensions. 
The IDR data proved to be abundant and for most risk factors relatively 
consistent once corrected for different characteristics ofthe population stud-
ied. This supports the hypothesis that the relative risk is a biological con-
stant. In the previous section it was shown that given the assumption of 
an independent distribution of risk factors and multiplicative relative risks, 
the existence of unknown confounders in the population of the study will 
not affect the relative risk found. Thus relative risk estimates can indeed 
be transferred from one population to another as long as they are strati-
fied by age, sex, and exposure category. This stratification of the relative 
risks is an essential element for the causality of the Prevent model, so IDR 
values were used with as much detail as possible. In some cases additional 
dimensions were only available without for instance age stratification, in 
those cases precedence was given to the dimensions age, sex and exposure 
category. 
The most difficult IDR value to determine was the remnant IDR after 
cessation of exposure. Although many studies examine the effect of expo-
sure on disease incidence, cessation of exposure, especially in the general 
population, is far less frequently studied. Since the time between first ex-
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posure and mortality is often very long in chronic disease epidemiology, a 
preventive policy that aims at health benefits in the near future, will have 
to concentrate on both prevention and cessation of exposure. The extent 
to which the relative risk is reduced after cessation of exposure is therefore 
of great importance in policy making. For some risk factors we had to rely 
on expert judgement to determine the remnant IDR. 
The second category of required data is on the prevalence in the Dutch 
population of the risk factors for which IDR data existed. Those were usu-
ally available, although such data are often collected only after evidence of 
a risk factor-disease relationship has been found in other countries. This 
was one of the reasons why the risk factors finally incorporated in the Pre-
vent model are by necessity the more obvious ones. Most of the prevalence 
data were stratified by age, sex and exposure category and where the exact 
categories did not coincide with those used for the IDR data, the data were 
converted. Only in a few cases data were available over a number of years 
so that trends in prevalence could be deduced. 
For some risk factors the prevalence data do not stem from a representa-
tive sample of the Dutch population. In chapter 8 several initial prevalence 
input data were applied to see whether the model is very sensitive to small 
variations in the initial risk factor distribution. 
Finally data are needed concerning the time dimensions LAG and LAT. 
For some risk factors these could be deduced from the longitudinal studies 
with sufficient length of follow up, for others these data could not be found 
and again had to be supplied by expert judgement. 
The following chapters will give a brief overview of the epidemiologic 
literature from which the data were derived. In the appendix C a short 
summary of the values of the input data is given and some of the summary 
tables of trials published elsewhere are included in appendix B. 
Chapter 5 
The choice of variables 
5.1 Diseases and their risk factors 
Two criteria were applied to decide which risk factors to include in this 
version of the model: the availability of good quantitative data, and the 
magnitude of the effect of the risk factor on the populations health. 
1. Quality of the evidence 
Since the quantification in this model is primarily meant for pol-
icy making rather than for hypothesis generation, those risk factors 
for which a reasonable consensus exists about their influence on dis-
ease incidence, were most interesting. In most reviews the traditional 
epidemiological criteria such as consistency, strength, specificity, co-
herence and temporal relationship of the association, were applied 
to determine causality. However the quantity and the quality of the 
evidence varied considerably. This meant that for some disease cate-
gories or risk factors the quantitative evidence was as yet insufficient 
to include them in the current version of the model. 
2. Magnitude of the influence 
The magnitude of the overall influence of a risk factor on the health 
of a population was the second important criterion. Several variables 
determine the magnitude of the influence of a risk factor (intervention) 
on the health of a population. 
• The relative risk, which quantifies the extent to which a certain 
exposure will increase the individuals absolute risk of getting a 
specific disease. 
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• The prevalence of the risk factor in the population, which, to-
gether with the relative risk, will determine the influence of a 
risk factor on the incidence of a specific disease at the popula-
tion level. 
• The relative importance of the disease category in question for 
the health benefit measure used. 
Risk factors that have a low relative risk such as hypertension will 
be included because of the high prevalence of hypertension in the 
population and because of the importance of IHD in the mortality 
of the Dutch population, while a risk factor such as asbestos with a 
very high relative risk will be omitted even though lung cancer is an 
important cause of death, simply because so few people are exposed 
to asbestos nowadays. 
5.1.1 Ischemic Heart Disease 
Figure 5.1: The risk factors for Ischemic Heart Disease 
Cigarette Smoking 
Hypertension 
Hypercholesterolaemia 
Cardiovascular disease, with special emphasis on acute myocardial infarc-
tion and other ischemic heart disease, has received considerable attention 
in recent decades: the epidemic of premature death due to ischemic heart 
disease among_ middle-aged men in the 1950's and 1960's did indeed warrant 
such attention (3-11). 
Initially epidemiological research concentrated on identifying the risk 
factors in that epidemic. The Framingham Study ( 4, 12, 13) in the US, is 
maybe the best known of the many prospective studies that have identi-
fied subgroups in the population that were apparently at a greater risk of 
developing ischemic heart disease (5, 11, 13, 15-35). They were followed 
by an even larger number of studies attempting to measure the effect of 
interventions on these risk factors (36-69). 
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Many different risk factors were hypothesized: serum cholesterol levels, 
hypertension (systolic and diastolic), cigarette smoking, level of physical ac-
tivity, Type A personality, lipoproteins LDL and HDL (70), diabetes, etc. 
The final conclusion from the literature has been that there are three inde-
pendent, major risk factors identified that are important in the occurrence 
of ischemic heart disease (71-75) 
• Hypertension 
• Hyperlipidemia (serum cholesterol, LDL and the protective influence 
of HDL) 
• Cigarette smoking 
On the relative importance of these three risk factors authors may still 
disagree. Goldman (76) claims that changes in serum cholesterol and smok-
ing habits are responsible for more than half of the considerable decline in 
IHD mortality rates in the US between 1968-76, while Pell (77) in the 
DuPont Company Study, identifies "improved control of hypertension as a 
major factor in the declining incidence of coronary heart disease". 
The intervention studies, of which the MRFIT ( 40) study attracted 
much interest, have not yielded the expected positive results. Although in 
theory it was easy to identify "the right thing to do" (78, 79), the effect 
of the risk factor intervention is not yet conclusively agreed upon (37, 41, 
80-86). 
These disappointing effects have generated a discussion on the possi-
bility and the acceptability of different preventive interventions, such as 
population versus high risk approach or lifestyle changes versus medication 
(36, 42, 45, 62, 69, 87-92). 
5.1.2 Cerebrovascular Disease 
Figure 5.2: The risk factor for cerebrovascular disease 
~~-Hy-pe_rt_•n-sio_n ______ ~~L-cv_A----~ 
Although cerebrovascular disease encompasses a number of different disease 
processes (for instance ischemic cerebrovascular disease, and hemorrhages), 
these distinctions are not always correctly made in mortality statistics. In 
most epidemiological studies therefore, the diagnoses are considered at an 
aggregated level. 
76 CHAPTER 5. THE CHOICE OF VARIABLES 
Contrary to the ischemic heart disease, there has been a reduction in 
cerebrovascular disease mortality both for men and for women for some 
decades. The most important risk factor identified in CVA remains hy-
pertension. In some instances it is suggested that hypertension is only an 
intermediate risk factor, which itself can be influenced by diet, ( 47, 93), 
oral contraceptives (94) or alcohol (95). Intervention trials have shown a 
marked improvement in CVA mortality. Randomized trials on the treat-
ment of mild hypertension pooled together (87) seem to indicate that even 
a small lowering (7 mm Hg) of blood pressure over longer periods of time 
could result in large gains in preventing premature mortality due to stroke. 
5.1.3 Lung cancer 
Figure 5.3: The risk factors for lung cancer 
Cigarette Smoking 
Occupational Exposure 
Lung cancer may perhaps be viewed as the prime example of the contribu-
tion that epidemiological research can provide towards the understanding 
of a chronic disease epidemic in a population. Although Doll and Hill's pub-
lication in 1950 (96) is often viewed as the first study presenting reliable 
data on the relationship between cigarette smoking and lung cancer, some 
skepticism continued to exist even after its wide acclaim (97, 98). Many 
similar studies were set up to find correlations between cigarette smoking 
and lung cancer. They all confirmed the relationship found by Doll (99-
105). The result was among others that governments took an interest in 
smoking as a major threat to the populations health. 
As early as 1964 the US Department of Health published the first of what 
would prove to be a long succession of reports from the Surgeon General 
on Smoking and Health. The British DHSS and the WHO also produced 
reports on the subject. 
Nowadays there is little doubt about the strong causal relationship be-
tween cigarette smoking and lung cancer. The causal nature of the relation-
ship has recently been further reinforced by reports of a falling lung cancer 
mortality rate, presumably due . to a drop in the prevalence of cigarette 
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smoking (106-109). 
Probably several factors are involved that ultimately decide which in-
dividual will develop lung cancer: for instance a genetic component (110) 
or an excess risk in those exposed to occupational hazards such as asbestos 
or ionizing radiation. But even within these subcategories smoking will 
greatly enhance the risk of ultimately developing lung cancer. 
5.1.4 Breast cancer 
Figure 5.4: The risk factors for breast cancer 
The incidence of breast cancer is of particular importance in industrialized 
countries where it usually is the most frequent cause of cancer mortality in 
women. The Netherlands are no exception, in fact their age adjusted death 
rate for this disease is one of the highest in the world. 
Some interesting hypotheses for possible risk factors have been postu-
lated by epidemiologists (review by Kelsey 111). It appears beyond doubt 
that there is a genetic predisposition to breast cancer that is important: in 
general a 2 to 3 fold increase in risk has been reported in women with a 
first degree relative affected. In a few situations there appear to be even 
higher associated risks. 
Because of the nature of the organ involved it is not surprising that 
some of the hypotheses explored have been in the field of the reproduc-
tive variables. It now seems well established that an early first birth (i.e. 
full-term pregnancy) can be considered a protective factor. There is some 
suggestion that high parity also has a protective effect, independent of the 
age at first birth. Breast feeding, once thought to reduce the risk, appears 
to be unimportant once a correction for parity has been made. Age of 
menarche however remains of importance. 
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A logical sequence to the interest in reproductive variables, was the 
investigation of the role of hormones in the risk pattern of human breast 
cancer. Both endogenous hormones and exogenous estrogen were reviewed 
(112-119). There has been consistent evidence that estrogen increases the 
risk of breast cancer, resulting among others in a suggestion at one point 
to adopt tamoxifen (an anti-estrogen drug) as a preventive measure (120). 
The latest results of the "nurses study" in the US, reported by Lipnick 
(121), however suggest only a very slightly elevated risk in pre-menopausal 
women who currently use oral contraceptives. 
The other large field of hypotheses lies in the direction of diet, obesity 
and body build (122-125). Intercountry studies have shown a very strong 
association between total dietary fat intake and age adjusted breast cancer 
death rates. 
Even differences within countries, regionally as seen in England (126) 
or between sub populations such as the Seventh day Adventists in the US 
population, have shown positive correlations between fat intake and breast 
cancer mortality. However these studies are not considered definite proof 
of a direct causal relationship. One of the hypotheses postulated has been 
that obesity is the intervening variable explaining the relationship (127). 
Measures of body build such as weight, weight/height ratio's, height and 
total body mass have been explored among others by de Waard (125, 128, 
172). 
Recently alcohol consumption has been implicated in the occurrence of 
breast cancer. The results of different studies {129-131) remain contradic-
tory but the hypothesis deserves to be explored more fully since even a 
very weak association would be of considerable importance because of the 
widespread consumption of alcohol in industrialized countries. 
Finally, one interesting finding of the epidemiological studies on breast 
cancer, has been the distribution of cases over socioeconomic classes. Con-
trary to most other causes of death the risk of breast cancer is higher among 
the higher socioeconomic classes (22, 132). Whether this is due to an un-
even distribution of the above mentioned risk factors over the socioeconomic 
classes has not yet been fully established. 
5.1.5 Colon cancer 
In recent reviews of the literature concerning possible explanations for the 
variation in the occurrence of colon cancer (125, 133, 134) the suggestion 
was made that the reported incidence is greatly influenced by diagnostic 
traditions. The correlation between the incidence of colon cancer and rectal 
cancer suggests that there is no clear distinction between the two categories 
(135). 
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Figure 5.5: The risk factors for colon cancer 
In both instances, but particularly in the case of colon cancer, dietary 
variables have been suggested as possible risk factors (136). In their in-
tercountry study Armstrong and Doll (137) identified a strong correlation 
between total fat intake and meat consumption or animal protein content in 
the regular diet, and the occurrence of colon cancer. Phillips (138) found an 
association, within the Seventh day Adventist population, of several more 
specific food items such as coffee, meat, dairy products and green salad. 
Total weight was also negatively implicated, not only in persons who are 
overweight as would be expected, but also in those who are more than 10% 
underweight. It has been suggested that the underlying mechanism of the 
influence of dietary factors is represented by the endogenous production of 
bile acids, and that one of the important intervening variables is the speed 
of passage of the stool through the colon. Factors that appear to be of 
interest in this respect are fibre content of the diet (139), which increases 
stool bulk and helps dilute bile acids, and physical activity which tends to 
stimulate colon peristalsis (140-142). Another protective agent against bile 
acids and hence against colon cancer, appears to be the presence of calcium 
salts. 
In Millers review article for the IARC (125), two additional factors are 
discussed: the apparent protection provided by cruciferous vegetables and 
the still unresolved controversy over the relationship between serum choles-
terol and colon cancer. Results from preventive intervention trials for car-
diovascular disease (for instance the MRFIT and the WHO clofibrate trials) 
revealed an increased mortality from cancer in the intervention group, with 
a supposedly lowered serum cholesterol. However other studies have shown 
contradictory results, even implicating high dietary cholesterol levels as a 
risk factor in colon cancer (143-148). 
Cambien {149) proposes as an explanation, that the lowered serum 
cholesterol is not a risk factor in colon cancer but that on the contrary 
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it is the direct result of the cancer disease process. Miller on the other 
hand suggests: "that high fat (and/or cholesterol) levels in the diet of in-
dividuals with a metabolism that maintains a low serum cholesterol, result 
in a high excretion of cholesterol breakdown products in the intestine .... ". 
There have also been occupational factors implicated in the occurrence 
of colon cancer. Spiegelman (150) reports a large number of possible ex-
posure effects most notably solvents, fuel oil and abrasives for men and 
solvents for women. She also reports a strong correlation with occupational 
stress especially with regard to "high demand low control" jobs. 
5.1.6 Stomach cancer 
Figure 5.6: The risk factors for stomach cancer 
I Diet H Stomach Cancer I 
The point of interest in this particular type of cancer, to epidemiologists 
and health planners lies in the fact that the age specific incidence (and 
mortality) rates have been steadily going down in most countries for both 
men and women since the 1960's. The Netherlands form no exception as 
can be seen in from the CBS adjusted death rates, figure 5.7. 
Figure 5.7: Mortality from stomach cancer in the Netherlands, indices of 
adjusted death rates, 1960=100 
25 ~~~~~~~~~~~uw~ 
1960 1965 1970 1975 1980 1985 
1960-1968 I.C.D. 1955 nrs. 1 151 
1969-1978 I.C.D. 1965 nrs. 151 
vanaf 1979 I.C.D. 1975 nrs. 151 
Although several suggestions about possible causes for this decline have 
been put forward, for instance that of an improvement in the storage of 
food (due to refrigeration possibilities) and a subsequent decrease in the 
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contamination by micro organisms (135), no agreement has been reached 
beyond the fact that it seems to be the nutrition in childhood and early 
adult life that determines the incidence of stomach cancer. 
Armstrong and Doll (137) have reported a negative correlation with 
total fat consumption as the strongest intercountry association with stom-
ach cancer. Other dietary factors have been investigated. A recent case-
control study, reported by Risch et al (151) found results that did not differ 
markedly from what they found in a review of the literature: it implicates 
nitrite, chocolate and carbohydrates as risk factors in stomach cancer, while 
dietary fiber, and citrus fruit intake (Vit.C. to a lesser extent) provided a 
protection against stomach cancer. At this moment we feel the quantitative 
evidence is not sufficient to include risk factors for stomach cancer in the 
model. 
Accidents 
Accidents in general, form an important cause of mortality and of use of 
medical services as a result of injury. Contrary to the other disease cat-
egories however, the risks involved are largely dependent on man made 
products and on individual behavior. Even the environmental variables 
that may influence exposure risk or injury risk are often created by man. 
The result is that types of accidents and injuries are very much cultur-
ally and geographically determined: what is considered dangerous driving 
on the crowded highway between Amsterdam and The Hague, is virtually 
without risk on lonely stretches of road for instance in Alaska, traditions of 
child rearing will make medicines and cleaning products a hazard in some 
countries, but much less so elsewhere. 
Contrary to other disease categories there is no direct simple relationship 
between prevalence of risk factors and incidence of injuries. Some risk 
factors may influence the risk of accidents, while others will influence the 
risk of injuries as a result of the accident. 
At both levels, risk factors and preventive interventions can be consid-
ered. Factors influencing the risk of exposure are mostly determined by the 
availability of the "object" containing a risk of accidents. Availability is 
the result of general socioeconomic developments and fluctuations outside 
the health field: new technological developments such as the invention of 
the automobile, postwar prosperity bringing the automobile within finan-
cial reach of many, the oil crisis of 1973 followed by a sharp reduction in the 
use of the automobile etc. Sometimes it is possible to intervene at this level 
for instance by strictly regulating the sales of dangerous products. However 
most often factors other than the health risks take priority. Exposure rates 
are often unavailable at population level. 
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The risk of accidents among the exposed is better quantified, in statistics 
about the number of automobile accidents per km. travelled or per hour 
exposed to traffic. These can be of interest for comparative studies over 
time or between countries, but since they are based on population averages 
there are no distinct exposure categories. Furthermore many accidents are 
not recorded either because they were too unimportant to involve the police 
or the insurance companies, or there were no personal injuries. The risk 
of accidents to the exposed therefore is likely to be under recorded. Risk 
factors of importance on this level concern the safety of the product and 
the behavior of the individual. In the latter we are not only concerned with 
"risk seeking behavior" or "accident proneness" but also for instance with 
the use of alcohol. 
At a third level the number of injuries among all accidents is of interest. 
Here again the relevant statistics are often not available, since the total 
number of accidents is not known and there is often no connection between 
the registration of accidents on the one hand and the number and type of 
injuries on the other hand. Data are available on the type of activity or 
product involved per number of injured and type of injury. They do give 
an idea of the most frequently involved products or situations but they are 
not incidence rates. 
The effect on mortality due to accidents is known for certain preventive 
interventions in the past, for instance on the use of motorcycle helmets. 
The changes in certain host characteristics, considered as risk factors, and 
the concurrent changes in the severity or lethality of certain injuries have 
sometimes been explored, such as osteoporosis for fractures of the lower 
extremities in the elderly (153). 
In the following paragraph some risk factors at the individual level and 
some estimates of the preventive effect of certain regulations in the past 
will be presented, based on the available literature. 
5.1. 7 Traffic Accidents 
Traffic accidents have been included in this study because of their impor-
tance as a cause of death. What makes them particularly relevant for a 
policy based on prevention is the fact that the victims are often young so 
that traffic accidents contribute substantially to premature mortality and 
to potential years of life lost. They are also responsible for a large category 
of the severely handicapped patients. 
Looking at the age adjusted mortality due to of motor vehicle accidents 
over the last 35 years in the Netherlands, there is a rapid rise in the first 
two decades, followed by the equally rapid decline in the subsequent years. 
Some of this trend may be due to the experience gained as a nation 
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Figure 5.8: The risk factors for traffic accidents 
Figure 5.9: Hospital admissions by age and by type of vehicle 1982-83 
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becomes motorized and used to the presence of automobiles. However some 
of the decline can be attributed directly to preventive measures (154). This 
does not only apply to motor vehicle accidents but also to motorcycle and 
bicycle accidents. Some of the measures mentioned have been: speed limits, 
compulsory seat belts, child restraints, motorcycle helmets, safety of the 
roads, visibility of cyclists etc. 
Figure 5.9, the hospital admissions by age and by vehicle involved in 
the accident, shows a very distinct pattern, which has been confirmed in 
other countries. It appears that the age groups that just start participating 
in a certain type of traffic situation are most often victims of an accident. 
Young children (6-11 years) first walking to school alone, the 12-14 year 
olds first riding their bicycles alone, the 16 year olds allowed to ride a 
bicycle with auxiliary engine and the 18 year olds with their new drivers 
licence. As they gain experience with their particular vehicle the accident 
rate drops sharply, only to rise again when old age makes traffic participants 
vulnerable. The first element is interesting since it has nothing to do with 
increasing incidence with age often encountered in other disease categories, 
but is the result of a distinct influx of inexperienced first users at a certain 
age. As such this risk factor will be influenced by regulations determining 
age limits as well as by demography. The third risk factor to be included 
is the use of alcohol. 
5.1.8 "Other" accidents 
In the Dutch statistics other accidents are called "accidents in private life" 
to distinguish them from occupational and traffic accidents. It also makes 
them a very diverse rest group. They include: drownings, poisoning, acci-
dental falls, sports accidents and all the cuts, fractures and other injuries 
that are serious enough to warrant medical attention. Some of them seem 
to be the inevitable consequence of living and especially of growing up. Not 
all of them can be prevented, although serious efforts are made, for instance 
through health education at the well baby clinics, to limit the more serious 
accidents. Because they are such a diverse group it is difficult to identify 
important risk factors, 
We have therefore chosen to limit ourselves to the accidental fall, for two 
reasons: the elderly are most often seriously injured by an accidental fall, 
and it is an important cause of death but an even more important cause of 
disability and of dependency and institutionalization, especially for elderly 
women. With the increasing demographic shift towards the older ages it is 
therefore bound to be an important health problem in the years to come. 
The other reason for this choice was the evidence of recent shifts in the 
incidence, particularly of hip fractures following accidental falls suggesting 
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an influence of exogenous risk factors possibly amenable to prevention (155). 
The most likely hypotheses at the moment concentrate on the role of 
alcohol and osteoporosis. 
Alcohol is involved in the risk of accidents while osteoporosis is a factor 
that influences the risk of injury following an accidental fall. Osteoporosis 
has received considerable attention in epidemiology lately (156), partly be-
cause statistics show a sharp concurrent increase of osteoporosis and of hip 
fractures (157, 158). Hoogendoorn (153) has shown that there is a sharp 
increase in hip fractures in the Netherlands and Duursma (157) has used 
data on trends in osteoporosis and hip fractures to estimate incidence in 
the future. It should be kept in mind however that these are based on 
hospital admission data and as such may not necessarily illustrate a rise in 
incidence. 
Cummings (156) shows that osteoporosis is primarily a risk factor for 
post menopausal women. Estrogen has been identified as a protective fac-
tor for osteoporosis and post menopausal estrogen has been shown to be 
beneficial. Continuous (sometimes cyclical) use of estrogens for at least 5 
years after menopause appears to reduce the risk of hip fractures by 50%. 
Other reproductive factors such as age at menarche and age at first full 
term pregnancy do not appear to be important. 
Other risk factors investigated are in the dietary field. Obesity seems 
to protect against bone loss, possibly by increasing the amount of available 
estrogen. The evidence on calcium intake is controversial. Probably the 
diets of most western women contain insufficient calcium to prevent persis-
tent net loss of calcium, especially after menopause, however the efficacy of 
calcium in the prevention of osteoporotic fractures is not proven. The re-
cent consensus meeting on osteoporosis in the Netherlands (159) suggested 
an increase in the recommended daily calcium intake, not only for post 
menopausal women but also for children and young adults in an effort to 
increase the peak bone mass. Other dietary hypotheses such as the negative 
effect of our western levels of protein intake, and its influence on the phos-
Figure 5.10: The risk factors for accidental fall 
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phorusfcalcium balance (159, 160) are not yet sufficiently agreed upon to 
warrant interventions, except in an experimental setting. The same applies 
to fluoride therapy {161 ). 
Physical activity appears to have some influence on peak bone mass in 
youth and on bone loss in the elderly. The Dutch consensus meeting has 
advised to include regular exercise in any therapeutic regimen (159). 
Conclusions 
From a survey of the existing evidence it is evident that often the same 
risk factors are implicated. There are several possible explanations for 
this phenomenon. It is quite conceivable that the strong correlation found 
between a risk factor and a disease inspires epidemiologists to investigate 
the same risk factor in relation to other diseases as well. This was certainly 
the case for cigarette smoking. Following its "discovery" by Doll it was 
tested for a large array of other diseases, some of which did indeed show a 
relationship. 
It is in itself not surprising that concurrent changes in incidence such 
as IHD and lung cancer are explained by the same risk factors. After all 
those risk factors represent the most significant changes in the "macro & 
micro environment" during that same period and may well be responsible 
for several different diseases processes. 
One of the theories suggested as an explanation in this context has 
been that of the free radicals and excited oxygen. For the time being this 
issue has not yet been resolved, but the phenomenon of the concurrent risk 
factors remains and in fact is a major point of interest in this study. In the 
following paragraphs the relationships described so far will be presented 
from the risk factor i.e. the preventive policy point of view. 
5.2 Risk factors and diseases 
5.2.1 Cigarette smoking 
Smoking, and in particular cigarette smoking, is the most widely studied 
risk factor in epidemiology (25, 26, 74, 103, 105, 162-164). Although several 
trials have shown correlations with a large number of disease categories, we 
shall concentrate on the three most important ones. 
The relationship between cigarette smoking and lung cancer and is-
chemic heart disease has already been extensively discussed in the previous 
pages. We have added here the category of Chronic Obstructive Lung Dis-
ease (COLD) which is now "the best understood of all the diseases caused 
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Figure 5.11: Diseases influenced by smoking 
by smoking" (165). 
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Important variables in the relationship between smoking and these dis-
ease categories are: 
• the amount smoked 
• the age at which smoking was first started 
• filter versus non-filter cigarettes and inhalation habits or more gen-
erally the tar and nicotine contents of cigarettes for lung cancer and 
the CO contents of the smoke inhaled for ischemic heart disease (19, 
58, 166) 
• the number of years that elapsed since smoking cessation 
5.2.2 Hypertension 
Figure 5.12: Diseases influenced by hypertension 
IHD 
Hypertension 
CVA 
Hypertension, or more realistically blood pressure level, is a strong predictor 
for ischemic heart disease and cerebrovascular accidents (167). Originally 
it was thought that only "malignant" hypertension, that is blood pressures 
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of> 160 mmHg (systolic) and/or> 105 mmHg (diastolic), was dangerous. 
Now there is evidence that the risk of IHD and of CV A simply increases 
with the higher blood pressures measured. There is no real cut-off point 
below which there is no increased risk. 
For the purpose of this exercise the WHO classification in mild and 
severe hypertension is used, with the albeit arbitrary cut-off-points of: 
Normotensive 
Mild hypertensive 
Severe hypertensive 
DBP <90 and SBP <140 
DBP 90-94 and/or SBP 140-159 
DBP ~95 and/or SBP ~160 
In this classification the lowest category is considered the reference pop-
ulation against which the relative risks are measured. We are well aware 
that this artificial segmentation becomes especially troublesome in popula-
tions where blood pressure increases with age. There has been discussion 
about whether one should consider that age related risk as pathological or 
not. Given the fact that there are populations where this increasing blood 
pressure with age is not observed, we will assume that even for elderly peo-
ple a higher blood pressure is a pathological though common phenomenon. 
However the relative risk for the elderly is lower than for younger people 
with the same level of hypertension. 
5.2.3 Diet 
As has been discussed in the analysis of the disease categories, many dietary 
elements seem to be important in the etiology of diseases. Some are very 
specific and well documented, for others the evidence is still controversial. 
Although it may be interesting at a later stage to run the model for some of 
these more controversial food items, to get an impression of their possible 
impact, we have decided to limit ourselves in this first exercise to two major 
diet related elements: 
• Serum cholesterol 
• Measure of obesity 
Serum cholesterol has since long been identified as a risk factor in the 
occurrence of atherosclerotic disease and its clinical manifestation of cardio-
vascular disease (168). Intervention trials, set up to reduce cardiovascular 
risk factors (45, 88, 169), have successfully managed to lower serum choles-
terol levels, resulting in a decreased number of cardiovascular deaths in the 
intervention groups. However, investigators discovered that these health 
benefits were accompanied by an increased number of cancer deaths, most 
notably from colon cancer. Since then several studies were started to test 
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the hypotheses that a high or a low serum cholesterol level may be a risk 
factor for cancer of the large bowel. As has been discussed earlier, the 
question is still controversial. 
Obesity in itself appears to be both a direct and an indirect risk factor 
(123, 170, 171). It influences conditions like hypertension (and diabetes) 
which, although themselves causes of illness and death, are also important 
as risk factors in other disease categories. The same applies to the estrogen 
levels: it has been hypothesized that estrogen products are produced in 
fat cells and that as such obesity increases the levels of available estrogens, 
especially in post menopausal women. There is strong evidence from studies 
like those from de Waard c.s. (172) that obesity is correlated directly to 
the risk of breast cancer for post menopausal women. 
Direct evidence is available and recognized as important by a.o. the 
Committee on Diet, Nutrition and Cancer (173), for the cancer sites of 
breast and colon. There also appears to be a relationship between the 
dietary fat intake and the level of serum cholesterol, although the influence 
on disease incidence (f.i. IHD) then becomes indirect. The same applies to 
obesity: a high fat intake is often associated with a high total caloric intake 
and hence with obesity. High fat is therefore not considered separately. 
5.2.4 Alcohol 
Figure 5.13: Diseases influenced by alcohol 
Alcohol abuse has long been recognized as a major cause of disease (17 4). 
Prevention of excessive drinking has been tried in different periods of his-
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Figure 5.14: Alcohol consumption (in liters alcohol ad 100%) in the Dutch 
population 1960-83 
Source: 234 
Income 
X1000 
40 
Alcohol 
Consumption 
35 14 
13 
30 12 
11 
25 
20 
15 
10 
5 
0 
-Income development 
-·-·alcohol consumption 
--- Relat.price index alcohol 
Years 1960 62 64 66 68 70 72 7 4 76 78 80 82 84 
tory. Now, with the increasing financial possibilities of most families in 
Western European countries, there has been an important increase in the 
prevalence of drinking. Figure 5.14 shows the average amount of alcohol 
consumed by the Dutch population since the Second World War. 
Much of this drinking is so called "social drinking" and not generally 
classified as alcohol abuse. However recent epidemiologic literature has 
shown that even such "moderate" amounts of alcohol intake influence a 
persons health (28, 130, 131, 175-177), for certain diseases it is a risk factor, 
for others there appears to be a protective influence. 
Liver cirrhosis is included in this version since it so directly related to 
alcohol abuse. 
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5.2.5 Reproductive variables 
From the hypothesis that apart from lifestyle differences (178,179), hor-
monal factors may be partly responsible for the differences in life expectancy 
between men and women (180), studies evolved within the female popu-
lation comparing pre- and post menopausal disease. From these studies 
estrogen has come forward as an important factor influencing health. 
For osteoporosis and IHD, estrogen is a protective factor, and the risks 
increase sharply after menopause. In the case of breast cancer and cancer 
of the corpus uteri (63, 119, 181-183), estrogen has to be considered a risk 
factor. Women with an early menarche and a late menopause (therefore a 
long exposure to estrogen) have an increased risk for breast cancer (184). 
The evidence on oral contraceptives and an increase in risk of IHD, cancers 
and CVA remains controversial and mostly seems to affect pre menopausal 
women (94, 185, 186). 
There is a direct link between the risk of breast cancer and the mothers 
age at first full-term pregnancy. A mother under 20 years will have 1/3 the 
risk of a mother over 35 (187). 
Conclusion 
Although the health model used in the Health 2000 Report includes a wide 
range of determinants of health, not only individual lifestyles but social and 
physical environmental factors as well, these last risk factors have proved to 
be much more elusive in epidemiological research than the so-called lifestyle 
factors. 
This lack of suitable data on the relationship between risk factors present 
in our physical environment, was already mentioned in the Health 2000 
Report. Proposals were made for scenario studies, especially on the possible 
long term toxic effects of chemical products. As soon as reliable data on the 
relationship between these risk factors and specific disease entities become 
known they can be incorporated in the present model. 
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Chapter 6 
Data used in the model 
In this chapter the quantitative data both for the prevalence of the risk 
factor in the Dutch population and for the relative risk ratio's that apply 
to these risk factors and each specific disease category will be discussed. 
These data were used in the runs with this basic version of the model 
described in the following chapters. 
Prevalence data 
The prevalence data on risk factors in the Netherlands are scarce. There 
have been a number of surveys in the first half of the 1970's (COPIH, CB 
project, KRIS, ONNO, Boot, etc.) in which some prevalences were mea-
sured. These were primarily geared towards cardiovascular risk factors, and 
covered rather different populations, none of which was really a represen-
tative sample of the Dutch population. There has been one health survey 
since, which is more general in scope but which is restricted to one resi-
dential area, Zoetermeer (188). The results of that survey tend to differ 
somewhat from the earlier surveys. 
For alcohol and smoking the data are more complete: there have been 
continuous surveys on smoking behavior in the general population since 
1970 and they are considered reliable, especially on the total percentage 
of smokers. They are less reliable on the amount smoked, when compared 
to figures on the tobacco taxes administered by the National government 
and the statistics issued by the industry. It is generally assumed that the 
under reporting of the number of cigarettes consumed is merely an under 
reporting by smokers, not an under reporting of the number of people who 
smoke. It amounts to an average of 6-7 cigarettes a day per smoker. The 
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data on the amount smoked have therefore to be used with caution. 
The same applies to the available statistics on alcohol consumption. 
Again the data come from two different sources: surveys of drinking habits 
in the general population (a very recent.survey was conducted in the prepa-
ratory phase of the recent national anti-alcohol campaign) and the statistics 
of the alcohol industry. The estimated under reporting of the amounts of 
alcohol consumed is 40% in the general surveys and 20% in the surveys 
done for the industry. As with smoking, the general impression is that 
there is primarily an under reporting of the amount consumed rather than 
an under reporting of the number of people who drink alcohol. 
A third source of information on the prevalence of risk factors comes 
from the routinely collected data by the Central Bureau of Statistics (CBS). 
These include household surveys on food consumption and data on the age 
of mothers at the birth of their first child. 
Criteria applied to the choice of prevalence data: 
• Representativity of the Dutch population. Some studies only include 
certain age groups or selective sub populations. Where there was 
not a representative sample of the Dutch population, data were com-
bined from different sources to achieve a coverage as representative 
as possible. 
• The reliability of the data. 
• The subcategories presented. Risk factor influence depends very much 
on variables such as age, sex and exposure dose. In most of the 
surveys, such subcategories were used. Preference was given to data 
sources where the subcategories coincided with those used for the 
relative risk ratio's. 
• Time trends. When data on the development of prevalence over time 
were available from the same source, these were used to estimate a 
trend in risk factor prevalence, when data were available on only one 
point in time, trends were estimated based on circumstantial evidence. 
Relative risks 
The data on the relative risk ratio's associated with risk factors, that were 
used in this study, stem mostly from longitudinal trials in the USA or the 
UK. Use was also made of secondary sources such as the Health Conse-
quences of Smoking reports of the Surgeon General in the US or similar 
documents from the UK and the Netherlands. For certain risk factors very 
good and comprehensive review articles in leading journals exist. Although 
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these review documents give a good overview of the studies done, they usu-
ally do not draw quantitative conclusions from the articles reviewed. We 
combined these review articles with recent publications on the major risk 
factor trials and selected which relative risk ratio's to include in the basic 
runs with the Prevent model. 
Criteria applied to the choice of relative risks: 
• Type of study population. Relative risk data came from non-Dutch 
populations. To be able to transfer them to the Netherlands, data 
were selected on white populations, in western industrialized coun-
tries, if possible specified according to age and sex and exposure cat-
egory, and corrected for known confounders. 
• Follow up period. The lag period between risk factor cessation and 
diminished relative risk obviously are more fully appreciated in studies 
with a long follow up period. The one disadvantage to long follow up 
periods, is the impossibility to control for the cohort effect. The 
recent hypotheses about infant nutrition and the subsequent risks of 
cardiovascular disease and breast cancer (126, 189) would be such an 
example. However these factors mainly influence the absolute risk and 
the evidence is controversial whether such factors will also influence 
the relative risk ratio. 
• Extreme values. When comparing such a large number of study re-
sults it is inevitable that some differences remain even after adjusting 
for differences in study design. Differences between dose-related cat-
egories or age groups were only used if the differences were large. 
The choice of data, used in the basic runs of the Prevent model, will be 
presented by risk factor. 
6.1 Cigarette smoking 
6.1.1 Prevalence data 
There are two major sources on the smoking habits of the Dutch population: 
survey data and the yearly statistics of the government taxes on tobacco. 
These last ones are available and have been analyzed (190) since 1946. They 
show a steady increase in tobacco sales and assuming that relatively few 
cigarettes are left unsmoked, therefore a steady increase in the consumption 
of tobacco from 1 kg per person in 1946 to 2 kg in 1950 and more than 3 
kg in 1981. 
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Survey data are available in the Netherlands since 1958. Several inde-
pendent surveys were conducted since then, for research purposes and for 
marketing. In 1970 continuous surveys were started. These data are from a 
large sample (currently 22000 respondents per year) and can be considered 
representative for the Dutch population. The data are reported among 
others by age, sex, level of education, and recently also by the amount 
smoked. 
Unfortunately when the results of the surveys are compared with the 
statistics on the taxes paid by manufacturers there appears to be a severe 
under reporting. The total amount smoked as reported by smokers in the 
surveys would need to be augmented by some 6 to 7 cigarettes per smoker 
to achieve the total consumption as can be deduced from taxes. Earlier 
studies have attempted to correct for the under reporting (191) with the 
assumption that the under reporting is distributed evenly over the different 
categories. It has been suggested (Baan, personal communication) that the 
under reporting may be primarily in the categories of smokers who smoke 
more than 13 cigarettes a day, partly because it is much more difficult to 
make a mistake about 2-5 cigarettes a day than it is when one smokes as 
many as 20. There is also a hypothesis that the under reporting, which did 
not exist in the 1958 survey, is due to the prevailing social anti-smoking 
climate. Although aware of this discussion on under reporting, we decided 
to use the data on amounts smoked, as an indication of dose, without further 
correction (table 6.1) In the historic testing on smoking and lung cancer (in 
chapter 8) a variable IDRfac is introduced to correct for the discrepancy 
between sales taxes and survey data. In table 1.1 we did correct for an over 
reporting of the number of never smokers. From the earlier survey's the 
cohort data were used to find the more realistic number of never smokers. 
Table 6.1 shows that there has been a major trend in smoking cessation 
for males since 1958. In the 1950's almost all men over 20 years smoked, this 
was reduced to less than 70% in the early 1970's and reached levels just over 
40% by 1982. For women there is a different trend. After the second world 
war less than a third of all women smoked. In the following years, smoking 
habits became more pervasive in women, and by 1970 more adolescent girls 
started to smoke than adolescent boys. However older women smoke far 
less than the men in the same age group do. The other major difference 
between men and women is the percentage of the population that has never 
smoked: except for the youngest cohorts this is consistently much higher for 
women than for men. Looking at time trends in smoking cessation, there 
appears to be a sudden decrease in the number of smokers between 1979 
and 1982, which is subsequently followed by a stabilization or very slow 
further downward trend. These trends were used for the historic cohort 
data on smoking cessation. 
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Table 6.1: Percentage of smokers by sex and age in the Netherlands from 
1958-1982 
1958 1963 1967 1970 
Males: 
15- 19 - - 58 55 
20-34 91 78 79 77 
35- 49 91 85 80 77 
50-64 89 81 82 78 
65+ 88 76 83 74 
All ages 90 82 78 75 
Females: 
15- 19 - - 57 57 
20- 34 46 45 58 57 
35- 49 32 38 46 48 
50-64 18 20 26 27 
65+ 5 3 13 13 
All ages 29 32 42 42 
Age-groups for 1958: 21-40, 41-50, 51-70, 71+ 
Source 191 
1975 
46 
68 
69 
68 
66 
66 
48 
58 
47 
29 
12 
40 
6.1.2 IDR data by disease category 
Smoking and lung cancer 
1979 1981 1982 
29 27 18 
56 49 45 
58 50 44 
61 51 45 
57 51 43 
52 47 41 
39 30 27 
52 48 45 
40 39 36 
30 28 27 
13 13 13 
38 36 33 
In 1982 the USDHHS published the cancer volume in the series of reports 
on the Health Consequences of Smoking (193). This volume was a follow 
up report whereby the evidence collected since the landmark report of 1964 
(194), is reviewed using the same criteria necessary for a causal relationship 
as established by the Advisory Committee in 1964: 
1. The consistency of the association 
2. The strength of the association 
3. The specificity of the association 
4. The temporal relationship of the association 
5. The coherence of the association 
The report covers a great many cancer sites all of which are affected by 
smoking. The lung cancer data are used in this project. 
In table B.1 (Appendix B) the results of the 8 major prospective studies 
on smoking and lung cancer are shown as they have been summarized for 
this report. It is obvious that smokers have a much higher risk of lung 
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Table 6.2: Lung cancer mortality ratios for men and women, by current 
number of cigarettes smoked per day (prospective studies). 
Men Women 
Cigarettes Mortality Cigarettes Mortality 
Population smoked per day ratio smoked per day ratio 
ACS 25-State Nonsmoker 1.00 Nonsmoker 1.00 
Study 1-9 4.62 1-9 1.30 
10-19 8.62 10-19 2.40 
20-39 14.69 20-39 4.90 
40+ 18.71 40+ 7.50 
British Nonsmoker 1.00 Nonsmoker 1.00 
Physicians 1-14 7.80 1-14 1.28 
Study 15-24 12.70 15-24 6.41 
25+ 25.10 25+ 29.71 
Swedish Study Nonsmoker 1.00 Nonsmoker 1.00 
1-7 2.30 1-7 1.80 
8-15 8.80 8-15 11.30 
16+ 13.70 16+ -
Japanese Study Nonsmoker 1.00 Nonsmoker 1.00 
All ages 1-19 3.49 <20 1.90 
20-39 5.69 20-29 4.20 
40+ 6.45 
U.S. Veterans Nonsmoker 1.00 
Study 1-9 3.89 
10-20 9.63 
21-39 16.70 
>40 23.70 
ACS 9-State Nonsmoker 1.00 
Study 1-9 8.00 
10-20 10.50 
20+ 23.40 
Canadian Nonsmoker 1.00 
Veterans 1-9 9.50 
10-20 15.80 
20+ 17.30 
California Nonsmoker 1.00 
males in 9 about! pk 3.72 
occupations about 1 pk 9.05 
about 1tpk 9.56 
Source: 193 
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Table 6.3: Reduction in relative risk {lung cancer) after smoking cessation, 
by number of years since cessation 
Study Years Mortality ratio 
British Physicians 1-4 16.0 
5-9 5.9 
10-14 5.3 
15+ 2.0 
Current smokers 14.0 
U.S. Veterans1 1-4 18.83 
5-9 7.73 
10-14 4.71 
15-19 4.81 
20+ 2.10 
Current smokers 11.28 
Japanese Males 1-4 4.65 
5-9 2.50 
10+ 1.35 
Current smokers 3.76 
Number of cigarettes 
smoked per day 
1-19 20+ 
ACS 25-State Study 
(males 50-69) <1 7.20 29.13 
1-4 4.60 12.00 
5-9 1.00 7.20 
10+ 0.40 1.06 
Current smokers 6.47 13.67 
1 Includes data only for ex-cigarette smokers who stopped for other than physicians' 
orders 
Source: 193 
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cancer mortality than nonsmokers. However the level of relative risk varies 
considerably between studies. This is probably due to the different mix of 
the amount smokers smoke. The data in table 6.2 show that this greatly 
influences the relative risks found. There is also a difference in the relative 
risks found for men and for women. The hypothesis is that this is not so 
much due to a different influence of smoking on women but more likely a 
consequence of the period in which these studies were done: most studies 
were started in the 1950's and early 60's (all except for Japan and these 
data differ markedly from the other studies). In that period few women 
smoked and more importantly women smoked less and inhaled less than 
men did. The development of lung cancer mortality in the US for women 
now is remarkably similar to that for men 25 years ago. From these data 
one could conclude that lung cancer mortality for women may unfortunately 
have to reach the peak levels of males before it will decrease. 
In 1983 the Royal College of Physicians in Britain published a report: 
Health or Smoking? (195) in which essentially the same data were dis-
cussed. Particular attention is given to the fact that lung cancer rates for 
males are now falling in the UK. The report suggests that this is due to 
the falling levels of tar and nicotine in cigarettes in recent years. No such 
falling of mortality rates have yet been noted for women. This is one reason 
why it was eventually decided that women in Prevent are assigned the same 
IDR's as men. 
Since this USDHSS report there has been a number of new publications 
on smoking and lung cancer (99, 103, 104) but all are case control studies 
and although they differ somewhat on the relative risks reported they do 
not present data that make the results of the earlier prospective studies 
obsolete. In table 6.2 a dose related response is found in all prospective 
studies, although the exact relative risk may vary. 
Four of the eight prospective studies have reported data on what will 
happen to lung cancer mortality risk ratio's after smoking cessation (see 
table 6.3). 
Nothing happens to the risk ratio's in the first 4 years after cessation, 
if anything they are slightly higher than those of current smokers. This 
phenomenon can be explained by the fact that those who already feel, or 
have been diagnosed, ill will very often quit smoking, so a relatively high 
mortality is to be expected among recent quitters. After that period the 
risk ratio's diminish over a period of approximately 10 years to reach a 
stable, low level, but still not that of lifelong nonsmokers (197). From the 
data we assume a LAT of 4 years and a LAG of 10 years to reach the 
remnant IDR of 2. 
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Smoking and IHD (Ischemic Heart Disease) 
There have been innumerable studies on the major risk factors for car-
diovascular disease and it is now common knowledge that cigarette smoking 
is an important and independent risk factor. The USDHHS has reviewed 
the quantitative evidence in 1979 (196) and again in 1983 (73) and the 
Royal College of Physicians has also reported on these study results in 
1983 (195). Since then several major intervention trials (MRFIT, WHO 
collaborative, Gothenburg) have published their final results. In 1979 US-
DHHS reports the results of 14 major prospective studies. All but one have 
concentrated on men, which is understandable considering the period in 
which these studies were started. Most of the results as shown in table 
B.2 (Appendix B) are similar except for the Japanese data (just as in lung 
cancer). All report a higher relative risk for the younger age groups and 
contrary to the lung cancer data there appears to be very little difference 
between men and women. 
As with lung cancer we are also interested in the development of the risk 
ratio's after smoking cessation (12, 52, 82). There appear to be two distinct 
mechanisms whereby smoking increases the risk of IHD: it promotes and 
accelerates the development of atherosclerotic disease but it also affects the 
clotting mechanism. This dual mechanism would account for the very rapid 
reduction of risk in the first year followed by a slower risk :reduction in the 
next five years. Table 6.4 shows the data on 4 major studies, all of which 
show a reduction of risk following smoking cessation. 
Contrary to lung cancer this reduction is already apparent in the first 
year and approaches a maximum after 5 years. Some studies report a lower 
relative risk for ex smokers as compared to lifelong non smokers, but this 
is not supported by evidence from the intervention trials. We shall assume 
that the risk of IHD diminishes immediately upon smoking cessation and 
linearly reaches its lowest level of 1.2 for both men and women in 5 years 
(57). 
Smoking and COLD (chronic obstructive lung disease) 
In 1964 the Advisory Committee to the Surgeon General acknowledged 
the relationship between smoking and chronic bronchitis and emphysema 
although they had to conclude that the causal nature of the relationship had 
not yet been established. In 1984 no such doubts remain and the USDHHS 
report states: "Cigarette smoking is the major cause of chronic obstructive 
lung disease in the US for both men and women. The contribution of 
cigarette smoking to COLD morbidity and mortality far outweighs all other 
factors." (165). It has even been said that COLD rarely exists among non 
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Table 6.4: The effect of the cessation of cigarette smoking on the incidence 
of CHD. (Incidence ratios- actual number of cases or events are shown in 
rentheses) pa 
Author, 
year, 
country 
Jenkins, 
et al., 
1968 
USA 
Hammond 
and Garfinkel 
1969, 
USA 
Shapiro, 
et al., 
1969, 
USA 
Pooling Project 
American Heart 
Association 
1970, 
USA 
1 Male data only 
Source: 196 
Mortality ratio 
myocardial 
CHD infarction 
Never smoked 1.00 (30) 1.00 (21) 
Current 
cigarette smokers 2.36 (84) 2.78 (68) 
Former 
cigarette smokers 2.15 (19) 2.47 (15) 
CHD 
by cigarettes/ day 
1-19 >20 
Never 
smoked regularly 1.00 (1,81) 1.00 (1,81) 1 
Current 
cigarette smokers 1.90 (1,063) 2.55 (2,822) 
Stopped <1 year 1.62 (29) 1.61 (62) 
1-4 1.22 (57) 1.51 (154) 
5-9 1.26 (55) 1.16 (135) 
10-19 0.96 (52) 1.25 (133) 
>20 1.08 (70) 1.05 (80) 
All ex-cigarette smokers 1.16 _(_253) 1.28 (564) 
myocardial infarction 
Never smoked 1.00 
Current cigarette smokers 1.87 
Stopped $5 years 0.76 
All CHD First major 
deaths coronary events 
Never smoked 1.00 (27) 1.00 (53) 
>~pack/day 1.65 (34) 1.65 (72) 
1 pack/day 1.70 (86) 2.08 (205) 
>1 pack/day 3.00 (68) 3.28 (154) 
Ex-smokers 0.80 (19) 1.25 (51) 
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Table 6.5: COLD mortality ratios for men and women, by number of 
ciga rettes smoked per day (prospective studies) 
Cigarettes Mortality COLD disease 
Study per day ratio classification 
M F 
British Nonsmoker 1.00 1.00 Chronic bronchi-
physicians 1-14 17.00 10.50 tis, emphysema or 
15-24 26.00 28.50 both 
25+ 38.00 32.00 
US veterans Nonsmoker 1.00 Chronic bronchi-
1-9 3.63 tis 
10-20 4.51 
21-39 4.57 
40+ 8.31 
Nonsmoker 1.00 Emphysema 
1-9 5.33 
10-19 14.04 
21-39 17.04 
40+ 25.34 
Nonsmoker 1.00 Chronic bronchi-
1-9 4.84 tis and emphysema 
.10-19 11.23 
21-39 17.45 
40+ 21.98 
Canadian Nonsmoker 1.00 Chronic bronchi-
veterans 1-9 7.02 tis 
10-20 13.65 
21+ 14.63 
Nonsmoker 1.00 Emphysema 
1-9 4.81 
10-20 6.12 
21+ 6.93 
Japanese Nonsmoker 1.00 1.00 Emphysema 
<100,0001 0.51 2.28 
<200,000 2.57 3.14 
>300,000 1.93 10.93 
California men Nonsmoker 1.00 Emphysema 
in various oc- About t pk 8.18 
cupations About 1 pk 11.80 
About 1~ pk 20.86 
American Cancer Nonsmoker 1.00 All pulmonary 
Society 9-State 1-9 1.67 diseases other 
10-20 3.00 than cancer3 
20+ 3.64 
1 Data for the Japanese study are for lifetime exposure by total number of cigarettes 
consumed 
2 Nonsmoker in the California occupations study also includes smokers of pipes and 
cigars 
3 Pneumonia, influenza, TB, asthma, bronchitis, lung abscess, etc. 
Source: 165 
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smokers. 
Contrary to the disease categories discussed above (lung cancer and 
IHD) COLD is a much more important cause of morbidity than of mortality. 
Most COLD patients die "with COLD not of COLD". This means that the 
disease burden caused by COLD is much larger than would be expected 
from the mortality statistics. However there is no evidence that the relative 
risk ratio differs when looking at the mortality risk rather than the incidence 
risk. 
There have been a great number of cross sectional studies. However 
these cross sectional studies usually record lung function levels instead of 
diagnosed morbidity. For instance the Dutch longitudinal study measuring 
lung functions regularly in the populations of Vlagtwedde and Vlaardingen 
(198,199), which reports a severely restricted lung capacity in heavy smok-
ers. For our IDR values we looked at the mortality ratio's for emphysema, 
chronic bronchitis or both from the prospective studies available. 
As can be seen from table 6.5, 6 of the 8 studies report dose related data 
on COLD mortality among smokers and non smokers. The Swedish and 
the ACS 25 state study have only more general risk ratio's. The latter is 
important because it is the only one to report risk ratio's by age category. 
Contrary to the previous disease categories there appears to be an increase 
in relative risk with older age. It is obvious from the data that the risk 
ratio's increase sharply with the amount smoked to reach values that are 
even higher than those found for lung cancer. The IDR values selected are 
based on the British doctors study and the US veterans study. 
Although there tend to be marked differences in the mortality ratio's 
found in the prospective studies, these are likely to be due to the length 
of follow up. COLD mortality occurs most often after the age of 65, and 
considering the long latency periods before COLD results in death, studies 
with a short follow up or a population mostly under 65 years of age will 
tend to severely underestimate the relative risk of COLD. From the Ameri-
can Cancer Society 25 state study we know that the IDR's sharply increase 
with age. However these data only concerned emphysema and more impor-
tantly did not differentiate by the amount smoked. Because of the nature 
of the damage done to the lungs, that result in COLD symptoms, the ef-
fect of smoking cessation is less impressive on COLD than on lung cancer 
mortality. Two of the prospective studies have reported on the effect of 
smoking cessation. 
Table 6.6 shows that the first four years after quitting the mortality 
risk ratio barely changes, after which it becomes higher than for current 
smokers. This is probably the result of the higher rate of smoking cessation 
among people diagnosed as COLD patients. During the next 9 years the 
ratio slowly falls. However even at its lowest point, the risk of COLD mor-
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Table 6.6: Mortality ratios for bronchitis and emphysema in nonsmokers 
and in ex-smokers and current smokers by number of cigarettes smoked 
daily and number of years of cessation, US veterans study 
Cigarettes/ day 
Smoking status 0 <10 10-20 21-39 >39 
Nonsmoker 1.00 
- - - -
Ex-smoker - 1.64 5.35 7.68 9.91 
Current smoker - 4.84 11.23 17.45 21.98 
Years of cessation 
Current 
Nonsmoker smoker <5 5-9 10-14 15-20 >20 
1.00 12.07 11.66 14.35 10.19 5.66 2.64 
Source: 165 
tality remains much higher for ex-smokers than for life long non smokers. 
We assume that COLD mortality ratio's will not change for the first 10 
years after smoking cessation, after that they will slowly diminish over the 
next 10 years to reach the remnant IDR of 2.6 for both men and women. 
6.2 Hypertension 
6.2.1 Prevalence data 
In 1983 the Health Council in the Netherlands published a report with 
recommendations concerning Hypertension (200). It contains an overview 
of the surveys done in the Netherlands between 1960 and 1977 in which 
population data were collected on blood pressure (table 6.7). None of these 
population surveys are truly representative of the Dutch population, how-
ever when the average blood pressure levels found in all these different 
studies for the different age groups are compared, they do not differ sub-
stantially. As can be seen the largest survey is the COPIH. This also has 
the advantage of being spread over the country so as to minimize the ef-
fect of regional variations. A major drawback however is the fact that it 
looked at employees only, which in 1971 certainly did not represent the fe-
male population in that age group in the Netherlands. Furthermore it has 
recorded only the first blood pressure measurement, which may over report 
hypertension. In an effort to see whether the above mentioned drawbacks 
really affected the data, the Health Council committee asked investigators 
of the different studies to publish their results for the· common age group 
of 35-44 according to the model used by the COPIH project (see table B.3 
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Table 6.7: Population Studies in which blood pressure data were collected 
in the Netherlands 
Study 
1. Zutphen 
2. Vlagtwedde-
Vlaardingen 
3. COPIH 
4. CB 
5. K.R.I.S. 
6. Voedingsraad 
7.EPOZ 
8. Voedingsraad 
9. Boot 
10.Milit.keur-
lingen 
1l.Cordon 
12.NIP 
N: Population size 
Source: 200 
Starting Age 
year 
1960 40-59 
1970 20-50 
1971 35-64 
1971 20-50 
1972 45-59 
1973 8 
1975 5-75 
1976 15-16 
1976 5-75 
1976 18-19 
1976 40-65 
1977 20-50 
N Sex Location 
900 m Zutphen 
1400 m/f Vlagtwedde-
Vlaardingen 
21600 m Several 
8000 m/f Rotterdam 
Til burg 
Doetinchem 
3400 m Rotterdam 
900 m/f National 
3500 m/f Zoetermeer 
1000 m/f National 
2000 m/f Den Haag 
3100 m National 
7000 f Utrecht e.o. 
4500 m/f Re_gio Nijmegen 
in appendix B). There are some differences between the percentages found: 
EPOZ reports a significantly lower percentage of hypertensives both for 
men and women while COPIH has very high values for women. We have 
attempted to look at the results of these surveys for the other age groups in 
a similar way (for the detailed tables see appendix B). Three categories of 
blood pressure were applied following the WHO guidelines: a reference pop-
ulation of normotensives, a group with mild hypertension (Diastolic blood 
pressure, DBP, 90-94 and/or systolic blood pressure, SBP, 140-159) and a 
group with "severe" hypertension (DBP;:::95 and/or SBP;:::160). In the sur-
veys from which these data have been extracted some subjects were known 
to have hypertension and an, albeit small (13%) percentage was treated 
by their family physician. Therefore the initial percentage of hypertensives 
in the population may be higher, but since the increased risk is related to 
the current blood pressure rather than to the initial blood pressure these 
treated hypertensives are inserted in the risk category of the blood pressure 
as measured at the time of the survey. 
Looking at table 6.8 one is struck by the rapid rise in the prevalence of 
high blood pressure in the age group 45-49. To a certain extent this is due to 
the fact that in the higher age group the most reliable and complete source 
of information is the COPIH survey. As seen earlier this is characterized by 
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Table 6.8: Prevalence of hypertension in the Dutch population by age and 
sex category, 1976 
35-44 45-49 50-54 55-59 60-64 
M F M F M F M F M F 
Normotensive 58.4 78.4 45 49 41 45 34 35 28 25 
Hypertensive 
Mild 24.6 13.3 27 26 26 26 29 30 29 31 
Severe 17 8.3 29 25 32 29 37 35 43 44 
Table 6.9: Prevalence of hypertension in the Dutch population by age and 
sex category, based on the EPOZ data 
5-19 20-34 35-49 50-64 65+ 
M F M F M F M F M F 
Normotensive 92.7 96.4 76.3 89.1 68.2 68.5 44.2 33.1 27.8 .8 
Hypertensive 
Mild 6.5 3.2 17.8 6.1 18.2 13.7 29.5 25.9 26.6 35.2 
Severe 0.8 0.4 5.0 2.6 10.2 9.1 18.9 24.0 29.6 34.5 
Ex .9 2.2 3.4 8.7 7.4 17.0 16.0 31.1 
a relatively high overall prevalence of hypertension especially for women. 
There are no population data on the prevalence of hypertension in the very 
old. The Health council report however assumes that there is no further 
rise in blood pressure after the age of 70. The age group over 65 years will 
be assigned the same prevalence data as the age category 60-64. 
Little is known about the trend in the incidence or prevalence of hyper-
tension. The awareness of family practitioners of the importance of regular 
blood pressure measurements and subsequent treatment of hypertensives 
has probably increased over the last ten years. The lower prevalence of hy-
pertension found in the more recent EPOZ study also points in the direction 
of a reduction in incidence. We assume a 1% yearly increase in the number 
of hypertensives being successfully treated before major disease symptoms 
have been diagnosed. These will not be returned however to the pool of 
normotensives but will remain in the category ex hypertensives. The data 
in table 6.8, in 1976, result in an estimated prevalence of hypertension in 
1985 shown in table C.5. 
Since the EPOZ data are so different from the other surveys, while 
they come from a population sample, some special runs with the Prevent 
model using the EPOZ material, were done to see whether it made much 
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difference. For the hypertension prevalence data we have gone back to the 
raw data and regrouped the categories as shown in table 6.9. 
As said earlier, the EPOZ prevalence data suggest a lower incidence of 
hypertension, especially of severe hypertension. However it is striking to 
see that almost no woman over 65 years of age appears to be normotensive 
without antihypertensive medication. 
6.2.2 IDR data by disease category 
Hypertension and IHD 
The interest in the risk factors of IHD in the postwar years has resulted 
in a number of prospective studies concerning the relative risks associated 
with hypertension in the population. There have also been a fair number 
of intervention trials that produced data on the reduction of risk following 
treatment of hypertension. It is important for the interpretation of the 
results of the model to keep in mind that there are two ways of prevention 
of the adverse effects of hypertension: primary prevention at a population 
level, which will mostly concentrate on what is commonly called a "prudent 
life style", and the possibility of secondary prevention by screening and 
subsequent treatment of diagnosed hypertensives. For the latter type of 
prevention the opinions on the benefits to be expected of the treatment of 
mild hypertension still differ. 
Table 6.10 summarizes the results of the major longitudinal studies in 
the US. The best known and the one with the longest follow up period is 
undoubtedly the Framingham study. There seems to be a dose response 
relationship. The Framingham study has found the SBP to be the better 
predictor of risk, but other surveys the DBP. For men there seems to be 
a decrease of risk ratio in the older age groups. This is less obvious for 
women. The rise in risk ratio for women in the 40-49 age group in the 
Framingham study is probably an artifact. It does seem however, that 
women with severe hypertension have higher relative risks for IHD then 
men. The risk ratio's that were applied in the basic runs are presented in 
table C.6. 
For the category of ex-hypertensives the intervention trials report are-
duction of risk in the order of 10-20%. However these trials are mostly multi 
factorial and it is therefore sometimes difficult to assess the influence of the 
individual risk factors. Collins c.s (87) have combined a great number of 
intervention trials on moderate hypertension and report a significant effect 
even of a reduction of blood pressure by as little as 7mm. We will assume 
that hypertension controlled by medication will result in an immediate re-
duction of the IHD mortality ratio. After 2 years the remnant IDR will be 
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Table 6.10: Mortality ratios for IHD from the major prospective studies 
Study N Years of Reported IHD 
follow up mortality risk ratio's 
Evans 3102 7yrs 35-44 45-54 55-64 65+ 
County Males SBP Mild 2.52 1.54 1.37 1.78 
SBP Severe 1.43 1.61 2.02 2.34 
DBP Mild - .36 1.88 1.46 
DBP Severe 2.26 1.73 1.63 1.95 
30-39 40-49 50-59 
Framing- 5209 26 yrs MildM 1.88 1.32 1.65 
ham MildF 1.63 1.78 1.60 
Severe M 2.34 1.76 1.88 
Severe F 2.95 2.69 2.71 
Nat.Coop 7342 10 yrs DBP 
pooling 85-94 1.7 
project 95-104 1.9 
105+ 3.6 
1.6. For the mild hypertensives a complete elimination of the excess risk is 
assumed. 
Hypertension and cerebrovascular accident (CVA) 
There are only a few population studies concerning the relationship between 
hypertension and CVA. The most reliable data come from the Framingham 
study (see table 6.11). 
Table 6.11: CVA Mortality ratios as reported in the Framingham study, by 
age and sex. 
30-39 40-49 50-59 
Men Women Men Women Men Women 
Hypertension 
Mild 3.86 2.06 1.78 1.96 2.02 1.49 
Severe 10.20 3.38 3.27 3.46 2.98 2.70 
The dose response relationship is apparent, as well as the increased 
risk for the younger age groups. Men seem to be affected more severely 
by mild hypertension than women are, which is not so obvious for severe 
hypertensives. The very high value found for men in the age group 30-39 
is most likely the result of the very small numbers of death in this age 
category. The IDR's assumed are reported in table C.7. 
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The intervention trials by the HDFP and the pooled results of Collins 
report a much larger impact of blood pressure reduction on CVA mortality 
than on IHD mortality. Risk reductions of as much as 50% have been 
found. We assume that hypertensives who are effectively treated will have 
an immediate reduction in the risk of CVA mortality, but the remnant IDR 
remains 1.5. 
6.3 Serum cholesterol 
6.3.1 Prevalence data 
The same population surveys that measured the level of hypertension in the 
Netherlands have also included data on the serum cholesterol levels (201). 
In the investigations on serum cholesterol the cutoff points appear to be 
even more arbitrary than was the case with blood pressure. Some investi-
gators consider levels of 240-280 mg% to be a mild hypercholesterolemia, 
others consider any level above 200 mg% to be elevated. Some put the 
cutoff point for severe hypercholesterolemia at 300 while others consider 
this to be 260 or 280. In 1983 the Nutrition Council in the Netherlands 
published an overview on diet in relation to coronary heart disease (202), 
in which the available literature on both the prevalence and relative risk 
data were reviewed. In table 6.12 the results of the data on the prevalence 
of hypercholesterolemia as found in the different Dutch population studies 
are summarized. 
The prevalence of hypercholesterolemia appears to increase with age for 
both men and women. While initially women have much lower rates than 
men, this changes after the age of 50. The COPIH project, the largest sur-
vey but with the drawbacks discussed earlier, shows this for both mild and 
severe hypercholesterolemia (table 6.13). These results are corroborated by 
the findings of Boot in a sample of the general population. The absolute 
numbers vary considerably between investigators. We are inclined to use 
the COPIH data because of the continuous data on all age groups. 
The serum cholesterol level appears to be influenced by the dietary 
fat intake in a population. Evidence for this relationship is mostly found 
in cross cultural studies, although recently intra population correlations 
have been reported as well. The Dutch diet and the distribution of macro 
nutrients that can be distilled from this, does not differ from other Western 
diets in that it contains a relatively high fat intake (some 40%) and a 
ratio between polyunsaturated and saturated fats of .36, which can both 
be considered risk factors for atherosclerotic disease. 
From table 6.14 can be seen .that the percentage of fat in the diet has 
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Table 6.12: Prevalence of elevated total serum cholesterol1 from different 
studies in the Netherlands 
Study 
COPIH 
(1974-1976) 
CB 
(1973) 
KRIS 
(1972) 
Vlagtwedde 
(1970) 
Westland 
(1974) 
Heerenveen 
Roermond 
Harderwijk 
(1974-1976) 
Den Haag 
(1979) 
1: according to Huang 
Source: 202 
Age 
35-64 
35-49 
45-59 
20-49 
9-12 
4-13 
30-59 
Sex Threshold level Prevalence 
m 7,8 mmol/1 22% 
(300 mg %) 
m 7,3 mmol/1 16% 
(280 mg %) 
f idem 10% 
m 6,7 mmol/1 26% 
(260 mg %) 
m 6,7 mmol/1 45% 
(260 mg %) 
m 5,7 mmol/1 14% 
(220 mg %) 
f idem 16% 
m 5,6 mmol/1 19% 
(215 mg %) 
f idem 25% 
m 6,1 mmol/1 7% 
(236 mg %) 
f idem 10% 
m 6,1 mmol/1 67% 
f (236mg %) 27% 
Table 6.13: Prevalence of mild and severe hypercholesterolemia m the 
Dutch population, 1976. 
35-39 40-44 45-49 50-54 55-59 60+ 
serumcholesterol M F M F M F M F M F M F 
<240 mg% 66 76 59 72 56 64 54 46 52 38 53 35 
240-300 mg% 23 18 27 21 28 26 30 34 31 32 30 38 
>300 mg% 11 6 14 7 16 10 16 20 17 30 17 27 
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Table 6.14: Macro nutrients in the Dutch diet in 1936/38 and 1973 
Year 1936/38 1973 
Total energy 11,4 MJ (2714 kcal) 12,5 MJ (2978 kcal) 
_lexcl. alcohol) 
g energy% g energy% 
Animal protein 39 6 54 7 
Vegetable protein 42 6 31 4 
Total protein 81 12 85 11 
Saturated fat 49 16 62 19 
Monounsaturated fat 36 12 53 16 
Polyunsaturated fat 13 4 23 7 
Total fat 102 34 138 42 
Oligosacdtarides 137 20 192 26 
P olysacdtarides 231 34 157 21 
Total carbohydrates 268 54 349 47 
Cholesterol (mg/4200 kJ) 116 137 
Fibre (g/ 4200 kJ) 11.8 8.9 
Alcohol (kJ) 113 563 
Source: 202 
Table 6.15: Prevalence of mild and severe hyper cholesterolaemia in the 
Dutch population based on EPOZ data 
serum 30-44 45-49 50-54 55-59 60+ 
cholesterol M F M F M F M F M F 
<240 53.8 68.4 49.7 39.0 44.4 34.1 47.4 30.4 60.8 43.4 
240-270 24.0 18.6 25.0 28.0 22.9 26.5 30.1 27.7 23.8 26.3 
270+ 22.2 13.0 25.3 33.0 32.7 39.4 22.5 41.9 15.4 30.3 
!DRs 
Mild 3.5 3.0 2.0 1.7 2.0 1.7 1.3 - 1.3 -
Severe 5.5 5.0 13.0 2.0 3.0 2.0 1.9 - 1.9 -
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gone up in the postwar years. However more detailed analyses of recent 
dietary changes show some more positive developments in nutritional habits 
since 1970 (202). 
The COPIH data also show a reduction in hypercholesterolemia in the 
subsequent years of the study. A 1% yearly reduction in the prevalence of 
hypercholesterolemia was applied to the prevalence data in table 6.13 to 
arrive at the 1985 values used in the basic runs (see table C.8). 
As with hypertension, the prevalence data on serum cholesterol levels 
found in the EPOZ study differ from the COPIH data. From the raw 
EPOZ data two tables were constructed. One (table 6.15) with the same 
categories as the COPIH data and one according to the criteria of the 
recently released MRFIT analysis (table 6.16). These data were used in 
the sensitivity analysis (chapter 8) to see the effect of a change in the 
initial input data. In the analysis, the effects of elevated serum cholesterol 
on IHD mortality were found to be more pronounced than assumed earlier 
(203, 204). Since the exposure categories differed as well as the relative 
risks reported, the IDR's found in the MRFIT study were used only in the 
sensitivity runs. These are shown in table 6.16 as well. 
6.3.2 IDR data by disease category 
Serum cholesterol and IHD 
The same prospective studies that have yielded the data on the influence 
of smoking and hypertension on IHD also included serum cholesterol (205-
208). The mortality risk ratios found in the different prospective studies 
are summarized in table 6.17. 
The most striking finding is the wide range of reference populations used 
by the different studies, which accounts for the differences between values 
reported. The relative risk rapidly diminishes in the older age groups, to 
become virtually non existent for the elderly women. This is of interest 
because of the high prevalence of severe hypercholesterolemia found for 
that age group. 
The multi factorial intervention trials on IHD risk factors that were re-
ported in the hypertension paragraph have often included interventions on 
dietary factors as well. Besides those, a number of mono factorial interven-
tion trials were set up. The Nutritional Council concluded in 1983that the 
results of these trials were not always statistically significant but all pointed 
in the direction of a reduced IHD risk following dietary changes that lowered 
serum cholesterol. The dietary changes included both a reduction of total 
fat intake and an increase in the P /S ratio of the fat intake. It is estimated 
that an 8% reduction in the saturated fat intake in the Netherlands would 
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Table 6.16: Prevalence of serum cholesterol levels according to Mr.Fit, in 
the Dutch population based on EPOZ data, with corresponding IDR's 
Prevalence 35-39 40-44 45-49 50-54 55-59 
lmg %)_ M F M F M F M F M F 
A <181 6.2 9.2 3.7 10.8 3.3 3.8 3.7 0.9 7.5 2.2 
B 181-195 19.7 28.0 14.4 30.0 12.5 13.1 13.1 7.6 8.1 8.2 
c 210-225 28.2 20.6 26.5 15.8 33.9 22.1 27.6 25.6 31.8 20.1 
D 226-240 10.4 13.3 17.5 12.1 12.5 13.1 13.5 12.6 18.5 16.3 
E 240+ 35.5 28.9 37.9 31.3 37.8 47.9 42.1 53.4 34.0 53.3 
lOR's 
A 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
B 1.14 1.14 1.79 1.79 1.26 1.26 1.28 1.28 1.20 1.20 
c 2.32 2.32 2.63 2.63 1.79 1.79 1.43 1.43 1.74 1.74 
D 2.44 2.44 3.69 3.69 2.36 2.36 1.96 1.96 1.93 1.93 
E 7.75 7.75 5.79 5.79 3.88 3.88 2.93 2.93 2.40 2.40 
Table 6.17: Mortality ratios for coronary heart disease according to serum 
cholesterol level 
Study 
Framingham 
Pooling project 
Whitehall Study 
Western Colla-
borative Study 
Stockholm Pros-
pective Study 
Evans County 
Study 
1 Pso 
2 P2o 
Source: 202 
Age 
35-44 
45-54 
55-64 
all ages 
40-64 
40-62 
39-49 
50-59 
35-39 
15-75+ 
Total Relative risk ratio 
serum cholesterol 
(mg %) M F 
~265 versus <220 5,5 5,0 
" 2,4 1,5 
" 1,7 1,3 
" 2,5 1,5 
>240 versus <218 2,0 
> 2341 versus < 159~ 2,0 
~260 versus 260 2,9 
>260 versus <260 1,7 
~280 versus <280 2,1 
~260 versus <220 1,3 
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lead to an average reduction of serum cholesterol of 22mg%. In the basic 
runs we shall assume that a reduction in serum cholesterol as the result of 
dietary changes will indeed lead to a lowered risk ratio. The remnant IDR 
will be considered 3 for the younger age groups and 1.5 for those over 45. 
This level will be achieved over a period of 3 years (202). 
6.4 Obesity 
6.4.1 Prevalence data 
Obesity has long been considered an important risk factor for premature 
mortality (209, 210). This was first noted by the life insurance companies 
in the USA. Since then there has been a lively debate about the validity of 
the data. Part of the problem appears to be the measurement of obesity. 
Weight as a simple index soon proved to be relatively poorly correlated with 
excess body fat. Other measures were introduced of which the QI, Quetelet 
index (weight/height2) seems to be the least dependent on the variation in 
height. Better still are the skinfold measurements or the direct body fat 
measurements but these are usually too elaborate to be of practical use for 
large scale population studies. In the Netherlands several studies were done 
to determine the level of obesity in the population. The most important of 
these are listed in table B.4 (appendix B). In the recent report by the Dutch 
Health Council (211) the cut off point for obesity was put at a QI of 30 or 
more. This is a change from earlier cut off points which were in the range 
of a QI of 26-27 (123, 127). This change reflects the general trend in the 
opinion that overweight is not as harmful as was long thought. The choice 
of cut off point will however greatly influence the perceived prevalence of 
obesity in the population. 
Table B.4 shows that the percentage of the population that can be 
considered obese increases with age and is slightly higher for women than 
for men. 
6.4.2 IDR data by disease category 
Obesity and IHD 
In many of the prospective IHD studies obesity was investigated as a pos-
sible risk factor. The results are not conclusive. In the Pooling Project a 
positive correlation was found between obesity and the incidence of IHD for 
the younger men( <50) but an inverse relationship was found for the older 
men. The same results were found in the Manitoba study. In the Seven 
Country study no relationship was found, however when the Dutch data 
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were analyzed separately a positive relationship was found between skinfold 
measurements and IHD mortality. We shall adhere to the conclusions of 
the Dutch reports ofthe Health Council and the Nutrition Board that there 
is as yet no conclusive evidence that obesity contributes to IHD mortality. 
Obesity and cancer 
The relationship between obesity and cancer incidence dates back to animal 
experiments in the 1940's. Tannenbaum reported that rats fed on a very 
low calory diet lived much longer. However the diet used by Tannenbaum 
(135) was so extreme that it could never be tried out on humans. The 
results of the large ACS (American Cancer Study) trial that have already 
been referred to elsewhere, have yielded some mortality ratio's by weight 
categories. These are listed in table 6.18. Unfortunately they did not use 
the Quetelet index but the simple weight/height measure. 
Doll and Peto (135) conclude that there appears to be some correlation 
between obesity and cancer mortality especially in women. This effect 
is most pronounced for endometrial cancer which could be explained by 
the increased level of estrogen found in obese post menopausal women. 
De Waard has found a correlation between body mass indices and breast 
cancer (212), whereby a QI of >29 was associated with a relative risk of 
1.3. There is a continuing debate whether this really constitutes a causal 
relationship or whether body mass is simply a risk indicator masking a true 
risk factor such as for instance early menarche, high consumption of milk 
fat or body surface index. In the current version of the model, obesity in 
post menopausal women is a risk factor for breast cancer, with a relative 
risk ratio ofl.3 for all women over 50 years of age with a QI of more than 
30. After weight reduction the relative risk ratio return to 1 over a period 
of 1 year. The LAT for obesity and breast cancer will be set at 5 years. 
The effect of obesity on the incidence of colon cancer is still controversial. 
It has been measured in the Seventh day Adventist studies by Philips (138). 
He found a U-shaped curve and reports a relative risk of 1.6 for all those 
outside the "normal" weight range. These values will only be available in 
a special run and will not be used in the basic runs. 
6.4.3 Relationship to other risk factors 
Obesity also affects some of the more traditional risk factors which makes it 
difficult to discern between direct and indirect effects of body weight. In the 
research on this subject it is often easier to find a relationship between the 
reduction of overweight and a reduction of risk than a direct relationship 
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Table 6.18: Mortality ratios from various types of cancer, by weight index1 
Mortality ratio for weight index~ in ranges: 
Cancer Sex <0.80 0.80- 0.90- 1.10.- 1.20- 1.30- ~1.40 
0.89 1.09 1.19 1.29 1.39 
Endometrium f 0.89 1.04 1.00 1.36 1.85 2.30" 5.42 
Gallbladder, f 0.683 0.74 1.00 1.59 1.74 1.80 3.58 
plus biliary 
passages 
Cervix f 0.76 0.77 1.00 1.24 1.51 1.423 2.39 
Kidney f 1.12 0.70 1.00 1.09 1.30 1.85 2.03 
Stomach m 1.34 0.61 1.00 1.22 0.97 0.733 1.883 
f 0.74 0.95 1.00 1.07 1.28 1.26 1.03 
Colon, rectum m 0.90 0.86 1.00 1.26 1.23 1.53 1.73 
f 0.93 0.84 1.00 0.96 1.10 1.30 1.22 
Lymphoma f 0.83 1.14 1.00 1.06 1.00 0.92 1.13 
Brain f 0.86 0.89 1.00 0.95 1.52 0.693 1.10 
Leukemia f 0.73 1.00 1.00 1.01 0.88 0.85 1.24 
Breast f 0.82 0.86 1.00 1.19 1.16 1.22 1.53 
Prostate m 1.02 0.92 1.00 0.90 1.37 1.33 1.29 
Lung m 1.78 1.38 1.00 0.85 1.04 1.00 1.27 
f 1.49 1.20 1.00 1.10 1.06 1.06 1.22 
Ovary f 0.86 0.98 1.00 1.15 0.99 0.88 1.63 
Pancreas m 1.20 0.82 1.00 0.91 0.88 0.763 1.63 
f 1.17 1.06 1.00 1.36 1.43 1.18 0.61 
All cancers f 0.96 0.92 1.00 1.10 1.19 1.23 1.55 
m 1.33 1.13 1.00 1.02 1.09 1.14 1.33 
1 Based on report by Lew and Garfinkel {1979) of datafromACS study of one million U.S. 
men and women during the 1960's. The tabulated ratio's, all of which are standardized 
for age and sex a few crude categories of tobacco usage, compare cancer death rates with 
cancer death rate among people whose weight index was 0.90-1.09. 
2 Actual weight divided by the average weight for people of similar height and sex. 
Values in the range 0.90-1.09 are close to average weight. 
3 Ratio based on only 5-9 deaths. 
Source: 135. 
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between the prevalence of obesity in the population and the prevalence of 
the other risk factors. 
• Serum cholesterol level: In the Zutphen study in the Netherlands a 
reduction in weight by one Kg was found to be associated with a 
reduction of serum cholesterol by 0.05 mmoljliter. 
• Hypertension: The prevalence of hypertension has been found to be 
positively associated with the prevalence of obesity. In the Fram-
ingham study a 10% weight increase resulted on average in a 6mm 
increase in systolic blood pressure and a 4mm Hg increase in diastolic 
blood pressure. Although the exact mechanism whereby bodyweight 
affects blood pressure has not yet been fully understood it is com-
monly accepted that a weight reduction is accompanied by a decrease 
in blood pressure and as such is one of the first steps in treating mild 
hypertensives. 
• Estrogen: There appears to be a positive correlation between the 
amount of body fat and the level of estrogen in post menopausal 
women. However we were not able to find data on the quantitative 
estimates of this relationship. 
These relationships will not be present in the Prevent model, but will be 
considered when formulating preventive policy measures. 
6.5 Fruit and vegetables 
In the continuing search for dietary carcinogens an protective agents in 
the diet, fresh fruit and vegetables are found to be protective against all 
cancers, but especially colon cancer. Two hypotheses are put forward to 
explain this relationship. The fibre hypothesis assumes that it reduces the 
length of time stools remain in the bowel and that it decreases the concen-
tration of carcinogens in the stools (by increasing their bulk). The other 
hypothesis concerns the as yet unexplained protective effect of a high intake 
of cruciferous vegetables and possibly also of vitamin C on the incidence of 
colon cancer. 
6.5.1 Prevalence data 
In table 6.19 we can see that the consumption of vegetables but especially 
of fresh fruit has increased in the last thirty years. If an effect is to be 
expected it would therefore be quite large. However at this point we do 
not feel that the quantitative evidence is sufficient to incorporate fruit and 
vegetable consumption in the basic runs of the Prevent model. 
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Table 6.19: Trends in nutritional intake during 1950-78 (in kg. or liters) 
1950 1955 1960 1965 1970 1975 1978 
Flour 86.6 81.9 74.9 67.1 60.3 58.3 56.2 
Potatoes 128.5 91.0 100.0 90.3 84.4 79.9 82.1 
Sugar & Glucose 39.1 42.0 47.8 46.5 51.4 50.5 47.1 
Fresh vegetables 40.2 41.1 42.1 41.4 45.6 48.4 51.2 
Fruit 42.1 46.5 53.6 60.1 70.0 69.0 72.6 
Nuts 2.2 2.0 2.7 3.2 3.9 5.4 5.2 
Milk 187.9 174.1 145.0 120.1 96.7 73.1 61.4 
Lowfat milk 
- - - -
4.2 17.8 25.5 
Cheese 4.6 6.2 7.4 7.9 8.2 10.2 11.6 
Butter 2.6 3.0 4.7 4.3 2.8 2.6 3.2 
Margarine 17.0 19.2 19.9 19.6 17.7 13.5 12.9 
Lowfat margarine - - - - 0.6 3.1 2.8 
Oil 5.0 5.2 5.3 6.8 8.1 9.6 9.9 
Beef 12.2 16.2 16.3 17.4 19.0 20.1 19.6 
Pork 14.0 15.1 18.2 21.1 26.5 31.7 35.0 
Chicken 0.2 0.5 2.1 4.4 6.0 7.0 8.2 
Eggs 4.7 8.0 11.8 12.1 11.9 11.1 11.1 
Fish 10.3 8.7 9.2 10.7 11.7 13.4 13.8 
Coffee 1.3 2.4 3.6 4.9 6.0 7.1 6.5 
Tea 0.8 0.7 0.8 0.6 0.6 0.7 0.6 
Soft drinks 
- - -
32.0 55.5 58.9 60.4 
Beer 10.6 16.2 23.8 37.2 57.4 79.0 85.2 
Liquor (100%) 1.5 1.2 1.1 1.9 2.0 3.4 3.0 
Wine 0.5 1.2 1.9 3.4 5.1 10.3 12.2 
Source: 202 
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Table 6.20: Prevalence of alcohol consumption, in glasses per week by age 
and sex 
number of glasses total 15-24 25-34 35-44 45-60 
of alcohol/week (n=324) (n=147) (n= 68) (n= 61) (n= 48) 
Men 
0-1 16 20 17 11 15 
2-5 21 27 24 14 20 
6-10 23 20 18 25 31 
11-20 25 18 26 27 23 
21-30 8 5 3 12 11 
30+ 7 10 12 11 0 
total 100% 100% 100% 100% 100% 
Women 
(n=418) (n=189) (n= 68) (n= 73) (n=88) 
0-1 28 37 22 16 35 
2-5 34 30 36 39 30 
6-10 24 16 30 29 23 
11-20 11 12 10 11 11 
21-30 2 4 0 5 1 
30+ 1 1 2 0 0 
total 100% 100% 100% 100% 100% 
Source: 218 
6.6 Alcohol intake 
6.6.1 Prevalence data 
As with smoking data the major problem with the prevalence of alcohol 
intake in the Dutch population is not the lack of data but more the abun-
dance of data both from industry and from surveys and the discrepancy 
between the two (213-217). Again there is evidence of severe under report-
ing. The three major population surveys of 1958, 1970 and 1981 all show 
an approximate under reporting when compared to the industrial statistics 
of that same period, of 40-50%. In carefully analyzing these data Knibbe 
(216) concludes that much can be explained by unintentional misjudgment 
of the amount consumed. We will therefore not correct the data for under 
reporting (table 6.20). 
The data in table 6.21 show an increase in the number of heavy drinkers 
in the population. This is corroborated by the data from the industry 
that show an increase in the total consumption of alcohol in the Dutch 
population of some 300% over that same period. This has resulted in an 
overall increase of heavy drinkers from 2% in 1958 to more than 15% for 
men in 1981. 
Table 6.21: Alcohol consumption (glasses per week) of different subpopulations in 1958, 1970 and 1981, in percentages 
1958 
Abst. <3gl. 4-12 13-31 
Men 11.6 62.11 19.31 5.01 
Women 25.83 65.21 7.1 1 1.81 
Men 
21-40 11.1 58.81 22.11 5.71 
>41 12.11 65.11 16.71 4.31 
Women 
21-40 19.5 68.81 10.31 1.41 
>41 30.71 62.31 4.61 2.2 
Men 
(total 2035) 63 337 27 11 
Women 
(total 2095) 171 433 47 12 
1: Significant difference between 1958 and 1970 
2: Significant difference between 1970 and 1981 
3: Significant difference between 1958 and 1981 
Two sided t-test sign at ~0.05 
Source: 216 
>22 Abst. <3gl. 
2.01 13.7 28.2'l 
0.21 31.3 42.22 
2.31 8.8 23.6 
1.81 19.8 33.32 
- 22.8 42.4 
0.3 38.2 43.32 
5 117 242 
1 238 338 
1970 1981 
4-12 13-21 >2 2 Abst. <3gl. 4-12 13-21 >22 
33.5 13.9" 10.7" 13.2 20.~ 32.4~ 18.3~ 15.7~ 
19.02 5.2 0.72 30.3 32.63 26.13 8.63 2.43 
33.7 19.4 14.5 11.3 18.43 35.33 18.43 16.63 
31.6 8.42 6.92 15.2 22.~ 29.53 18.13 14.g3 
27.6 6.2 1.02 27.13 36.73 23.63 9.03 3.53 
13.62 4.42 0.5 33.7 28.~ 28.83 8.03 1.2 
287 119 92 84 129 206 116 100 
145 39 5 202 217 174 57 15 
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However in recent years the total percentage of abstainers does not 
change much. The major shift is away from the light drinkers (less than 4 
drinks per week) towards the category of moderate and heavy drinkers. 
6.6.2 IDR data by disease category 
Alcohol and IHD 
In 1979 an article in the Lancet (in 219) generated considerable interest 
because the suggestion was made that moderate alcohol consumption, and 
especially wine, could be a protective factor in IHD. This was not the first 
time that such hypotheses were launched. Since then several authors have 
reported similar results (28, 219, 220, 221). 
Marmot in his review article (222) on the subject concluded that al-
though there are several hypotheses about the biomedical mechanism by 
which alcohol protects, there is not yet conclusive evidence that the rela-
tionship between moderate alcohol consumption and IHD is indeed causal. 
Nevertheless he concludes that, given the results of both case-control and 
longitudinal studies, one can assume that moderate alcohol consumption 
(less than 4 drinks a day) reduces the risk of IHD. 
Based on the data in table 6.22, which include very diverse populations, 
we will assume that moderate drinkers have the lowest IHD mortality. The 
relative risks reported by the different studies are not completely consistent 
and do not give data on different age groups nor do they agree on the dose-
effect relationship. Because the relationship is still controversial a moderate 
risk ratio of 2 for abstainers as well as excessive drinkers was assumed. In 
both cases the excess risk will disappear upon cessation. 
Alcohol and cirrhosis 
It has long been recognized that in most cases, cirrhosis of the liver is a 
disease that is caused directly by excessive alcohol consumption. Very few 
cirrhosis deaths are recorded in abstainers or moderate drinkers. Most are 
found in alcoholics. As with the definition of moderate drinkers there is a 
confusion in the literature about who is to be considered an alcoholic. We 
have few data on the prevalence of real alcoholism in the Netherlands since 
data are limited to those seeking treatment. Compared to surrounding 
countries there still is a low incidence ofliver cirrhosis in the Netherlands, 
given the current alcohol consumption. One explanation proposed, has 
been a leadtime, before the rapid increase in consumption results in notice-
able increase in liver cirrhosis. This expected mortality increase has in the 
meantime already been noted by Hoogendoorn (215). Another explanation 
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could be that although the absolute alcohol consumption has gone up since 
the second World War, this may be the result of a cohort effect. In that 
case the younger cohorts, as they age, will have a different "alcohol history" 
and the incidence of liver cirrhosis may increase even more sharply. 
There are detailed case control studies (223-225) available but to fit 
cirrhosis of the liver in the model with the other disease categories we 
have had to use a more general relative risk based on the same categories 
of alcohol consumption used for other diseases. The data come from a 
longitudinal study by Klatsky (221) on the Kaiser-Permanente population 
(see table 6.22). 
This will apply for all age categories and both sexes, for the heaviest 
drinkers only. The remnant IDR of 3 will be reached after 1 year with a 
LAT of 4 years. 
Alcohol and accidents 
Although alcohol is important in accidental deaths, both accidental falls 
and traffic accidents, it is extremely difficult to obtain data on relative risk 
ratio's. In the previous chapter it was shown that there are data on the 
number or proportion of accidents in which alcohol is implicated but that 
there are few data on the prevalence of alcohol use in the total population at 
risk. One could rely on the percentages found in the alcohol traffic controls 
but these are obviously not a representative sample of the automobilists 
nor of the hours in which autokilometers are covered (226). 
Again we relied on the data collected by Klatsky on the Kaiser-Perma-
nente population where he also recorded the number of deaths classified as 
due to accidents. Since he made no distinction between traffic accidents 
and accidental fall we shall use the relative risk ratio of 2 for both causes of 
death. This relative risk will apply only to the heavy drinkers and will be 
identical for men, women and both age groups. This excess risk disappears 
completely, immediately after cessation. 
Alcohol and breast cancer 
Although there have recently been suggestions (129, 131) that there is an 
increased risk for breast cancer in women who habitually drink even mod-
erate amounts of alcohol, we feel that at the moment the evidence is not yet 
sufficient to include this relationship in the current version of the model. 
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Table 6.22: Death by cause1 according to alcohol consumption 
Cause of death" Usual Nwnber of Drinks/Day 
(n=2015, Each Group) 
0 9 3-5 6+ 
n (%) mortality 
All malignant neoplasms, 45 (2.2) 42 (2.1) 53 (2.6) 75 (3.7) 
(140-209) 
Oral cavity and esophagus 2 (0.1) 0 (0.0) 5 (0.2) 8 (0.4) 
(140-150) 
Stomach (151) 3 (0.2) 3 (0.2) 3 (0.2) 4 (0.2) 
Colon and rectwn (153- 3 (0.2) 7 (0.4) 5 (0.3) 4 (0.2) 
154) 
Pancreas (157) 2 (0.1) 5 (0.3) 3 (0.2) 6 (0.3) 
Lung (162) 15 (0. 7) 7 (0.4) 16 (0.8) 24 (1.2) 
Breast (174) 4 (0.2) 1 (0.1) 3 (0.2) 3 (0.2) 
Genitourinary (180-189) 3 (0.2) 8 (0.4) 7 (0.4) 4 (0.2) 
Central nervous system 2 (0.1) 3 (0.2) 3 (0.2) 4 (0.2) 
(191-192) 
Lymphatic and hemato- 7 (0.4) 7 (0.4) 3 (0.2) 7 (0.4) 
poietic (200-209) 
Primary site unspeci- 2 (0.1) 0 (0.0) 3 (0.2) 7 (0.4) 
fied (196-199) 
Other specified site 2 (0.1) 1 (0.1) 2 (0.1) 4 (0.2) 
All cardiovascular (390- 88 (4.4) 64 (3.2) 82 (4.1) 77 (3.8) 
458) 
All coronary disease 66 (3.3) 40 (2.0) 47 (2.3) 55 (2.7) 
(410-414) 
Acute myocardial in- 36 (1.8) 22 (1.1) 29 (1.4) 22 (1.1) 
farction (410) 
Other coronary (411-414) 30 (1.5) 18 (0.9) 18 (0.9) 33 (1.6) 
Stroke (430-438) 10 (0.5) 15 (0.7) 16 (0.8) 9 (0.5) 
Other cardiovascular 12 (0.6) 9 (0.4) 19 (1.1) 13 (0.6) 
(390-409, 415-429, 439-
458) 
Respiratory ( 460-519) 7 (0.4) 3 (0.2) 12 (0.6) 18 (0.9) 
Cirrhosis (571) 5 (0.3) 0 (0.0) 12 (0.6) 33 (1.6) 
Accidents (800-959; E800- 16 (0.8) 8 (0.4) 19 (0.9) 39 (1.9) 
919) 
Other causes 16 (0.8) 9 (0.4) 9 (0.4) 13 (0.6) 
Total deaths 177 (8.8) 126 (6.3) 187 (9.3) 255 (12.7) 
1 In California from time of entry into study (1965 to 1968; mean dates = July 1966 
through 31 December 1976) 
2 Nwnbers in parentheses indicate code numbers of the lntemational Classification of 
Diseases Adapted, 8th revision 
3 Comparisons between groups were significant at p<0.05. Source: 221 
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Table 6.23: Differences in the prevalence of hypertension between groups 
with a high or a low alcohol consumption 
Authors Definition hypertension1 
Liam 
Klatsky et al 
Arkwright et al 
D 'Alonzo et al 
Dyer et al 
Kanneletal 
Mathews 
? 
160 and/or 95 
140 (syst.) 
160 and/or 95 
160 and/or 95 
160 and/or 95 
> 120 (pressure average) 
1 Systolic and diastolic blood pressure in mmHg 
2 P1 = high alcohol consumption, prevalence of hypertension 
P2 = low alcohol consumption, prevalence of hypertension 
Source: 231 
P1/P2" 
4.0 
1.5-2.4 
4.0 
2.3 
1.8 
2.0 
2,7 
6.6.3 Relationship to other risk factors 
The most important relationship of alcohol to other risk factors is the 
effect of heavy drinking on the prevalence of hypertension (227-230). This 
correlation has been noted by a number of investigators. The shape of 
the curve is not linear, it has been described as J shaped. As with the 
data on IHD deaths there are problems with the definition of moderate and 
heavy drinkers. In table 6.23 an overview of the relative risks found by the 
different investigators is summarized by Grobbee (231, 232). These are not 
yet routinely included in the current version of the Prevent model. 
6.7 Age of the mother at time of the first 
birth 
6.7.1 Prevalence data 
In the Netherlands data on the age of the mother at the time she gives birth 
to her first child, are available for all women born after 1932. Contrary to 
other risk factors, this variable can not change over a persons lifetime. Once 
a woman has had her first child, she is assigned to a risk category which 
will remain unchanged as she grows older. This means that the data are 
presented in a different way. Each age group represents a cohort of women 
of which a certain percentage has had a first child. As time proceeds this 
cohort will move to an older age group and will take the distribution of 
ages at first birth along. For the cohorts now over forty, few births will be 
added as they grow older but in the younger age group the percentage of 
women that has never had a child will continue to decrease over time. 
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Figure 6.1: Cumulative percentage of women who have had a first child in 
1984, by age at birth and by birth cohort 
cohort 
'SQ-'54 
cohort 
'45-'49 
cohort 
'40·'44 
cohort 
before 1935 
7.7 
69.2 
7.5 
Figure 6.1 shows the distribution of age specific fertility in 1984 for 
women born after 1932. Unfortunately no comparable data exist for older 
cohorts. Obviously the younger women will continue to have baby's and 
for the age group 25-29 we do not know how many will have had their first 
child before the age of 30. For the other age groups it is easier since we only 
need to make assumptions about the total "first fertility rate" that each 
cohort will achieve to calculate the percentage of first births occurring after 
the age of 30 and 35. We assume that this first fertility rate will remain at 
89%. More women may remain childless in the younger cohorts (although 
the current wave of "quick before its too late pregnancies" seems to belie 
this hypothesis) but misclassifications between women who have their first 
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Table 6.24: First fertility rate by age of the mother for different birth 
cohorts in 1984 
<20 20-29 30-34 35+ Never 
25-29 7 56.2? 31.8? 11 
30-34 11.5 60.7 8? 9? 11 
35-39 11.9 68.1 5.7 3.3? 11 
40-44 10.25 72.5 5.2 1 11.05 
45-49 8.1 72.3 6.5 1.2 11.9 
50-53 7.5 69.2 7.7 1.6 14 
child after the age of 30 and women who never have any children should not 
give rise to considerable error, since both have an increased risk for breast 
cancer. 
In table 6.24 the percentages by age group which were not available, 
were derived by assuming that each cohort would have a yearly fertility 
rate equivalent to that of the year before. This method was only used for 
the categories with partially complete data. The assumption was made 
that total first fertility remains constant and the remaining percentages are 
thus calculated. All data arrived at by these assumptions are marked with 
a question mark. 
As can be seen from these data there has been an important shift in 
the age at which women have their first child. After an initial rise in 
the percentage of women who had a child under the age of twenty in the 
fifties and sixties, there is a sharp drop after the early seventies which is 
probably related to the increasing availability of effective contraceptives. 
Most women have their children between the ages of 20 and 29. However 
this percentage starts to drop for the cohorts born after 1944. At the same 
time there is a rise in the percentage of first time mothers over 30 and 
increasingly over 35. 
6.7.2 IDR by disease category 
Age of mother at first birth and breast cancer 
It has been shown in many different populations, that the risk of breast 
cancer is related to childbearing. In fact the age at which the first child is 
born is the most important determinant in the relationship between fertility 
and breast cancer. McMahon et al (233) in their international collaborative 
study in the 1960's were able to quantify this relationship. They found a 
linear increase in the risk with the rising age of the mother as is shown in 
figure 6.2. 
128 
Source: 233 
CHAPTER 6. DATA USED IN THE MODEL 
Figure 6.2: 
Relative risk• of breast cancer according 
to age at first birth; data for all centres 
combined 
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Women who never bore children are the reference category and the birth 
of a child protects if the child is born before the mother reaches the age of 
35. These same results are given in table 6.25. 
The data on risk ratios presented by MacMahon were adjusted to fit 
the prevalence data (table C.13). 
Conclusion 
From this chapter it becomes obvious that although many relationships 
between risk factors and disease incidence/mortality rates are accepted as 
causal (see chapter 5), the exact quantification of that relationship in terms 
of risk ratios is often problematic. Where possible the empirical data were 
used. In some cases, as for instance with obesity and breast cancer, no 
trials are available on the effects of interventions, so that values for the 
remnant risk ratio for the ex-exposed and the lag and latency periods were 
estimated (prof. de Waard, personal communication). 
The current input data are a deliberate choice, necessary to illustrate 
the use of the Prevent model in the following chapters. Other users may 
prefer other values, but this will not change the type of data necessary, nor 
the type of results produced by Prevent (see also chapter 8 on the sensitivity 
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Table 6.25: Estimates of relative risk of breast cancer by age at delivery, 
for women of parity 1 only 
Relative risks1 , age at delivery being: No. of: 
Centre <20 20-24 25-29 30-34 ;::35 Any Cases Controls 
age 
Boston 19 72 60 107 118 76 77 233 
Glamorgan (50) 29 100 55 106 68 117 345 
Athens 44 64 65 120 81 76 129 433 
Slovenia 123 81 83 126 88 93 136 399 
Sao Paulo 66 70 102 (74) (175) 78 63 165 
Taipei (92) (61) (121) (50) (81) 74 22 48 
Tokyo 52 61 67 119 152 82 135 302 
All centres 58 62 77 98 104 78 679 1925 
1 Relative risks are expressed relative to a risk of 100 for non-parous women. 
Estimates are based on direct comparison of cases and controls, without adjustment. 
Values for cells containing less than 20 controls are shown in parentheses. 
Source: 233 
runs). 
This chapter is meant to show where we derived our data from. Since 
the reader may wish to have an overview of the input data files they are 
brought together in appendix C. 
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Introduction and 
summary 
In this section we shall show and analyze some of the results produced with 
the Prevent model. For this purpose a basic version of the model is used as 
an example. It is obvious that different opinions may exist on the choices 
made about input data and on past and future trends. Prevent offers the 
methodology, other users may eventually adjust input data to suit their 
population or specific interests. 
Using a very simple and straightforward intervention as an example, 
we shall show in the first chapter what kind of results Prevent produces 
and how the information they provide could be used to weigh policy deci-
sions. Two important outcome measures will be discussed: total mortality 
reduction and Actual Years of Life Gained (AYLG). In the total mortality 
reduction the different disease specific mortality reductions are reflected in 
the evolution of the curve over time. Both its peak value and the devel-
opment over time are important. The AYLG is the best overall outcome 
measure since it not only reflects the total mortality reduction but also the 
length of survival after a death avoided. For both benefit measures it is of 
interest to look not only at the total value but also at the distribution of 
health benefit in the population, for instance between men and women. 
To show the level of confidence that can be attached to the results of 
a model, it is often subjected to a form of testing. This can be sensitivity 
testing to see how sensitive the model is to the choice of the initial input 
data, or a historic reconstruction using the model to check whether, given 
the right data, the model will yield the correct results. In chapter 8 the 
results of the testing done with Prevent are presented. The sensitivity 
testing shows that the initial input data for IDR's and prevalence sometimes 
affect the level of outcome of the model but that it is the time dimension 
and the remnant IDR which really determine the characteristic shape of 
the result curves. In the historic testing an attempt was made to simulate 
151 
152 
the development oflung cancer mortality in the Netherlands between 1970 
and 1985, using historic data on smoking. The final conclusion must be 
that the available data leave some interesting questions unanswered, which 
may be worth additional research in the future, but which at present are 
outside the scope of Prevent. 
Chapter 7 
A basic Prevent run 
In the current version of the Prevent model, used in this example, the risk 
factors and disease categories included are shown in table 7.1. 
When considering risk factors and disease incidence, the first question 
to ask is to what extent these risk factors can explain the variance in disease 
specific incidence and mortality. The outcome measure of interest is the 
Etiologic Fraction at time 0. In the Prevent model the Etiologic Fraction 
is an age and sex specific value. Table 7.2 shows the Etiologic Fraction for 
the age group 60-64, for all the risk factor-disease combinations considered 
in the model, separately for men and women. 
The etiologic fraction not only gives an indication of the amount of 
variance in disease specific mortality that can be explained by the known 
risk factors, but it also sets the limits for the potential mortality reduction 
that can be achieved by an intervention on this risk factor. In table 7.2 
cigarette smoking can be held responsible for 86% of lung cancer mortality 
Table 7.1: Risk factors and diseases in the basic runs 
Risk factors Disease categories 
Cigarette smoking (Cig.Smoking) Ischemic heart disease 
Hypertension Cerebrovascular accident 
Hypercholesterolemia (Serumchol) Chronic Obstructive Lung 
Alcohol consumption Disease 
Obesity Lung cancer 
Age of mother at first birth (AMFB) Breast cancer 
Traffic accidents 
Accidental fall 
Liver cirrhosis 
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Table 7.2: Etiologic fractions in the Dutch population 1985 
Cig. Hyper- Serum- Alcohol Obesity AMFB 
smoking tension chol. 
M F M F M F M F F F 
IHD 36 23 33 47 19 - 34 39 - -
CVA 
- -
51 49 
- - - - - -
Lungca. 86 41 - - - - - - - -
Breastca. 
- - - - - - - -
4.3 23.5 
COLD 92 72 - - - - - - - -
Traffic 
accidents 
- - - - - -
13 1.2 - -
Accidental 
fall - - - - - - 13 1.2 - -
Cirrhosis - - - - - - 54 9 - -
and 92% of COLD mortality in 60-64 year old men and a lower but still 
impressive percentage in women. The EF for IHD is much lower. However 
although lung cancer is an important cause of mortality for men it is not 
nearly as important as ischaemic heart disease. A small percentage of IHD 
mortality prevented may still constitute a larger mortality reduction than 
a large percentage of lung cancer mortality prevented. This is the reason 
why it is also important to look at absolute measures of benefit. 
What is of interest in the etiologic fractions, is that these can give an 
impression of the extent to which disease categories are preventable. The 
above results show for instance that COLD could largely be eliminated 
through primary prevention, but not breast cancer. 
The following examples will show how the different variables in Prevent 
affect the health benefit estimates, both in proportional and in absolute 
terms. To show how the different variables interact they will be introduced 
one by one and the effect on outcome measures will be shown for one risk 
factor only, smoking. The other risk factors will only be used to illustrate 
specific interactions. Finally the health benefits of a 50% prevalence reduc-
tion on each risk factor, will be presented to compare the potential impact 
of primary prevention for the different risk factors. 
7.1 Smoking and health 
In the Prevent model cigarette smoking affects the following diseases: IHD, 
lung cancer and COLD. The input data are summarized in appendix C, 
and a future autonomous trend of a 1% reduction per year is assumed for 
all age, sex and exposure categories. 
7.1. SMOKING AND HEALTH 
Figure 7.1: 
Lung cancer mortality for men, three alternatives 
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As intervention, an immediate reduction by 50% of the prevalence of 
smokers in 1985 is assumed, in all age, sex and exposure categories. This 
highly unrealistic assumption of an immediate reduction is chosen because 
it allows us to illustrate the effect of the different time variables in Prevent. 
7 .1.1 Time dimensions 
In figure 7.1 the estimated development of total lung cancer mortality over 
time is shown under three different assumptions. Curve "a" represents 
the so called "null" scenario in which only the demographic aging of the 
population affects the total lung cancer mortality. This is what would be 
expected if the effects of smoking cessation were immediate and there were 
no changes in smoking prevalence in the future. 
Curve "b" shows the effect of adding a time variable and assuming a 
moderate future autonomous reduction in smoking prevalence ( -1%), based 
on the past trends. This is the reference or trend scenario as it will be 
used in these example runs. The initial dip in the lung cancer mortality is 
the result of the substantial reduction in smoking prevalence in the years 
before the simulation started. Because of the LAG and LAT variables this 
reduction continues to affect lung cancer mortality in the future. After 
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the effect of this past reduction wears off, the influence of demography and 
of the trend determine the evolution of the mortality. The negative trend 
in smoking prevalence makes the rise in lung cancer mortality due to the 
aging of the population, less steep than in the "null" scenario. Otherwise 
the curves "a" and "b" would have been parallel. 
Finally curve "c" shows the effect of an intervention in 1985. Lung 
cancer mortality is not affected by that intervention until after LAT years, 
until1989 the mortality evolves as it did in the reference scenario (the LAT 
for smoking and lung cancer is assumed to be four years). After 1989 the 
mortality starts to decrease slowly over LAG years. This is the lag time 
(ten years) necessary for the complete risk reduction of the ex-smokers, and 
thus also the time period necessary to see the full effect of the intervention. 
After LAG+LAT years, in 1999, the trend and the demography take over 
again and the mortality evolves parallel to the reference scenario. The pro-
portional reduction of lung cancer mortality due to the intervention remains 
the same but the absolute level of mortality increases due to demographic 
changes, although it does not again reach the 1985 level in this 25 year 
simulation. 
7.1.2 Multi factorial model 
Smoking does not only affect lung cancer mortality. Figures 7.2 and 7.3 
show the trend and the intervention scenario for IHD and COLD mortality, 
under the same assumptions as before. IHD has a short LAG+LAT period 
so that the effect of the intervention reaches a maximum already after 6 
years. 
For that same reason the effect of past reductions in smoking prevalence 
are not very marked. In the case of IHD mortality the effect of the aging of 
the population is so pronounced that despite the lowering of the age specific 
mortality due to the intervention, the absolute mortality exceeds the 1985 
level after approximately 10 years. 
For COLD on the other hand the LAG+LAT is extremely long (20 
years) so that past reductions in smoking continue to have a visible effect 
on mortality until 1995. After 1995 the demography and the assumed 
future trend in smoking cessation determine the COLD mortality in the 
trend scenario. In the intervention scenario, the effect of the intervention 
starts to be visible in 1995, but continues to affect the COLD mortality 
until 2005. However, there is also an initial rise in COLD mortality. This 
is the result of the long LAT period, in which COLD mortality is not yet 
affected by the intervention while IHD age specific mortality has already 
been markedly reduced: COLD mortality is in a sense substituted for IHD 
mortality. This is noticeable only for men, since the reduction in IHD 
7.1. SMOKING AND HEALTH 
Figure 7.2: 
Disease Specific Mortality (numbers) 
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Table 7.3: Total PIF and mortality reduction in 2000, by disease, after a 
50% reduction in smoking prevalence in 1985 
Lung cancer IHD COLD 
M F M F M F 
PIF (%) 33 29 5 3 16 14 
Mortality 
reduction 2501 383 954 376 533 248 
mortality is so much larger for men than for women. 
To illustrate the difference between the proportional and the absolute 
level of health benefit table 7.3 shows the PIF (proportional reduction in 
mortality) for all age groups and the absolute disease specific mortality 
reduction in the year 2000 for IHD, lung cancer and COLD after a 50% 
reduction in smoking in 1985. 
For men lung cancer represents both the highest proportional and abso-
lute mortality reduction. For women lung cancer also represents the highest 
proportional reduction but the absolute mortality reduction for IHD is al-
most as large. 
7 .1.3 Demography 
Ultimately it is the total health benefit to be derived from this hypotheti-
cal intervention, which is of interest. Figure 7.4 shows the total mortality 
reduction for men as well as the mortality reduction in each of the three 
disease categories affected by smoking. The total mortality reduction rep-
resents the absolute number of deaths prevented each year for the full simu-
lation period, as a result of the intervention. The effect of the different time 
dimensions of the three disease categories is easily recognized in the differ-
ent slopes of the top curve. It reaches its maximum after all the LAG+LAT 
years have passed. After that the mortality reduction starts to diminish. 
This is not because of the diminishing effect of the intervention on these 
three causes of death, but a result of the increase in mortality from other 
causes that is bound to occur in an aging population. 
The maximum mortality reduction in each disease category is reached 
after LAG+LAT years and then remains approximately constant while the 
total mortality reduction starts to go down. The fact that the disease spe-
cific mortality reduction is not completely constant is the result of the fact 
that the PIF is a proportional reduction in mortality. If the disease specific 
mortality changes considerably over the simulation period, for instance as 
a result of the aging of the population, the absolute mortality reduction 
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The two other composite outcome measures are the PYLG (potential 
years of life gained) and AYLG (actual years oflife gained). Figures 7.5 and 
7.6 show the PYLG and the AYLG resulting from the above intervention. 
PYLG in figure 7.5 shows very clearly that this measure is nothing but a 
mortality reduction weighed for the age at which death occurs. Since for the 
above diseases the age of death does not vary very much, the shape of the 
PYLG curve is basically identical to that of the total mortality reduction, 
with a slight extra emphasis on the effect caused by IHD mortality, which 
tends to occur at a slightly younger age than lung cancer or COLD. 
By contrast the actual years oflife gained, which shows how the "saved" 
individual remains part of the total population until he dies from another 
cause of death, develops in a very different way. It slowly builds up as more 
and more cases of death are prevented and accumulate in the population 
before dying. For the period of 25 years for which we have simulated in 
this run, the measure of AYLG continues to rise. This measure is maybe 
the best indication of the health benefit of an intervention since it shows 
the increase in the population over time, due to the intervention, a true 
cumulation of the year by year effect of the intervention. 
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Figure 7.5: Potential Years of Life Gained after smoking cessation 
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7.2 Other risk factors 
7.2.1 Hypertension 
The effects of a 50% reduction in hypertension in all age, sex and exposure 
categories in the Dutch population is shown in figure 7.7. 
Hypertension affects both IHD and CVA. In both cases the effect of the 
intervention is proportionally small. The short LAG and LAT times are 
clearly apparent by the immediate effect of the intervention and the short 
period after which both populations evolve in a parallel way again. 
However the total mortality reduction shows that the relatively small 
proportional change in disease specific mortality does lead to a sizable re-
duction in total mortality. The peak level is comparable to the peak level 
achieved by the smoking intervention but both the evolution over time and 
the individual contribution of female and male mortality reduction differ 
greatly. 
The male/female contribution to the health benefit is interesting. For 
IHD we see that although the level of mortality is lower for women than 
for men, the effect of a reduction in hypertension prevalence is greater 
for women than for men, due to the higher prevalence of hypertension 
especially among older women and the higher IDR values for women. In 
the case of CVA women have higher initial mortality rates, and the effect of 
the intervention is almost identical for men and for women. Together the 
effect on IHD and CVA is initially higher for women than for men but after 
approximately 20 years this is reversed. Probably this crossover is the result 
of the fact that the aging of the population seems to affect the male IHD 
mortality much more than the female IHD mortality. This is an illustration 
of the difference between proportional and absolute mortality reduction 
mentioned earlier: after a certain number of years the same proportional 
reduction in mortality means a larger number of deaths prevented for men, 
while the number for women barely increases over the years. 
If we compare the effect of a 50% reduction in smoking and a 50% reduc-
tion in the prevalence hypertension (see figure 7.4 and 7.8), an important 
difference is the fact that the mortality reduction in the case of smoking 
is almost entirely in the male population while in the case of hypertension 
both men and women benefit from the intervention. The peak mortality 
reduction achieved by a 50% reduction in hypertension is only slightly lower 
than in smoking, but the mortality reduction as a result of smoking cessa-
tion persists for a longer period, therefore the total benefit (the area under 
the curve) is much greater in the case of the smoking intervention. 
This example illustrates two points that should be considered when 
comparing benefits. In the first place the total benefit may be identical but 
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Disease Specific Mortality (numbers) from IHD 
....,, trend 
..-n,. lntarv. 
wotMn,. lnt•ru. 
--------··················· 
a 
PREUENT 
u.r:alon 0.2 
20000 
15200 
12800 
10400 
........................................................................... 
.................... ...-------------------------------------·---------------
... ~~~~· ----~--
' ____ ... ~ 
~~ ........... .. 
8000 
1985 1990 
_ ... ---
1995 2000 2005 2010 
Disease Specific Mortality <numbers) 
10000 
from CUA 
..an, trend 
....,, lnteru. 
wototen, lnt•ru. 
b 
PREUEHT 
v.rslon 0.2 
8600 
. 
.......
........................................................ . 
__________ ., __ ... -
.. ........ ,.... . .. ------·-------··-·· 
........ -
................ ________ ... -------------------------7200 
.................. -
5800 
4400 
3000 
1985 
......... 
1990 1995 2000 2005 2010 
7.2. OTHER RISK FACTORS 
Figure 7.8: 
Total Mortalit~ Reduction (numbers) 
PREUEHT 
v.rslon o.a 
3000 
2400 
1800 
1200 
600 
0 
163 
the distribution of the benefit over sub populations may differ. In this case 
it concerned the male/female distribution but similar differences may arise 
between age groups or between socioeconomic groups. Secondly the peak 
mortality reduction is not the best measure of effect since the persistence 
over time may vary. The AYLG measure of effect is therefore more reliable 
as comparative measure since this shows the cumulative effect. Figure 7.9 
shows the AYLG for the intervention on smoking and hypertension and 
clearly illustrates the difference of the effect on population growth of both 
interventions. 
7.2.2 Alcohol 
An intervention on alcohol is used here to illustrate the importance of look-
ing at all the disease categories affected by a risk factor. In prevention 
there is always a lively debate on the population versus the high risk group 
approach. The point is whether more benefits can be achieved by slightly 
reducing the risk of many versus considerably reducing the risk of a few. In 
the prevention of alcohol related death another dimension is added to this 
debate by the Ledermann theory which states that the number of excessive 
drinkers is directly related to the total number of drinkers in a population. 
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Figure 7.9: Actual Years of Life Gained after smoking cessation or reduction 
in hypertension 
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The question then becomes whether one should reduce the number of ex-
cessive drinkers by reducing the total number of drinkers in a population 
or whether one should exclusively lower the number of excessive drinkers 
without affecting the number of moderate drinkers. Both strategies are 
analyzed here. 
Lets assume for a moment that the effect of moderate alcohol consump-
tion on IHD mortality is indeed causal and that a shift from moderate 
alcohol consumption to total abstinence, will indeed result in an increase 
in IHD mortality. An alcohol campaign aimed at reducing the number of 
alcohol related accidents or the number of cases of cirrhosis of the liver, by 
an approach aimed at the excessive drinkers only can be compared with 
the strategy of the reduction of total alcohol consumption in the popula-
tion. Figure 7.10 shows the effect on mortality reduction of a 50% reduction 
of the proportion of drinkers in all exposure categories (a) and the effect 
if the preventive intervention would affect only excessive drinkers in the 
population (b). 
As with smoking, the mortality reduction is the result of changes in 
several diseases each with different time dimensions. In the case of ex-
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cessive drinkers only (b), there is a second peak caused by the reduction 
in mortality due to liver cirrhosis, after the initial effect due to IHD and 
traffic accidents. Men benefit more from the intervention, which is logical 
given that very few women drink excessively and that the diseases affected 
by alcohol, except accidental fall, are a more important cause of death for 
men. 
Although the effect on accidents may be the same for both interventions, 
the total mortality reduction is very different. Since a shift from moder-
ate drinking to total abstinence increases the risk of IHD, an intervention 
aimed at the total population has a negative effect on total mortality. The 
small proportional negative effect on the most important cause of death, 
IHD, far outweighs the positive effects on the mortality due to accidents or 
cirrhosis. This example illustrates that the health policy maker needs to 
weigh the advantages and disadvantages of alternative interventions for the 
total health of the population and not just the disease specific benefit. 
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Table 7.4: Total mortality reduction and AYLG in 2000 and 2010, after a 
50% reduction of different risk factors and a combined intervention 
Mortality reduction AYLG 
2000 2010 2000 2010 
M F M F M F M F 
Smoking 3087 793 2159 992 25687 5808 53006 15443 
Cholesterol 436 35 204 32 9777 384 12678 739 
Hypertension 814 808 916 269 18547 23476 26477 28164 
Alcohol 475 34 346 40 9756 607 13636 963 
Obesity 
- 28 - 12 - 595 - 782 
Combination 1783 640 1294 477 22675 11953 38027 17551 
7.3 Comparing risk factors 
Although the actual levels of disease specific mortality in the future will 
differ from those calculated by the Prevent model, if only because cura-
tive care is assumed static, interventions all of which are of a preventive 
nature, can be compared by assuming that all other circumstances remain 
unchanged. 
From the runs presented in this chapter, it is apparent that the height 
of the effect curve (for instance mortality reduction), its evolution over time 
and its shape vary considerably depending on the risk factor studied. 
Table 7.5 presents the proportional changes in disease specific mortality 
in the year 2000, for all the disease categories in Prevent, after a 50% 
reduction in the prevalence of each of the different risk factors in 1985. 
Again the intervention is presumed to be immediate and identical for all 
age, sex and exposure categories. Finally the effects of a simultaneous 
reduction by 20% of the prevalence of smoking, hypertension and elevated 
serum cholesterol are shown. The range of the effect of a 50% prevalence 
reduction for the different risk factors varies considerably and to a certain 
extent is accompanied by a substitution of causes of death. 
In order to compare the ultimate health benefits, table 7.4 shows the 
total mortality reduction and the AYLG in the year 2000 and 2010 of each 
of these interventions. 
Smoking will affect mortality to a far greater extent than any of the 
other risk factors. In 2000 the AYLG of men and women combined may 
still be greater for hypertension, in 2010 AYLG is much greater in the case 
of smoking. 
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7.4 Comparing health benefits 
Because of the different outcome measures used, the ranking of interventions 
is not always straightforward. Three aspects need to be addressed in order 
to be able to use quantitative data to set priorities. 
7 .4.1 Distribution of health versus maximizing health 
benefit 
The majority of the risk factors included in Prevent affect male mortal-
ity to a much greater extent than female mortality, with the exception of 
hypertension. Considering that the male population has lagged behind in 
the increase in life expectancy this century and that cardiovascular disease, 
which has started non communicable disease epidemiology mainly affects 
men this is not surprising. The diseases studied and the risk factors iden-
tified have concentrated on the male population, and hence in the Prevent 
model it is male mortality that is most affected by preventive interventions. 
If the general health goal is to achieve an equal distribution of effect 
between men and women, the choice of an intervention might be different 
than when the goal is simply a maximum mortality reduction. On the other 
hand women currently have a longer life expectancy than men. If the health 
goal is to achieve a more equal distribution of mortality these risk factors 
offer a good starting point since most of the proposed policy measures will 
tend to reduce the mortality gap between men and women. 
7.4.2 Short term versus long term benefits 
In some cases preventive investments will immediately yield effect such as 
in the case of alcohol and accidents, in other cases it will take almost twenty 
years to see the maximum level of benefit, as in smoking and Chronic Ob-
structive Lung Disease. The introduction of a time lag creates the danger 
that preventive measures will not be attractive (especially politically) be-
cause the promised benefits are so far ahead. If using even a small discount 
rate this may make prevention in general seem less attractive than curative 
interventions. 
There are two things to keep in mind when considering the distribution 
of effects over time: 
• The effect of an intervention on a risk factor for the disease being 
considered may take many years to become visible, such as in smoking 
and lung cancer but other benefits of the intervention may already 
be apparent earlier. This is illustrated in the Cancer scenario report 
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(1). An intervention on smoking is much more attractive when the 
effects of a smoking cessation program are not only considered for 
lung cancer but also for IHD, since these benefits will be apparent 
much sooner. 
• The long LAG times mean that a long simulation period may be 
necessary to show the full effect of a measure. Given the relatively 
short planning horizon for most governments, this will negatively in-
fluence the perceived benefits of prevention. Very often the benefits 
considered when discussing alternative interventions are only a small 
fraction of the total benefits because the time span considered is too 
short. In table 7.5 it was clear that, when comparing the AYLG ben-
efits in 2000, the choice of intervention might have been different than 
when looking at the estimates for 2010. This illustrates the impor-
tance of considering at least the full LAG+LAT period to assess the 
benefits of interventions. 
7 .4.3 The health indicator chosen 
The outcome measures that are considered in these analyses are based on 
mortality only. However it has rightly been argued that mortality is often 
but a poor indicator of health in industrialized countries. Some diseases 
with a considerable burden of disease, such as COLD, cause relatively little 
mortality. A ranking of priorities by mortality outcome measures will tend 
to give insufficient weight to these diseases. It would therefore be useful in a 
further elaboration of Prevent to also add a measure of morbidity. However 
when several outcome measures are available, the ranking of priorities may 
depend on the health outcome chosen. Already now, the different benefit 
measures in the Prevent model may lead to different decisions. 
Rather than using composite measures (with different objective dimen-
sions and sometimes with subjective value weights) to arrive at one dimen-
sion on which alternatives are compared, we would suggest the use of many 
different concurrent outcome variables: when all agree on the same ranking 
of alternative interventions, it will reinforce the decision, when they do not 
agree, it will force an open discussion of the general health goals pursued. 
A quantification of effects will then not only show the health benefits to 
be expected from the proposed intervention but also the benefits foregone 
because of interventions not taken. 
170 CHAPTER 7. A BASIC PREVENT RUN 
7.4.4 Conclusions 
In this chapter we have shown how the different features of Prevent affect 
the benefit estimates of risk factor interventions. The ranking of risk factors 
by maximum effect, differs when looking at proportional or at absolute 
disease specific mortality reductions, when comparing mortality reductions 
or actual years oflife gained, and according to the time horizon used. When 
using effect estimates for priority setting, choices will have to be made about 
the dimensions on which to maximize effect1 such as the distribution versus 
the total health benefits, short- versus longterm effects, and simple versus 
weighed indicators. The interpretation of the results will depend on the 
above choices as well as on the estimates of the "costs" to achieve these 
reductions in risk factor prevalence. 
Chapter 8 
Testing the model 
Once a model is operational the question remains how valid the results are. 
The most basic check, that of the correct performance of the calculations 
can be done by tedious handwork, but the more difficult problem of the 
value of the results remains to be addressed. The validity of the results 
will depend on both the credibility of the data put into the model and on 
the methodology used. Consequently, two main categories of checks were 
performed: a number of sensitivity runs to see how sensitive the model 
was to variations in the initial input data, and a historical analysis to see 
whether the model would have accurately simulated the actual lung cancer 
incidence from the historic prevalence data on cigarette smoking. Both will 
be discussed in this chapter. 
8.1 Sensitivity runs 
In chapter 5 and 6 the choice of IDR values and data on the prevalence of 
risk factors in the Dutch population have been discussed. The values used 
as input in the basic runs done with this version of the Prevent model, are 
shown in appendix C. However these input data remain a choice and it is 
important to see whether this choice by itself will greatly determine the 
results of the model. 
The variables used in the model can be divided into four categories: 
• The demographic data on the Dutch population and the disease re-
lated mortality rates. These are not estimates but simply recorded 
data, and as such are not really amenable to sensitivity runs. The 
only check performed on these data was to see whether the popula-
tion, and the mortality rates, after a long simulation period would 
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yield a population comparable to the one predicted by the Central 
Bureau of Statistics. The results of the model closely followed the 
CBS predictions. These variables were not investigated further. 
• The data on the Incidence Density Ratio for risk factors and certain 
causes of death. These variables obviously are the backbone of the 
model. The values found in different studies vary, sometimes slightly, 
sometimes considerably. Furthermore these data usually come from 
populations other than the Dutch population. Although we tried to 
select data coming from populations as similar as possible, it remains 
a possibility that the relative risks used are not really suitable for the 
population in the model. To check whether our choice greatly influ-
enced the results of different simulation runs both lowest and highest 
values found in literature were applied for each disease category, as 
well as combined for several disease categories simultaneously. Fi-
nally the remnant IDR was tested, which is the lowest value the IDR 
will attain for the "ex" level, by assuming that the IDR will never be 
lower than the IDR of the lowest exposure category. 
• The different time dimensions incorporated in the model. The LAG 
time between the intervention and the moment when the remnant 
IDR is reached is especially important since this determines in what 
order and to what extent the incidence reduction will affect the health 
benefit measure chosen. By eliminating both LAG and LAT the re-
sults should in fact resemble those that are obtained in the traditional 
epidemiologic calculations. The risk factor prevalence trends in the 
past will then be of no importance. 
• The data on the prevalence of risk factors in the Dutch population. 
These data were derived from studies on samples of the population 
and as such open to sampling errors. Different initial input of preva-
lence data were tested by using the EPOZ data as prevalence data 
for the Dutch population. 
8.1.1 IDR's 
Smoking 
The first and most important risk factor tested for different IDR val-
ues was smoking. To make the results of different runs comparable the 
same intervention was applied in all runs, an immediate reduction of 50% 
in smoking prevalence in all age, sex and exposure categories, with a sim-
ulation period of 25 years. 
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Table 8.1: IDR values for smoking/lung cancer 
20-64 65+ 
Prevent highest lowest Prevent highest lowest 
1-12 cig. 7 16.2 4 7 8.6 4 
13-22 cig. 12 27.6 4 12 12.3 4 
23+cig 20 89.3 4 20 24.3 4 
Table 8.2: IDR values for smoking/COLD 
Prevent highest lowest 
1-12 cig. 12 17 5 
13-22 cig. 25 26 11 
23+ cig. 30 38 19 
Table 8.3: Percentage difference for mortality without and with intervention 
and mortality reduction in 2010, for the highest and the lowest IDR values 
for smoking 
Highest IDR value Lowest IDR value 
M F M F 
Lung cancer 
Mort. trend -3 8 5 -9 
Mort. intervention -9 -13 33 -4 
Mort. reduction 10 73 -57 -22 
IHD 
Mort. trend 7 19 
Mort.intervention -5 6 
Mort. reduction 224 470 
COLD 
Mort. trend -3 9 10 -5 
Mort .intervention -6 -4 27 12 
Mort. reduction 4 10 -25 -41 
Total 
mort. reduction 29 67 -44 -38 
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Figure 8.1: 
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The highest values used for the IDR smoking/lung cancer were those 
reported by Pathak for a New Mexico population (2). The biggest difference 
is in the lowest smoking exposure category and in the younger age groups. 
The lowest IDR values used were those found in Levins study (3). 
In the literature there is little variation in the IDR's found for smok-
ing/IHD. When applying the higher values found in the youngest age groups 
to the total population, the effect of the intervention on IHD is more pro-
nounced. As a highest IDR value for COLD Doll's ( 4) data for all age and 
sex categories were used. 
In table 8.3 the effects of the different IDR values are presented as the 
percentage of the outcome values compared to those found in the standard 
Prevent runs. 
That the effect of an intervention would vary with the initial IDR value 
was to be expected, since the difference between the IDR and the remnant 
IDR determine the extent to which a change in prevalence of a risk factor 
will affect the disease specific mortality. What is interesting however in 
table 8.3 is that the mortality as simulated without an intervention is also 
affected by the initial IDR value. This is because both past and assumed 
future trends in risk factor prevalence will affect mortality to a different 
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extent and will thus interact with demography in a different way. For 
smoking this is best illustrated by the difference in the effect of a higher 
or lower IDR value for smoking related diseases, between men and women. 
A higher IDR value will in general result in a lower mortality in the trend 
or reference population for men. This is the result of the fact that the 
substantial decrease in smoking prevalence in the last decades will have 
more effect on future mortality. Women on the other hand have a number 
of birth cohorts moving into the vulnerable age groups which have a very 
different smoking history than the current elderly women. More smokers 
will result in a higher trend mortality when the IDR's are higher. For both 
men and women the effect of an intervention will be greater if the IDR's are 
higher, but because of the higher trend mortality, the mortality reduction 
as a result of the intervention will increase more for women than for men 
with a higher initial IDR. 
An important point is illustrated by the large percentage differences for 
the highest IHD IDR values. The large possible risk reductions when the 
higher IDR's are applied, mostly affect the older age groups in which the 
IHD mortality is concentrated, in other words in those groups for which 
the absolute mortality is greatest. IHD mortality is therefore much more 
sensitive to initial input data than the less important causes of death. 
When the highest and the lowest IDR value for all the diseases affected 
by smoking were combined, the total mortality reductions found, are shown 
in figure 8.1. The differences in overall mortality benefits are considerable. 
IHD is again shown to play a major role in the overall mortality (see the 
difference in slope in the first 5-10 years of the simulation period). 
Hypertension 
Table 8.4: IDR values for hypertension/IHD (males). 
normal highest lowest 
<45 >45 
mild 1.9 1.6 1.9 1 
severe 2.3 1.8 2.9 1.8 
Hypertension not only influences IHD but also CVA. Again we compared 
the same intervention, an immediate 50% reduction in the prevalence of 
hypertension, for all age sex and exposure categories, with a simulation 
time of 25 years, under different assumptions of IDR's. This time the 
highest IDR values applied for IHD, were those reported for young women 
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(severe) and young men (mild), and the lowest those reported for older men 
(severe). 
The crossover between male and female mortality benefit discussed ear-
lier, disappears as soon as the higher IDR hypertension/IHD values are 
assigned (see table 8.4 and fig.8.2). The proportional effect on mortality of 
the intervention is now much higher, especially for the elderly women and 
the advantage of men is not any longer sufficient to create a crossover. The 
crossover reappears however with the lowest IDR values. 
Alcohol 
Alcohol affects four causes of death in the Prevent model, whereby abstain-
ers are given a higher risk for IHD than moderate drinkers. The IDR values 
found are more controversial than those discussed above, it is therefore more 
important to see how the results are influenced by the values chosen. As 
earlier we applied an immediate 50% reduction to "excessive" drinkers in 
all age and sex categories. 
Little is known about the effects of alcohol in comparison to the other 
risk factors mentioned so far. Few real intervention trials on population 
level have been attempted and few relative risk ratio's reported. We tested 
the hypothesis that alcohol is a much more important risk factor and ex-
perimentally assigned the highest IDR values shown in table 8.5. 
Table 8.5: IDR values for excessive alcohol consumption and related dis-
eases. 
normal highest lowest 
IHD 2 4 1 
cirrhosis 9 20 9 
traffic accidents 2 10 2 
accidental fall 2 5 2 
With the higher IDR values the total mortality reduction in 2010, after 
an intervention in 1985, went up by 61% for men and only 16% for women. 
Much of the health benefit came from traffic accidents (where men are more 
often killed than women), which was to be expected given the high increase 
in IDR alcohol/traffic accidents used in this run. 
Finally a run was made whereby alcohol was assumed to have no effect 
on ischemic heart disease neither as a risk factor nor as a protective factor 
in small quantities. The remaining effect of an intervention is minimal, and 
completely due to accidents and cirrhosis. The total mortality reduction is 
reduced by 78 % for men and 81 % for women. 
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Figure 8.2: Variation in expected mortality reduction with standard (a), 
high (b) and low (c) IDR 
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This last finding illustrates the importance of IHD on the quantitative 
effects of interventions. It is such a common cause of death that IHD 
mortality changes due to the varying IDR values, overshadow most other 
intervention effects. It is therefore clear that the uncertainty of the effects 
of alcohol consumption on IHD (see 5, the recent article from the Honolulu 
heart study) poses a major difficulty in estimating the potential health 
benefits of an anti-alcohol campaign. 
Remnant IDR 
In the final IDR sensitivity run it was assumed that interventions on risk 
factor prevalence through cessation programs are less successful than ex-
pected, because the final risk reduction of the "ex" category is not as great 
as assumed. We assumed that the remnant IDR's for ex-smokers were 
no lower than the IDR of the lowest exposure category. As expected the 
diseases with a high IDR and a large difference between lowest exposure 
IDR and final remnant IDR, such as lung cancer and COLD, are most af-
fected. Again as with the initial lower IDR it is the difference between the 
IDR and the remnant IDR which determines the range of the effect of an 
intervention. 
8.1.2 Time dimensions 
The time dimensions play an important role in the Prevent model. In pre-
vious chapters it was argued, that the lack of a time dimension in earlier 
epidemiologic effect estimates of risk factor interventions, may have been 
responsible for the disappointing results: too much was expected too soon. 
Three time dimensions were introduced: the LAG, the LAT and the possi-
bility to spread an intervention over a number of years. Only the first two 
assumptions need to be tested. 
The risk factor most affected by the LAG and the LAT is smoking, 
because of the very long time lags involved in both lung cancer and COLD. 
As a test we assumed there was no time lag (which in the model means 
setting LAG=l and LAT=O) and looked what the effect would be yet again 
of a 50% reduction of all age, sex and exposure categories in a 25 year 
simulation run. 
Fig. 8.3 show a sharp contrast with the traditional Prevent runs. Apart 
from the obvious difference in the tall and narrow peak early on, because all 
disease specific mortality gains occur at the same moment, it is interesting 
to see how the absence of a long LAG/LAT period reduces the importance 
of past prevalences. The disease specific mortality shows that immediately 
after the intervention the demography takes over again. 
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Figure 8.3: Health effects of smoking cessation with minimal time lags 
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Figure 8.3: continued 
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Figure 8.4: Variation in expected mortality reductions with varying initial 
hypertension prevalence data 
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8.1.3 Prevalence data 
Finally we looked at the possible effect of variation of initial prevalence data 
on the results of the model. Two risk factors were considered, hypertension 
and serum cholesterol, for which alternative prevalence data exist for the 
Dutch population from the EPOZ survey. In all trial runs the prevalence 
was again reduced by 50% for all age, sex and exposure categories. 
Fig. 8.4 show the combined results of the traditional Prevent run and 
the EPOZ run on hypertension and shows relatively little difference. 
Fig. 8.5 does the same thing for serum cholesterol. The differences 
this time are sizable. This is understandable, considering that EPOZ has a 
cutoff point of severe hypercholesterolemia of 270mg%. Consequently there 
is a far larger percentage of the population at high risk. The same effect 
is seen with the more recent MRFIT data. The EPOZ data were used 
to estimate the effect of lowering serum cholesterol when using the recent 
MRFIT data on exposure level and corresponding IDR values. 
Both runs show how sensitive Prevent is to such differences in initial 
prevalence data. In the standard run, interventions on serum cholesterol 
will have little effect on total mortality. But as soon as the EPOZ or MRFIT 
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Figure 8.5: Variation in expected mortality reductions with varying initial 
serum cholesterol prevalence data 
EPOZ H 
EPOZ F 
NortU~~l " 
Nor~l F 
PREUE>IT 
v.rslon o.a 
3000 
2400 
0 
Figure 8.6: Variation in expected mortality reduction with the MrFit ex-
posure categories 
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Table 8.6: Smoking habits by age, sex and amount smoked in 1958. 
Age 20-30 31-50 51+ 
sex M F M F M F 
non- 14.3 54.1 9.6 68.9 15.3 85.2 
smokers 
2-17 cig 54.9 40.9 48.4 27.1 39.6 12.7 
18+ cig 30.8 5.0 42.0 4.0 45.1 2.1 
data are used, the total mortality reductions are comparable to those found 
with interventions on smoking and hypertension. 
8.1.4 Conclusions 
The above examples have shown that the results of a model such as Prevent, 
depend on the input data. The height of the mortality reduction curve is 
most influenced by the different assumptions about the IDR's, but the 
shape of the curve is primarily determined by the time variables included. 
In the basic runs discussed in this book, assumptions were made about 
the input data. This section illustrates that if other values are selected for 
policy purposes, it will always be necessary to explore to which extent these 
different assumptions influence the priority setting. 
8.2 Historical testing 
Models used to simulate future developments are often tested by applying 
them to historical data. In the case of Prevent a historical testing was done 
by looking at the development of lung cancer mortality in the Netherlands 
between 1970 and 1984. Lung cancer is a disease for which the case fatality 
and the survival period have not changed significantly for the period stud-
ied, the assumption of ceteris paribus is thus realistic. Furthermore lung 
cancer is influenced mainly by smoking and smoking is one of the few risk 
factors for which there are relatively detailed historical prevalence data. 
8.2.1 The Prevent estimate 
The first survey on smoking habits in the Netherlands was done by Gadourek 
in 1958. He interviewed 1300 individuals about their lifestyles and published 
these data in 1963 (6). He did not report smoking habits and the amount 
smoked by age but did provide information by birth cohort. 
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Table 8.7: Smoking habits by age, sex and amount smoked in 1970. 
Age 20-24 25-34 35-49 50-64 65+ 
Sex M F M F M F M F M F 
Smokers 
1-12 cig 55.9 45.7 49.4 39.9 46.1 32.8 49.9 20.4 54.4 10.7 
13-22 cig 14.7 10.3 18.3 9.1 20.0 8.8 18.8 3.8 14.1 1.1 
23+ cig 6.4 4.2 9.3 3.9 10.9 3.2 9.3 1.8 6.8 1.2 
Ex-
smokers 
1-12 cig - - - - - - - 5 - 2.0 
13-22 cig 
- - 12 - 11 - 10 - 7 -
23+ cig - - 6 - 7 - 8 - 5.2 -
Non-
smokers 23 39.8 5 47.1 5 55.2 6 69 12.5 85.2 
These data show that in 1958 virtually all men smoked and that es-
pecially in the older age groups they smoked heavily. The women show a 
different smoking pattern, few older women smoked but younger women 
were starting in larger numbers. However there are very few heavy smok-
ers among women. These data were used to reconstruct the number of 
ex-smokers in 1970. 
The NOP survey of 1970 reported the prevalence of smoking and asked 
about the amount smoked. Using the raw material data by age, sex and 
amount smoked were extracted (table 8.7).1 
These prevalence data were used with a future trend to fit the real de-
velopment in smoking prevalences. The number of ex-smokers was adjusted 
to fit the cohort data reported by Gadourek. 
The population data used were the CBS 1970 Dutch population with 
the corresponding mortality quotients. With these data the Prevent model 
was used to estimate the Dutch lung cancer mortality during the period 
1970-84. 
Figure 8.7 shows that the lung cancer mortality, as predicted by Pre-
vent, is substantially lower than the observed mortality in both men and 
women. It is not surprising that Prevent expects a reduction in age specific 
lung cancer mortality after the early 1970's, since smoking prevalences had 
been going down since 1958. The observed lung cancer mortality shows 
an increase in the age specific lung cancer mortality and the difference be-
1 To get data comparable to the 1985 input, the assumption had to be made that 
the amount smoked increased in a linear fashion. A second assumption was that those, 
who omitted to answer the question about the amount smoked, represented a unbiased 
sample of the population of smokers and could be distributed proportionally over the 
exposure categories. 
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Figure 8. 7: Observed and predicted lung cancer mortality 1970-1985 
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tween observed and predicted mortality poses questions about the validity 
of the input data or the parameters used to predict the lung cancer mortal-
ity. Both will be explored in the following paragraphs, to see whether the 
cause for the under estimate by Prevent can be found and more importantly 
whether this will affect the use of Prevent for future estimates. 
8.2.2 Parameters 
The nature of models like Prevent is that they use quantitative evidence of 
causal relationships from empirical studies to explain changes in an outcome 
variable such as lung cancer mortality. Another approach is to hypothesize 
a causal relationship in a mathematical model because certain variables 
correctly predict the variation in the outcome measure. For lung cancer 
mortality both approaches have been used (7, 8). 
Because of the choice in this project to start from the observed rela-
tionship between risk factors and disease mortality in epidemiology, it is 
not likely that the causal relationship between lung cancer and smoking as 
such will not be correct. One possibility for the under estimation is that 
the parameters used to predict the lung cancer mortality are not sufficient. 
It is possible that the exposure categories in the Prevent model are not the 
only relevant exposure dimensions that should be taken into account or that 
other risk factors than cigarette smoking determine lung cancer mortality. 
Townsend (7) and Peto (9) show for instance, that the age of first ex-
posure and the length of exposure may be important variables. Although 
the smoking prevalence data for the Netherlands are not as detailed as the 
British ones, the effect of these dimensions on the lung cancer mortality 
predictions by Prevent were explored. 
The data used to reconstruct the smoking history of the different cohorts 
are memory recall data on the age at which smoking was started, from 
Gadourek. Figure 8.8 and 8.9 show the percentage of each cohort that 
smoked over the years. 
Men in the early birth cohorts started to smoke as children, many before 
they were ten years old and by the age of 20 more than 90% of a cohort 
smoked. These men continued to smoke until the general downward trend 
in smoking prevalence started in the late 50's. However these data do not 
suggest that the age at which smoking started ever increased to over 20. 
It shows no indication that this parameter, if included, would result in an 
increase in age specific lung cancer mortality over time. 
Cumulative exposure in a situation where exposure starts approximately 
at the same age, as smoking did in men, can be expressed in an increase in 
relative risk for older age groups or can be related to the remnant IDR at the 
age of cessation. It may be realistic to assume that because of cumulative 
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Figure 8.8: Prevalence of smokers by birth cohort for men from 1887-1984 
100 Men 
90 
80 
70 
t 
0 
.c 
0 
" 
"' 50 t 
:1i 
, 
.0 
~ 
"' 
"' 
40 .... .... .... 0 :::: 
"' "' 
0 
.... .... .... 
"' "' " 
.... 
E 
"' ~ 
30 
20 !;; 
10 
5 
1887 '97 1907 '17 '27 '37 '47 '57 '67 '77 '87 Year 
188 CHAPTER 8. TESTING THE MODEL 
Figure 8.9: Prevalence of smokers by birth cohort for women from 1887-
1984 
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Table 8.8: Adjusted smoking/ lung cancer IDR's. 
20-34 35-49 50-64 65+ 
lOR Remn. lOR Remn. lOR Remn. lOR Remn. 
1-12 cig. 1.5 1.2 6 2 13.5 6 13.5 13.5 
13-22 cig. 3 1.2 12 2 27 12 27 27 
23+ cig. 4 1.2 16 2 36 16 36 36 
exposure, the effect of smoking cessation is not as great in the older age 
groups, and may even be non existent after a certain age. A run was done in 
which we assumed that smoking cessation after 50 years would only result 
in a limited reduction in risk and after 65 in no risk reduction. In the 
last case the remnant IDR remains identical to the IDR of the exposure 
category from which the ex-smoker comes. There is a rise in the mortality 
especially for men, but it is not sufficient to achieve a satisfactory fit. 
The above cohort smoking figures are not detailed enough to make a 
careful analysis of exposure history as done by Townsend but a rough es-
timate of the length of exposure can be added to the model, by increasing 
the IDR with age. 
In table 8.8 the IDR's were adjusted for the different age categories to 
show an increase with age as well as a high remnant IDR in the older age 
groups to simulate the irreversible damage of very long exposure. 
Although the above IDR adjustments result in a small increase in mor-
tality it is not sufficient to correctly predict the observed mortality increase. 
8.2.3 The input data 
The lung cancer mortality as modeled by Prevent, is determined by the 
following variables: 
• demography 
• age specific mortality in 1970 for lung cancer and for the total mor-
tality due to other causes. 
• smoking prevalence data by age, sex and exposure category 
• the time dimensions LAG and LAT 
• IDR's by exposure and the remnant IDR for ex-smokers 
For all of these variables choices were made for the initial input data. It is 
possible that these choices are responsible for the under estimates. 
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Demography 
Data on the real population in 1970 were used and the demographic devel-
opment in the model closely follows the development of the real population, 
so that this can not be an explanation for the absence of the rise in mortality 
in the predicted values. 
Age specific mortality 
Age specific mortality quotients used, are the observed numbers in the 
Dutch population in 1970. In the Prevent model changes in mortality quo-
tients are assumed to occur as a result of changes in risk factor prevalence. 
For smoking related causes of mortality this indeed happens in this his-
toric reconstruction. However for the other causes of death no change is 
assumed. If there were an important reduction in these causes of death this 
may account for a rise in absolute lung cancer mortality quite apart from 
trends in age specific lung cancer mortality due to the change in smoking 
behavior. 
When a trend in these mortality quotients was applied simulating the 
real development over that period this did result in an increase in lung 
cancer mortality. The increase however, was not sufficient to achieve a 
good fit. 
Prevalence data 
The crude prevalence of smoking in the population reportedly decreased 
since the first survey by Gadourek. Therefore a simple increase in the 
prevalence of smoking can not be the explanation for Prevent's under esti-
mation. However within the group of smokers a shift in the amount smoked 
could possibly explain the increase in incidence, either because there is an 
absolute increase in heavy smokers or because all smokers have increased 
the amount they smoke over time. 
Although the age and exposure categories do not quite correspond, ta-
ble 8.9 shows that the number of light smokers has diminished more than 
the number of heavy smokers. In a relative sense the prevalence of heavy 
smokers among smokers has increased. However the data do not show an 
increase in the absolute proportion of heavy smokers in the population. 
The reported increase in the sales of cigarettes until the late 1970's 
does not agree with the reported reduction in the number of smokers even 
when the shift to more heavy smokers is taken into account. This under 
reporting has already been discussed elsewhere. It indicates a general under 
reporting of amounts smoked, which may have increased over time due to 
the changing public attitude towards smoking. A general increase in the 
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Table 8.9: Proportion of the male population who smoke, by amount 
smoked and age for 1958, 1970 and 1985. 
Age 20-24 25-34 35-49 50-64 65+ 
Year 58 70 85 58 70 85 58 70 85 58 70 85 58 70 85 
Cig. 
1-12 56 22 49 21 46 20 50 22 54 23 
2-17 55 55 48 40 40 
13-22 15 14 18 19 20 17 19 16 14 12 
18+ 31 31 42 45 45 
23+ 6 4 9 7 11 10 9 10 7 6 
amount smoked over the period studied for all exposure categories could be 
expressed as an increase over that period of the IDR's associated with the 
different exposure categories. 
The time dimensions 
The LAG period of 10 years for smoking/ lung cancer was reported in 
the intervention trials. It may be that in reality the reduction of risk 
takes much longer and that a LAG of, for instance, 20 years may be more 
realistic. When tried it does result in an increase in mortality. There is also 
a postponement of the moment when the absolute mortality starts to go 
down. But it is not sufficient to achieve a realistic estimate of lung cancer 
mortality. 
An increase in LAT makes virtually no difference if it does not exceed 
12 years since the reduction in smoking after 1958 is almost linear. Further 
postponing the year in which changes in incidence become visible as changes 
in mortality, will not affect the absolute mortality results sufficiently as 
there was no proportional increase in smoking prevalence in the past. 
The IDR's 
The IDR's used as input in the Prevent model form a selection, as has 
already been discussed extensively in the previous pages. A higher IDR 
however, for instance because smoking affects lung cancer even more than 
thought until now, will not result in a sufficient increase in predicted mor-
tality. What is needed is an increase in IDR over time. 
If the development of the sales of cigarettes over time are a better indi-
cator of the amount smoked than the self reported exposure category, one 
would expect that the IDR associated with each exposure category would 
increase proportionally with the increase in cigarette sales. This increase 
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has to be calculated relative to the 1970 level, since it will result in propor-
tional changes in mortality relative to the 1970 mortality figures. 
An estimate of the lung cancer mortality after such a correction is made 
results in an acceptable fit between the lung cancer mortality as predicted 
by Prevent and the observed lung cancer mortality from 1970-84. This 
suggests that a correction in the reported amount smoked may be necessary 
to arrive at the correct prevalence data. Obviously the above correction is a 
very crude one: neither the distribution of the under reporting over different 
age, sex and exposure categories is considered nor the fact that the average 
tar and nicotine level of cigarettes has gone down in most western countries 
over that period (10). However it is remarkable that this simple correction 
not only achieves an acceptable fit but also correctly predicts the moment 
when the absolute lung cancer mortality for men reaches its highest level. 
From the above we must conclude that for the input data only a cor-
rection for the under reporting of cigarette consumption will result in an 
acceptable fit for the lung cancer mortality (see figure 8.10). To allow for 
such a correction, an IDRfac was introduced in the Prevent model. In the 
case of the relative sales of cigarettes, the IDRfac can be said to act as a 
period factor. 
8.2.4 A cohort effect 
The correction factor suggested above does not allow for a differentiation of 
effect by birth cohort. However if an IDR changes over time this could also 
be explained by changing susceptibility of the cohorts underlying the age 
specific prevalence data. To explore this hypothesis changes in lung cancer 
mortality should be described by birth cohort. 
One way to look at the differences by cohort is to show the percentage 
increase in age specific lung cancer mortality rate for men, in five year age 
group when one birth cohort is compared to the preceding birth cohort 
(see table 8.10). The rows are birth cohorts, the columns are years and 
the diagonals represent the same age groups. The 1950 mortality rates 
are the base line data. It shows for instance that the cohort, born in 1883 
consistently in each age group, had a lung cancer mortality rate 40% higher 
than the cohort born in 1878. 
Although table 8.10 is but a crude description, it does suggest that there 
is a strong cohort factor in the development of the lung cancer mortality. 
The fact that the percentage increases are so constant over the years for 
each birth cohort is highly suggestive. Our data on smoking or on the 
sales of cigarettes in no way explain the sharp increase for each successive 
birth cohort until1900 or the abrupt levelling off after that. The reductions 
after the 1913 cohort are accurately predicted by Prevent, and are therefore 
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Figure 8.10: Lung cancer mortality with correction for cigarette sales 
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Table 8.10: % increase in age specific lung cancer mortality /100.000, for 
each five year cohort compared to the previous cohort in that same age 
group, 1960, '65, '70, '75, '80. 
1960 1965 1970 1975 1980 
1873 30 
1878 50 47 
1883 40 40 40 
1888 50 40 40 47 
1893 60 50 50 60 40 
1898 40 50 40 40 30 
1903 20 20 20 20 20 
1908 20 20 20 14 20 
1913 1 5 2 2 0 
1918 8 8 5 3 1 
1923 -30 -7 -2 -9 -10 
probably the result of the reduction in smoking prevalence. 
The hypothesis of a cohort effect in the history of smoking and lung 
cancer is not a new idea. For the Netherlands it was already found and 
quantified by van der Hoff in 1977 (11). He made an analysis of the available 
mortality figures and concluded that he could extract a cohort factor, an 
age factor and a correction factor (which could be considered a period 
effect). The value of the cohort risk factor increases for all birth cohorts 
born before 1900, remains constant for those born between 1900-30. He 
predicts a sharp reduction of the cohort factor for later birth cohorts but in 
1977 this was based on very few deaths. A problem with this cohort factor 
for our analysis is, that it represents both the effect of the differences in 
smoking prevalence between the cohorts and the additional cohort factor 
which may explain the sharp increase in lung cancer mortality for the early 
birth cohorts. 
Hoogendoorn (12) has shown that the trends in lung cancer mortality 
for men between 1950-1980 differ by age group. Although this is not an 
analysis by birth cohort his data suggest a change in trends occurring at 
different moments for different age groups. Finally Verbeek et al.(13) re-
cently performed an analysis of the lung cancer mortality by period and by 
birth cohort. For men they found a levelling off of the increase in age spe-
cific mortality for the younger birth cohorts (those born after 1910), while 
the women continue to show a increase in age specific mortality rates for 
each new birth cohort. 
It is clear from these analyses that different birth cohorts have a differ-
ent age specific lung cancer mortality and that after years of rising rates 
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for men there appears to be a slight decrease, heralding the peak of the 
epidemic. Our original assumption was that these cohort specific lung can-
cer mortality rates would be explained by the differences in the prevalence 
of smoking among those cohorts. The Prevent runs in figure 8.7 show that 
the differences in smoking prevalences now and in the recent past can not 
adequately predict the evolution of lung cancer mortality. If there is in-
deed another cohort factor that influenced lung cancer mortality for the 
older birth cohorts, there should be a difference in how accurately Prevent 
predicts lung cancer mortality for the different birth cohorts. 
Figure 8.11 shows the age specific mortality rates for lung cancer for 
three different years. In each figure the observed mortality is shown as 
well as the original estimate of the Prevent model. The third line is the 
mortality as it is predicted by Prevent if the correction for the sale of 
cigarettes suggested earlier, is applied. 
It shows that the original underestimation by Prevent is especially im-
portant in the oldest birth cohorts. These seem to be the cohorts for which 
the smoking history does not correctly predict the lung cancer mortality. 
The lung cancer mortality of the younger birth cohorts is correctly esti-
mated by Prevent and in fact the correction as suggested earlier, certainly 
does not improve the fit for these cohorts. Our conclusion is therefore 
that there is indeed another cohort factor which influences the lung cancer 
mortality in the older birth cohorts. 
Many hypotheses can be put forward to explain this cohort effect, for 
instance the possibility that environmental factors known to affect lung 
cancer incidence, such as coal fumes or housing conditions or harmful ex-
posure in the working environment, account either directly for the rise in 
lung cancer mortality or for the increased susceptibility for the dangers 
of cigarette smoke in the earlier birth cohorts. At this moment there is 
insufficient data to corroborate any of these hypotheses. 
Prevent can however, through the introduction of the IDRfac, calcu-
late the value of this extra cohort factor necessary to fit the lung cancer 
mortality between 1970 and 1985. This was only done for men and for 
the birth cohorts born between 1906 and 1927 since those were the only 
groups for which sufficient deaths were recorded to do a useful analysis. 
We used the lung cancer mortality quotients by age, cohort and year of 
death as produced by CBS. For the years 1972, 75, 78 and 81 these were 
compared to the values predicted by Prevent and the necessary corrective 
IDRfac for that year was assigned to the respective cohorts. The IDRfac 
then represents the correction factor necessary for each birth cohort, in 
each year to achieve a predicted mortality that equals the observed lung 
cancer mortality. In figure 8.12 the resulting IDRfacs are shown. Although 
they all concern the same period (1970-85) the cohorts have been pulled 
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Figure 8.11: Age specific lung cancer mortality /100,000 observed and pre-
dicted 1975, 1978, 1984 (log scale) 
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Figure 8.12: IDRfac for men for the cohorts born from 1906-1927 
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apart to facilitate the interpretation. They show that the correction factor 
necessary diminishes for the younger birth cohorts, stabilising around 1 for 
those born after 1918. 
The results correspond with table 8.10: a correction is necessary for the 
older cohorts while the lung cancer mortality for the younger cohorts is pre-
dicted fairly well by the smoking history and thus by Prevent. These results 
suggest that whatever the factor may be that caused the sharp increase in 
lung cancer mortality for the early birth cohorts, it does not appear to af-
fect the younger birth cohorts. Since these younger birth cohorts will be 
important for the future estimates made with Prevent there is no indication 
that a similar under estimation will also occur in those future runs. 
8.2.5 Conclusions 
Although the initial estimation of the historic development of lung cancer 
mortality by Prevent was disappointing, the subsequent search for expla-
nations makes the following conclusions possible. 
Prevent and the simple epidemiologic model of risk factors and relative 
risks do not always describe reality adequately. An adjustment in the initial 
input data can not achieve a satisfactory fit. The introduction ofthe IDRfac 
correcting for the under reporting of the consumption of cigarettes did 
achieve an acceptable overall fit, but when shown by age group it resulted 
in an over estimate in the younger birth cohorts and a remaining under 
estimate for the older birth cohorts. 
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Different dimensions of exposure may be needed which are not always 
routinely available. The cohort development of lung cancer mortality sug-
gests that it may be very useful or even necessary to have exposure data 
by birth cohort. 
Even when the effect of a change in risk factor prevalence is correctly 
estimated, the confounding effect of other risk factors may distort the final 
results. As long as we do not know which factors those are, we will have to 
use the assumption of ceteris paribus for effect estimates into the future. It 
does mean that absolute numbers as predicted by Prevent have to be used 
cautiously. 
Two corrective factors were introduced in this chapter, a period IDRfac 
representing the proportional change in the sale of cigarettes, and the cohort 
IDRfac, for which we do not know at present what it represents. The fact 
that the latter appears to be only necessary for the birth cohorts born 
before 1920, makes it possible to assume that it will not be important for 
the cohorts determining the lung cancer mortality after 1985. The former 
allows for a correction based on expected sales of cigarettes. The availability 
of the IDRfac in the Prevent model however, allows users to make different 
assumptions. 
References Part IV 
1 Stuurgroep Toekomstscenario's Gezondheidszorg Kanker in Neder-
land. Deel 1. Scenario's over kanker 1985-2000 (1987) 
2 Pathak, D.R. et al. Determinants of lung cancer risk in cigarette 
smokers in New Mexico. J Natl Cancer Inst 76 (1986) p. 597-604 
3 Levin, M.L. The occurence of lung cancer in man. Acta Unio Inter-
nationalis Contra Cancrum 9 (1953) p. 531-541 
4 Doll, R., Peto, R. Mortality in relation to smoking, 20 years observa-
tions on male british doctors. Br Med J Dec.2 (1976) p. 1525-1536 
5 Donahue, R.P. et al. Alcohol and Hemorrhagic stroke. The Honolulu 
Heart Program. JAMA 255 (1986) p. 2311-2314 
6 Gadourek, I. Riskante gewoonten en zorg voor eigen welzijn. Een 
structurele sociologische analyse van het roken en het drinken. Wolters. 
Groningen (1963) 
7 Townsend, J.L. Smoking and lung cancer, a cohort data study of men 
and women in England and Walrs 1935-70. J R Statist Soc A141 
(1978) p. 95-107 
8 Hakulinen, T., Pukkala, E. Future incidence of lungcancer: forecasts 
based on hypothetical changes in the smoking habits of males. Int J 
Epidemiol10 (1981) p. 223-240. 
9 Peto, R. Epidemiology, multistage models and short term mutagenic-
ity tests. Origins of human cancer. Hiatt HH (ed) Cold Spring Harbor 
(1977) 
10 Doll, R., Peto, R. The causes of cancer, quantitative estimates of 
avoidable risk of cancer in the US today. Oxford medical publications. 
Oxford University Press (1981) 
199 
200 REFERENCES PART IV 
11 Hoff, N.M. v. d. Cohort analysis of lung cancer in the Netherlands. 
Int J Epidemiol 8 (1979) p.41-47 
12 Hoogendoorn D. Trends in kankersterfte Ned Tijdschr Geneeskd 127 
(1983) p. 1661-1668 
13 Verbeek, A.L.M., Peeters, P.H.M., Sturmans, F. Is de top van de 
longkanker-epidemie in Nederland in zicht? Ned Tijdschr Geneeskd 
129 (1985) p. 2365-69 
Part V 
DISCUSSION AND 
CONCLUSION 
201 

Chapter 9 
Policy making with 
Prevent 
So far it was shown how Prevent works, what data are incorporated and 
how the outcomes should be interpreted and valued. In this last section we 
discuss some illustrations of the possible uses of the model, and the results 
of the project in general. 
Prevent was initiated to translate known epidemiologic data on the re-
lationship between risk factors and disease incidence, into measures that 
could be used in health policy decisions. The ability to quantify the health 
effects of changing risk factor prevalence in a population can be of use for 
different aspects of health policy making. The following three implementa-
tions will be demonstrated in this chapter: 
• a straightforward quantification exercise of the health status changes 
in the population as a result of (autonomous) changes in risk factor 
prevalence, 
• the ability to quantify (realistic) disease specific targets and the changes 
of risk factor prevalence necessary to achieve these, 
• and finally the use of effect estimates in formal priority setting such 
as cost-effectiveness analysis. 
The ability of Prevent to calculate the effectofa change in risk factor preva-
lence, on the incidence of disease over and above the changes already occur-
ring because of autonomous trends in risk factor prevalence, demographic 
changes or competing death risks, allows for a quantitative estimate of the 
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net benefit to be derived from that intervention, in a situation where all 
other circumstances are assumed to remain unchanged. 
As such the use of Prevent may be a tool in health planning as pro-
posed by WHO. In this chapter we shall show some examples of the way 
Prevent could be used, using existing policy documents in the Netherlands. 
Obviously the assumptions about future trends and time spread of inter-
ventions, as well as the initial input data are choices we made. What is 
demonstrated here is the tool, the results are but illustrations. 
9.1 Health effects of risk factors 
The first example will concern itself with scenario's. In the Netherlands 
a number of expert committees has recently advised the government on 
possible and probable future development in certain fields of health and 
health care. These future developments are not presented as predictions 
but rather as alternative scenario's based on a combination of autonomous 
determinants and deliberate changes in relevant policy areas. Two of these 
scenario reports will be discussed here, the Lifestyle scenario {1) and the 
Cancer scenario report (2). 
9.1.1 Lifestyle scenario's 
The first is a scenario committee concerned with future development of 
lifestyles. The scenario committee did not have an easy task since they set 
out to analyze and if possible quantify a very broad range of lifestyle and 
socio cultural determinants of health. The outcome of that study was a 
number of alternative developments in the prevalence of certain risk fac-
tors, in the form of a reference scenario, as the most likely development if 
all circumstances remain equal, and several alternative scenario's resulting 
from varying assumptions about autonomous or deliberate changes in so-
ciety. In this example we shall look only at the smoking scenario's as they 
were presented by the committee, showing the changes in health outcomes 
that would result from these different smoking scenario's. 
The Lifestyle committee assumes that in a realistic (reference) scenario 
there will be a continuing downward trend in the prevalence of smoking 
resulting in 25% smokers for men and 24% for women in 2000. Offset 
against that is the pessimistic development, in which smoking prevalence 
remains unchanged and the optimistic scenario in which only 7% of the 
population will smoke in 2000. We have spread the percentage smokers over 
the exposure categories proportionally to match the current distribution. 
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Figure 9.1: The health effects of the three smoking scenario's of the Lifestyle 
scenario committee. (realistic, optimistic, pessimistic) 
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In the realistic scenario the continuing reduction in smoking prevalence 
is able to counteract the aging of the population and the absolute mortality 
for lung cancer remains fairly constant for men (see figure 9.1). For women 
however an increase occurs as the older, (virtually) non-smoking cohorts 
are replaced by younger women with a smoking history. The same was 
seen for COLD mortality. In IHD mortality a proportional reduction is 
achieved but demographic changes are so important that absolute mortality 
increases even in the realistic scenario. This illustrates the importance of 
showing absolute measures of health as well as proportional health benefits, 
since only the optimistic scenario's, which would mean sizable reductions in 
smoking prevalence, will result in a real reduction of the future case load. In 
the above figures the intervention is spread over many years, so as to have 
reached the full effect in the year 2000, as was indicated by the committee. 
This means that the full health benefit will not be apparent until 2020. 
In these scenario's it is not specified whether the smoking cessation is 
concentrated in certain age or exposure categories. Just to illustrate how 
much difference this will make, the total mortality reduction (for men) 
achieved by the intervention of the optimistic scenario is shown, based on 
different assumptions about the groups in the population, the intervention 
is aimed at. In the first case the original spread of the prevalence over ex-
posure categories is assumed, in the second case the remaining 7% smokers 
are all assumed to be light smokers, in the third case on the contrary the 
intervention is only successful for light smokers so that all the remaining 
smokers are the heavy smokers. The results are shown in figure 9.2. 
Finally the results are shown when the intervention reaches different 
age groups. The original age distribution is compared with alternatives in 
which the intervention affects only older or younger smokers. 
Figure 9.2 shows that these specifications of the same scenario produce 
very different results, and show the necessity of not only proposing global 
interventions but of also specifying their distribution in the population. 
9.1.2 Cancer scenario's 
The second illustration of a straightforward quantification of health benefits 
from risk factor prevalence changes is one of the intervention scenario's from 
the scenario committee on cancers. The committee analyzed the effect of a 
smoking cessation program for middle-aged men, in which smokers in the 
age groups under 35 quit for 50% and in the age group 35-59 for 40%. 
Figure 9.3 illustrates that the reduction of smoking prevalence in middle 
aged men over a period of 15 years, will not lead to very sizable health 
benefits in the near future. We need to simulate for a rather long period 
to allow the intervention on middle-aged men to take full effect in the age 
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Figure 9.2: Optimistic scenario's with light smokers only, heavy smokers 
only, young smokers only and only old smokers 
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Figure 9.3: The effect of a reduction in smoking prevalence on lung cancer 
mortality as quantified by the Cancer scenario committee and by Prevent 
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groups where the mortality rates are high. The difference between Prevent 
and the Cancer scenario is not so much due to the quantification of the effect 
of the intervention, since the Cancer scenario's also incorporate a certain 
lag time before an effect becomes apparent, but to the development of the 
reference lung cancer mortality. Prevent incorporates the continuing effect 
of the very sizable change in smoking behavior seen in the last decades. 
A final conclusion of the Cancer scenario study was that smoking is the 
one risk factor on which an intervention needs to be directed immediately, 
however it predicted that even if a sizable reduction in smoking prevalence 
were achieved immediately, the lung cancer mortality would not start to 
diminish until the turn of the millennium. This may be an unnecessarily 
pessimistic conclusion since it may underestimate the effects of health policy 
measures against smoking in the past, of which we will reap the benefits in 
the years to come, and furthermore it fails to acknowledge that although the 
effects on lung cancer mortality may take many years to become apparent, 
the effects on IHD mortality will result in important health benefits in the 
mean time. Figure 9.4 shows the mortality reduction expected from the 
smoking intervention proposed by the committee, from lung cancer only 
and the total mortality reduction. 
This last point illustrates the importance of looking at all the health 
benefits resulting from a risk factor intervention. Since the diseases have 
different time dimensions, the multi factorial approach in this case will 
present a much more optimistic effect estimate of an intervention on smok-
ing than would be the case if only lung cancer were considered, and this 
may be very important politically. 
9.2 Quantification of disease specific targets 
A recent development in health policy making was initiated by WHO in 
its Health for All campaign in the European region. The introduction of 
health targets as quantitative measures both of the intentions and of the 
results of health policy, has forced national governments to question the 
general goals of their public health policy and to quantify the present and 
future health status of their populations. 
The project of which Prevent is the result, is a direct consequence of 
this change of orientation in policy making. The use of quantitative targets 
was first practiced in the Dutch Health 2000 Report and has been further 
elaborated in the recent policy document on the Prevention of Cardiovas-
cular disease (3). In that last document, targets are expressed in terms 
of proportional reductions in cardiovascular mortality in those under 65 
years of age, over and above what would be expected from the autonomous 
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trends. 
More recently the Dutch government has designed "Target flow charts" 
for the three most important disease categories from the Health 2000 Re-
port. In these flow charts the disease specific targets are quantified and 
the risk factors on which interventions would need to achieve changes are 
indicated as well. 
In the case of the cardiovascular prevention program the target is quan-
tified as well as the proposed intervention on smoking. Prevent can only 
add to that the quantification of the necessary prevalence changes in the 
other risk factors to achieve the targets. With the target flow charts single 
versus multi factorial intervention strategies and the importance of com-
bining preventive strategies for several disease categories are explored. 
9.2.1 Cardiovascular prevention 
In the Nota Preventie Hart en Vaatziekten (the health policy document on 
the prevention of cardiovascular disease ) the target is defined as follows: 
"Around the year 2000 the mortality caused by diseases of the 
circulatory system, in persons under 65 years of age, will be 
reduced by at least 15% over and above what could be expected 
based on extrapolations of the past. This will be achieved by a 
reduction in smoking prevalence to 20% as well as a reduction 
of total tobacco consumption by 50%, and a reduction in the 
prevalence of elevated serum cholesterol and blood pressure by a 
reduction of total fat intake from 40% to 30-35% and a reduction 
in salt intake." 
In the discussion on the possible interpretations of this target we shall limit 
ourselves to ischemic heart disease (IHD). In the policy document it is in-
terpreted in a broader sense but the inclusion of other disease categories 
will make it more difficult to understand the results. The effects of inter-
ventions will be overestimated in our example since more risk factors are 
known for IHD than for the other diseases (CVA and peripheral vascular 
disease) included in the policy paper. The limitation to IHD will not affect 
any of the discussion points. 
Three possible interpretations of the above target will be examined as 
well as the changes in the prevalence of hypertension and hypercholes-
terolemia necessary to achieve that target, given a reduction in smoking 
prevalence to 20%. We have assumed an autonomous future trend in the 
prevalence of hypertension and hypercholesterolemia of -1% yearly. 
In the definition of the target it is not clear whether the 15% reduction 
in mortality due to Ischemic Heart Disease in the population under 65 years, 
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Table 9.1: Alternative changes in risk factor prevalence necessary to achieve 
target 1 in the prevention of cardiovascular disease. 
M<65 men M<65 women M<65 all PIF 
achieved achieved total <65 
Smoking -50% - - - -
Smoking -75% + + + -
Hypertension -60% - + - -
Cholesterol -100% + - - -
Smoking -50% + + + -
+Bldpr. -25% all cat. 
Smoking -50% + - + -
+Chol. -50% all cat. 
Smoking -50% + - - -
+Bldpr. -10% all cat. 
+Chol. -25% all cat. 
Smoking -50% + - - -
+exc.alcohol -50% 
Key:-=target not achieved, +=target achieved 
means an average reduction in the population (M<65 total) or that a 15% 
reduction will be achieved for both men and women or for each age group 
under 65 (all PIF <65). These three alternatives will be discussed. 
In the quantification the smoking prevalence is assumed to reach 20% 
over 15 years and the prevalence of smoking is spread over exposure cate-
gories to reduce the total tobacco consumption by 50%. We experimented 
with the lowest reduction in the prevalence of hypertension, of hypercholes-
terolemia or of a combination of both, necessary to achieve the target. The 
results are shown in table 9.1. 
The most interesting feature of the above list of possible interventions 
is that the reduction in smoking, as proposed, alone will not achieve the 
IHD target. Quite sizable reductions in the prevalence of hypertension will 
achieve the target for women but a reduction in hypercholesterolemia alone, 
will achieve the desired effect for men only with a complete elimination of 
hypercholesterolemia. Even in combination with the reduction in smoking 
proposed in the policy paper the reductions in the prevalence of hyperten-
sion or hypercholesterolemia will have to be large. These reductions will 
not be easy to achieve and it is unlikely that they will be achieved with 
lifestyle changes only. This illustrates a dilemma in preventive policy which 
is often disregarded when discussing preventive interventions at population 
level. Obviously reductions in hypertension will produce health benefits 
at the population levels, but when, such as in this analysis, no mention is 
made of the way in which these reductions are achieved, it is not possible to 
'I 
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weigh the health benefits achieved by the reduction in hypertension against 
the possible side effects of the preventive intervention. This point has been 
extensively discussed when the "prudent diet" was proposed in the USA, 
for the possible long term noxious effects for children of a reduced fat in-
take. The discussion becomes even more important when the intervention 
proposed involves long term medication. 
Another feature in the above table is that, although the overall target of 
M<65 may be reached, this does not necessarily mean that the PIF target 
is reached in every age group. So we may need more stringent interventions 
if the target indeed means that the PIF<65 is reduced by 15% in all age 
groups. This also applies for the sex differentiated target. Targets for 
health policy making that are not differentiated by sub population will be 
easier to achieve. 
The conclusions from the above exercise must be that, if quantitative 
targets are really to be used in health planning, it is important that they 
are formulated in great detail, however tedious this may seem, since the dif-
ferent interpretations lead to different policy measures necessary to achieve 
the target. For each interpretation of the target however we can formu-
late alternative preventive strategies, some of which are more realistic or 
acceptable than others. In this particular situation there was the restric-
tion of the already formulated reduction in smoking prevalence and tobacco 
consumption. In the next paragraph we will look at a situation where the 
alternatives can vary with respect to all risk factors. 
9.2.2 Target flow charts 
Figure 9.5 shows some flow charts as proposed for the Dutch Department 
of Public Health. They concern quantitative, disease specific, targets as 
formulated in the Health 2000 Report, on ischemic heart disease and lung 
cancer. Other cancers or accidents are not considered here since the risk 
factors at present incorporated in Prevent do not correspond with those 
used by the Ministry of Health for target setting in these areas. In this 
example it is assumed that the targets concern mortality reductions for the 
entire population. 
The purpose of this exercise is not to actually quantify the target flow 
charts, but to show how Prevent can be used in such a situation and which 
questions remain to be answered before priorities can really be set. 
Table 9.2 shows the smallest change in the prevalence of each risk factor 
individually, necessary to achieve each disease specific target. As can be 
seen immediately some of the intervention alternatives are clearly impossi-
ble. 
It is obvious that single risk factor interventions, which are realistic, will 
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Figure 9.5: "Target flow charts" for IHD and lung cancer 
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Table 9.2: Alternative changes in risk factor prevalence necessary to achieve 
the targets on IHD and lung cancer in the year 2000. 
IHD Lung cancer 
M<65=-15% M<65=-10% 
Smoking -17.5% 
- + 
Smoking -75% + + 
Hypertension -70% + -
Hyper chol. -100% - -
Exc.Alc. -100% - -
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never be able to achieve the targets for multi factorial diseases. If the IHD 
target is to be achieved, multi factorial interventions (as shown earlier in 
table 9.1) will be needed. 
The second point of interest is the fact that smoking influences both 
IHD and lung cancer mortality. The reduction in smoking prevalence nec-
essary to achieve the IHD target will automatically achieve the lung cancer 
target without any additional investment. This means that it is important 
in an organization concerned with preventive interventions to achieve dis-
ease specific targets, to avoid too strict a separation of policy decisions by 
disease category, but on the contrary to encourage the cooperation and co-
ordination in setting disease specific targets and priorities for interventions. 
9.3 Priority setting 
As mentioned in the introduction the effect estimates of preventive inter-
ventions as produced by Prevent can not be used directly to set priorities. 
There is no indication of the intervention mode used to achieve the change 
in risk factor prevalence nor is there an estimate of the costs involved. All 
Prevent does is to quantify the health benefits in such a way that they can 
be used in a cost-effectiveness analysis. 
When comparing alternative preventive interventions to achieve disease 
specific targets as illustrated in the previous paragraph there are two points 
to keep in mind: the time horizon of the effect estimates on which the 
decision is based and the total mortality reduction achieved together with 
the disease specific target. 
Both elements have been discussed already in chapter 7. To illustrate 
these, information for some of the intervention alternatives discussed in the 
previous paragraph is assembled in table 9.3. It shows the total mortality 
reduction and the actual years of life gained for each intervention both in 
the year 2000 and in the year 2020. The effect measure of total mortality 
reduction at one point in time is of course not only dependent on the size of 
the mortality reduction achieved but also on the time dimension of the risk 
factor disease combination. The difference between the level of mortality 
reduction in 2000 and 2020 illustrates how the year in which effects are 
compared, may arbitrarily influence the priority setting. A better measure 
on which to compare health benefits is the Actual Years of Life Gained, 
which shows the cumulation of effect over the years. 
The conclusion that can be drawn from this exercise is that it is unwise 
to look at the health benefits achieved by a risk factor intervention only in 
terms of disease specific mortality. If we look at the mortality reduction 
(as an example of more general measures of health benefit) of the differ-
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Table 9.3: Total mortality reduction and AYLG in 2000 and in 2020 for 
alternative interventions. 
Total mortality reduction AYLG 
2000 2020 2000 2020 
Smoking -7S% 4087 4049 24568 128845 
Smoking -50% 3858 3278 27489 11132S 
+Bldpr. -25% all cat. 
Smoking -SO% 310S 2971 2027S 96253 
+Chol. -SO% all cat. 
Smoking -SO% 3349 3020 22240 1004SO 
+Bldpr. -10% all cat. 
+Chol. -25% all cat. 
Smoking -50% 3200 3272 20994 100781 
+exc.alcohol -50% 
ent alternatives we see that, although they may achieve approximately the 
same effect on IHD mortality, their effect on total mortality is strikingly 
different. In the setting of priorities in preventive interventions, it seems 
important not only to look at the effect on the disease specific target but 
to consider also the side effects of the measure on total health. This is the 
type of information which can be crucial in choosing the most cost-effective 
intervention. 
It also shows that some intervention alternatives will not achieve their 
full benefit until many years after the intervention. If the time horizon for 
which benefits are compared is too short the real benefits may be obscured 
and priority setting ineffective. Or the time horizon of your target may in 
itself influence the perceived benefits of alternative interventions and thus 
the priority setting. 
9.4 Conclusion 
With the above examples of the use of Prevent it was shown how the quan-
tification of the health benefits of alternative risk factor interventions can 
help in health policy making. It must be clear however that Prevent will 
not dictate the priorities. Prevent only quantifies one step in the whole 
process of policy making. 
In the illustrations in this chapter certain choices were made. As al-
ways when the real decisions are made, other circumstances may dictate 
other choices. It is for this reason that Prevent is designed as a tool: an 
interactive model that can be used directly in policy making. Only after 
experimentation with the effects of alternative interventions can a feeling 
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be acquired for the important dimensions that will influence the outcome 
and for which political choices may need to be made. 
The goals of the user will determine the outcome measure chosen to rank 
the priorities and furthermore the proposed interventions will have to be 
assigned an estimate of cost, not only financially but also politically. The 
cost-health benefit equation that results from such analyses will determine 
the political decision. However in a careful analysis of costs and benefits 
of an intervention, it is crucial that the estimates of benefits are calculated 
with as much precision as the costs. This is the area in which Prevent can 
make a contribution. 
Chapter 10 
Conclusions 
The policy implications that can be deduced from the results of the model 
have been discussed in the previous chapter. In this chapter the empha-
sis is on whether the project was able to achieve its objectives and what 
recommendations can be made from the experience with the project. The 
general goal of the project was subdivided into three objectives: 
• To adjust existing epidemiologic measures to suit a multifactorial 
model with a time dimension 
• To collect the necessary input data from the existing epidemiological 
literature on relative risks and risk factor prevalence 
• To develop a policy making tool which could be used for effect esti-
mates of prevention, and as such be useful for priority setting. 
The conclusions will be presented along those same lines. 
10.1 The methodology 
It proved possible to adapt an existing epidemiologic measure of effect, the 
potential impact fraction, to incorporate both the multi factorial nature of 
the relationship between risk factors and diseases, and a time dimension to 
simulate slow risk reduction after cessation of exposure. 
It was also possible to express the health benefits in terms of absolute 
numbers for general health indicators, as well as proportional changes in 
disease specific incidence rates, by the incorporation of a dynamic popu-
lation model. This allowed for the influence of competing death risks and 
demography to be taken into account. 
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The resulting Prevent model was programmed for use with a micro 
computer and can be used in an interactive manner by policy makers. The 
model is best suited for estimating the effects of preventive interventions. 
It does not readily allow for the incorporation of changes in curative care. 
However in order to achieve this objective certain assumptions and cer-
tain simplifications had to be made. 
• To incorporate several risk factors and several diseases in one model, 
a certain simplification of the stratification dimensions of the input 
data was necessary. This implies that to be able to fit together the 
data about different risk factors in a consistent manner, important 
extra information was sometimes lost. 
• To simulate the effect of several risk factors on one disease it was 
assumed that risk factors are independently distributed in the popu-
lation and that the effect of a simultaneous exposure to more than one 
risk factor is a multiplication of the relative risks without interaction. 
• The assumption was made that whatever interaction may exist be-
tween different causes of death, was explained by a joint risk factor. 
When none was known, causes of death were assumed to be indepen-
dent. 
• The translation of proportional changes in incidence into absolute 
health benefits over the long simulation period dictated by the time 
dimensions, necessitated the assumption that over the simulation pe-
riod, the effect of curative care on the case fatality rate and the sur-
vival period remained unchanged. 
These assumptions are necessary because insufficient knowledge and data 
exist to allow a more detailed modelling of a multi disease model. The re-
sults produced with this multi factorial approach show that taking several 
diseases into account simultaneously, does alter the estimated benefits from 
an intervention. To improve such a model in the future, the following ele-
ments should be added: the interaction both between diseases and between 
risk factors, estimates of the effects of changing curative care on survival 
and case fatality and an estimate of both the costs of interventions and of 
the utilization of health services avoided by the intervention. 
10.2 The data for Prevent 
The objective of this project was to see if the available epidemiological 
data could be used more effectively for health policy decisions. Although 
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there is a large body of knowledge about risk factors and their influence on 
disease incidence, some problems were encountered when using the data for 
prospective effect estimates. 
Relative risks had to represent a causal relationship. This meant that 
only those risk factors were included for which a consensus was reached. 
With alcohol in relation to IHD, which is still controversial, it was shown 
how much estimates about the effects of an alcohol reduction program, 
could differ under different assumptions about this relationship. In general 
data on the effect of cessation of exposure are scarce. The remnant relative 
risk as well as the time dimensions are not reported consistently, while this 
information is especially important when interventions will be directed at 
cessation as well as prevention of exposure. 
Data on the prevalence of risk factors in the Dutch population were 
available. However the stratification by exposure category did not always 
correspond with the available stratification in relative risk. Few time trends 
of exposure prevalence are available. This made assumptions about the past 
changes in prevalence necessary. With the historical testing on smoking and 
lung cancer it proved essential to link certain exposure characteristics to 
birth cohorts. When prevalence data are available from one point in time 
only it is impossible to differentiate between age specific and cohort specific 
factors. 
As mentioned in the previous paragraph, limitations of available data 
made certain simplifications of the model necessary. These simplifications 
obviously will affect the results of the model as was shown with the historic 
testing. If epidemiologic information is to be of use in setting priorities for 
prevention, it will be necessary to include certain variables such as remnant 
relative risks, time dimensions and cohort characteristics, in the empirical 
epidemiologic studies. 
10.3 Prevent as a tool 
To evaluate the utility of such a model in health policy making, it seems 
useful to see whether the inclusion of 
• several diseases 
• a time dimension 
• the possibility to express benefits both in proportional and in absolute 
terms, 
significantly changes the expected health benefits. 
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The time dimension is the Prevent feature of which the effect is most 
easily perceived. The long time lags between an intervention on exposure 
and changes in mortality which can be seen in some diseases greatly affect 
the results. The inclusion of the time dimension not only emphasizes that in 
some cases results of preventive measures will not be noticeable immediately 
but it also shows that such a measure will continue to affect the populations 
health long after the intervention has ceased. To present the expected 
effects over too short a period may lead to serious underestimation of the 
ultimate benefits. 
In the current version of Prevent all outcome measures are based on 
mortality. The cause of death which still dominates the health profile of the 
Dutch population, ischemic heart disease, is so much more important than 
other diseases, that even small proportional changes in the IHD mortality 
will greatly affect the ultimate health benefit. This illustrates why effects 
of risk factor interventions should not be measured in proportional changes 
of disease specific mortality only. Often the cardiovascular risk factors have 
not been considered worth intervening upon, because reducing them would 
only marginally affect the IHD mortality rate. Interventions on risk factors 
for other diseases however, have been discussed based on high proportional 
effects without realizing that in absolute terms it would result in far fewer 
deaths prevented. 
The main interest in the multi factorial approach of the Prevent model 
lies in the fact that not all diseases affect a health indicator expressed in 
absolute numbers to the same extent, and that the important time variables 
differ by disease. This means that a risk factor intervention will reduce to-
tal mortality through several disease specific mortalities, each to a different 
extent and at different moments. This can be seen in the mortality reduc-
tion curve of a reduction in smoking prevalence, in which the contribution 
of the different diseases can be clearly discerned. 
It does make a difference whether the effects of an intervention are 
evaluated in a single disease model or a multi disease model. However the 
multi factorial approach also dispels another commonly held belief: that 
competing death risks in our aging population will eliminate all mortality 
reduction from one disease by substituting another cause of death. To a 
certain extent such a substitution occurs as was illustrated earlier, with 
the initial increase in COLD mortality after smoking cessation due to the 
decrease in IHD mortality. However the expected total mortality reduction 
of that same intervention shows that despite the initial extra mortality, the 
ultimate health benefit remains impressive. Although there is an increase 
in causes of death not affected by the risk factor intervened upon, there 
nevertheless is a large overall mortality reduction. When looking at the 
actual years of life gained by this intervention, one can conclude that the 
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deaths prevented have indeed resulted in substantially extended lives. It 
is a fallacy to think that prevention will achieve an important mortality 
reduction only in a young population. Even in our aging population we can 
achieve sizable mortality benefits. 
The aggregation of health benefits and the introduction of a dynamic 
population, simulating the demographic evolution of the Dutch popula-
tion is essential to the second step of the model. When looking at the 
disease specific mortality, even without an intervention, it is obvious that 
demographic changes in the coming years, will greatly increase the abso-
lute mortality for the diseases included in Prevent. In some cases even far 
reaching reductions in risk factor prevalence will not prevent that the total 
number of cases in the future will be higher than they are today. In the 
introduction it was stated that prevention is often difficult to sell politically 
since its effects take so long to become apparent. After the Prevent exercise 
we have to conclude it is even worse: effects will seldom be apparent as real 
reductions in disease. This conclusion should not be interpreted to mean 
that prevention will not have any beneficial effect in an aging population. 
On the contrary it can result in a sizable mortality reduction despite com-
peting death risks. It does mean however, that to be able to appreciate the 
effects it is important to show what would happen without the preventive 
intervention and not compare it to the current level of mortality. 
10.4 Recommendations 
Epidemiology has sometimes claimed to be a basic science for public health. 
Results from theoretical and empirical epidemiologic work can indeed be 
used in providing information essential to public health decisions. Global 
modelling for policy purposes with epidemiologic data is possible and use-
ful. However to make future results more realistic further research will be 
necessary along the lines mentioned above, especially concerning the inclu-
sion of possible changes in curative care in a more comprehensive public 
health model. 
This project was a first step on the road from etiologic and intervention 
research to the implementation of these results in health policy making. 
It shows that the health benefits of preventive interventions may differ 
from what would be expected from the traditional effect measures. Health 
policy making with such public health models can improve priority setting 
by providing more precise quantification of effect estimates, however it will 
also require precise target setting and an investment in the collection of 
data which are essential to such an exercise. 
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Appendix A 
EF and PIF in a multi 
factorial model1 
The interest in EF as a measure of the importance of a risk factor has 
greatly increased in recent years. This has generated a large methodolog-
ical literature on the computation of EF in different situations. One of 
the complications which has recently received considerable attention is the 
calculation of EF in a population where more than one risk factor for the 
disease considered, is present (1-12). Most of these deal with the problems 
of epidemiological analysis in which the joint distribution of several risk 
factors in the population and the ensuing IDR's are known. Walters paper 
in 1983 (8) acknowledges the parallel problems of the use of the traditional 
EF formula's when trying to estimate the effect of preventive interventions 
in the general population, where data on the joint distribution of more than 
one risk factor are seldom available. 
In the field of Health Risk Appraisal a similar discussion on the relative 
risk associated with joint exposure has evolved. Spasoff (12) showed how 
both the additive and the multiplicative (as well as a logistic) model could 
be used to calculate the effect of joint exposure. Their ultimate choice, 
based on expert opinion, was to assume a multiplicative model for most 
causes of death. 
For the Prevent model the problem is whether EF's and PIF's can be 
calculated for diseases which are affected by several risk factors, without 
knowing the joint distribution or the IDR's, and secondly whether this 
can be done sequentially for each risk factor or whether they need to be 
1 This appendix would have been incomprehensible without the valuable help of Gerrit 
van Oortmarssen, who simplified the equations despite his aversion to PIFs and TIFs. 
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Figure A.l: Distribution of risk factor A and B in a population 
considered simultaneously. 
In the following paragraphs it will be shown that the equation for 
the marginal attributable risk, the EF assuming no other risk factors are 
present, can be used to estimate the etiologic fraction of a risk factor when 
more than one risk factor is known. This can be done without knowledge 
of joint distribution, under two different assumptions of the IDR associated 
with joint exposure. The two assumptions do result in different equations. 
In a situation where two risk factors A and B exist, with only a di-
chotomous exposure, (no time lags or remnant !DR's are considered), the 
distribution of exposure can be depicted as in figure A:l. -
If P stands for the proportion of the population exposed to a certain 
risk factor and !DR for the relative risk associated with that exposure, 
Let: 
Poo = non exposed 
P1o exposed to A only 
Po1 = exposed to B only 
Pu = exposed to both A and B 
Pa = P10 +Pu 
pb = Po1 + Pu 
IDRa IDR10 
IDRb IDRo1 
IDRoo = 1 (by definition) 
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The I D R11 now can be defined in two ways: 
1. Multiplicative model: IDR11 = IDR10ID&n or 
2. Additive model: (IDRu -1) = (IDR1o- 1) + {IDR01 -1) 
We are interested to see whether EFa = EF1o,11 and PIFa = PIF10,1l· 
A.l Multiplicative model 
Let EFa be the etiological fraction in a situation where only risk factor A 
exists. Then: 
EFa = 
= 
Pa(IDRa- 1) 
Pa(IDRa- 1) + 1 
IDRa -1 
IDRa + 1 j,~a (A.1) 
Let EF1o,u be the etiological fraction for risk factor A in a situation where 
both risk factor A and B are present and because of the multiplicative 
model IDRu = IDR10IDRo1- Then: 
EFu 
= 
P10(I DRa- 1) + Pu(I DRu- I DRb) 
P1oiDRa + PuiDRu + Po1IDRb + Poo· 
P10(IDRa- 1) + PuiDRb(IDRa -1) 
Dividing numerator and denominator by P10 + P11IDRb : 
IDRa- 1 
IDR + PndDR.+Paa 
a P1a+P11 IDRb 
IDRa -1 
I DR + Pol(IDRb-1)+(1-Pa) 
a Pu(IDRb-l)+Pa 
(A.2) 
We assume both risk factors are indeed present and each have an IDR>l. If 
the two risk factors A and B are distributed independently in the population 
then: DJ..p,P = ~p,P = 1P.p" and IDR11 = IDR10IDR01 . Equation A2 = Al. 01 00 - 4 
This implies that: 
EF10,11 = EFa 
E Fa in a one risk factor situation is identical to E F10 ,11 , the etiological 
fraction of risk factor A in the presence of a second risk factor. The same 
can be done for multiple risk factors. A similar proof applies to PI Fa and 
PIF10,11· 
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This means that if a multiplicative model of relative risk and indepen-
dence of the distribution of risk factors can be assumed, EF's and PIF's can 
be calculated sequentially for each risk factor without necessary knowledge 
of joint distribution. 
A.2 Additive model 
Again let EFa be the etiological fraction of risk factor A in a situation 
where only A exists, and PI Fa the potential impact fraction in a one risk 
factor situation. Then: 
and 
Pa(I DRa- 1) 
Pa(IDRa -1) + 1 
IDRa -1 
IDRa + 1-j(· 
PI Fa= (PaiDRlo + 1- Pa)- (P~IDR1o + 1- P~) 
PaiDRlD + 1- Pa 
Now let EFto,u be the same etiological fraction for risk factor A in a 
situation where both A and B are present and 
(IDRu -1) = (IDRa -1) + (IDRb- 1) (A.3) 
or equivalently: 
IDRu- IDRb = IDRa -1 (A.4) 
Then: 
(P10(I DRa- 1) + (Pu(I DRu- IDRb) 
EFlO,ll P10(IDRa -1) + Pu(IDRu -1) + (Po1(IDRb- 1) + 1 
Or applying (A.4) to denominator and (A.3) to numerator : 
(Pto + Pu)(IDRa- 1) 
(P10 + Pu(IDRa- 1) + Po1 + Pu(I DRb- 1) + 1 
Pa(IDRa -1) 
Pa(IDRa- 1) + Pb(I DRb- 1) + 1 
-::f EFa 
(A.5) 
A.3. CONCLUSION 
In a similar way one can prove: 
PIF1o,u 
Pa(IDRIO -1) + Pb(IDRo1 -1) 
Pa(IDRlo -1) + Pb(IDRo1 -1) + 1 
(P~(IDR1o- 1) + P£(IDRol -1)) 
Pa(IDRlO- 1) + Pb(IDRo1- 1) + 1 
# PIFa 
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(A.6) 
With the assumption of additivity, the equations for EF and PIF will 
have to be adjusted. However no assumptions need to be made about 
the independent distribution of risk factors. One implicit condition in the 
equation used is that all the relevant risk factors are known since all must be 
included in the denominator. In the case of an as yet unknown confounder 
the attributable fraction may be overestimated. 
A.3 Conclusion 
For most diseases there is no consensus on the effect of joint risk exposure. 
Spasoff concluded from his search that except for accidents (which experts 
assumed were best described by an additive model) and IHD for which 
he applied a logistic model, all other diseases were best described by a 
multiplicative model. 
In the Prevent model this problem is further complicated because so 
few prevalence data on joint exposure exist. In the absence of such data 
we shall assume a multiplicative model of IDR for joint exposure as well as 
independence of the distribution of risk factors. Then the single risk factor 
equations for EF and PIF can be used. 
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Appendix B 
Background tables 
In this appendix some of the overview tables will be presented on which the 
input data are based. They have been published previously and the sources 
mentioned can be found in the references after part III. Only the data on 
the prevalence of hypertension by age group have not been published in this 
form before, however they have been constructed from published material. 
They contain the percentage of the Dutch population in each age group, 
in a certain range of blood pressure, according to the different available 
surveys in the Netherlands. In the final column a population estimate is 
given, based on these data. 
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Table B.l: Outline of eight major prospective studies. 
Doll Dom Best 
Authors Hill Hammond Kahn Hirayama Josie Hammond 
Peto Rogot Walker Hom 
Pike 
Subjects British Males and Fe- U.S. vete- Total popu- Canadian White males 
doctors males in 25 rans lation of 29 pensioners in 9 States 
States health dis-
tricts in Ja-
pan 
Popula-
tionsize 40,000 1,000,000 290,000 265,000 92,000 187,000 
Females 6,000 562,671 <1% 142,857 14,000 
Age range 20-85+ 35-84 35-84 40 and up 30-90 50-69 
Year of 1951 1960 1954 1966 1955 1952 
enrollment 1957 
Years of 20-22 12 years 16 yeacs 13 yeacs 6 years 4 years 
follow-up 
yeacs re-
ported 
Number of 11,166 150,000 107,500 39,100 11,000 12,000 
deaths 
Person 800,000 8,000,000 3,500,000 3,000,000 500,000 670,000 
years of 
experience 
Mortality M14 M8.5 M11.3 M3.8 M10.7 
ratio's F5 F3.6 2 
Source: 196 
Weir 
Dunn 
Linden 
Breslow 
California 
males in 
various oc-
cupations 
68,000 
33-64 
1954 
5-8 years 
4,700 
480,000 
M7.6 
Cederlof 
Friberg 
Hrubec 
Lorich 
Probabi-
lity sam-
ple of 
the Swedish 
population 
55,000 
27,700 
18-69 
1963 
10 years 
4,500 
550,000 
M7.0 
F4.5 
"-!) 
~ 
0) 
> ~ ~ 
~ 
!XI 
~ 
~ 
~ 
0 §§ 
t1 
~ 
tJj 
t-t 
~ 
Table B.2: Coronary heart disease mortality ratios related to smoking- some prospective studies (Actual number of deaths shown in parentheses)1 
Author Number and Follow- Number 
year type of Data up of Cigarettes/day Age variation Comments 
country population collection (yrs) deaths 
Hammond 187,783 Question- 3.5 5,297 NS 1.00 (709) 50-54 55-59 60-64 65-69 
and white males naire and All smokers 1.70 (3361) 
Horn, in 9 states follow-up <10 1.29 (192) 1.93 (765) 1.85 (962) 1.66 (921) 1.41 (713) 
1958, 50-69 yrs of death 10-20 1.89 (864) 1.38 (35) 1.38 (50) 1.17(49) 1.27 (58) 
U.S.A. of age certificate 20-40 2.20 (604) 2.00 (213) 2.04 (258) 1.91 (235) 1.58 (158) 
40+ 2.41 (nsj 2.51 (203) 2.47 (199) 1.92 (129) 1.56 (73) 
Doyle 2,282 Detailed 10 93 NS 1.00 (2) Data apply 
et al. males medical AI.\ smokers 2.40 (73) only to 
1964, Framing- examination <20 2.00 (17) aged40-49 
U.S.A. ham, and follow- 8 20 1.70 (20) and free 
30-62 yrs up >20 3.50 (36) ofCHD at 
of age entry, NS 
1,913 include 
males pipe, cigar 
Albany and ex-
30-35 yrs smokers 
of age 
Doll Approxi- Question- 10 1,376 NS 1.00 35-44 45-64 65-84 
and Hill rnately naire and All smokers 1.35 
1964, 41,000 follow-up 1-14 1.29 3.73 1.40 1.71 
Great male Bri- of death 15-24 1.27 4.45 1.73 1.27 
Britain tish phy- certificate >25 1.43 1.36 1.92 1.58 
Strobel 3,749 Question- 9 162 NS 1.00 
and Gsell male naire and 
1965 Swiss phy- follow-up 90 1.48 
Switzer- cisians of death >20 1.76 
land certificate 
Best Approxima- Question- 6 2,000 NS 1.00 30-49 50-69 70 andover 
1966, tely naire and All smokers 1.60 (1380) 
Canada 78,000 follow-up <10 1.55 (327) 0.97 (18) 1.56 (230) 1.71 (99) 
male Cana- of death 10-20 1.58 (766) 1.45 (115) 1.67 (557) 1.29 (94) 
dian certificate >20 1.78 (277) 1.85 (65) 1.76 (184) 1.73 (28) 
veterans 
t.:> 
e.:> 
-l 
Author Number and 
year type of 
country population 
Kahn US male 
1966, veterans 
U.S.A. 2,265,674 
person 
years 
Hirayama 265,118 
1967, Japanese 
Japan adults 
over age 
40 
Kannel 5,127 
et a!. males and 
1968, females 
age 30-59 
Hanunond 358,534 
and males 
Garfinkel 445,875 
1969, females 
USA age 40-79 
at entry 
1 NS = Nonsmokers 
Source: 193 
Follow-
Data up 
collection (yrs) 
Question- 8.5 
naire and 
follow-up 
of death 
certificate 
Trained in- 1 
terviewers 
and follow-
up of death 
certificate 
Medical ex- 12 
amination 
and follow-
up 
Question- 6 
naire and 
follow-up 
of death 
certificate 
Table B.2: Continued 
Number 
of Cigarettes/day 
deaths 
10,890 NS 1.00 (2997) 
All smokers 1.74 (4150) 
1-9 1.39 (439) 
10-20 1.78 (2102) 
21-39 1.84 (1292) 
>39 2.00 (266) 
96 NS 1.00 (17) 
1.24 1.13 (69) 
>25 1.00 (5) 
52 NS 1.00 (27) 
>20 2.20 (25) 
14,819 Males 
NS 1.00 
1-9 1.27 
10-19 1.60 
20-30 1.73 
>40 1.77 
Females 
NS 1.00 
1-9 0.84 
10-19 1.22 
20-30 1.52 
>40 0.61 
Age variation 
40-49 50-59 60-69 70-79 
1.60 1.59 1.48 1.14 
2.59 2.13 1.82 1.41 
3.76 2.40 1.91 1.49 
5.51 2.79 1.79 1.47 
40-49 50-59 60-69 70-79 
1.31 1.15 1.04 0.76 
2.08 2.37 1.79 0.98 
3.62 2.68 2.08 1.27 
3.31* 3.73 2.02* 
Comments 
Prelimi-
report 
*Based on 
5-9 deaths 
-
t-:> 
~ 
00 
> 
:g 
~ 
t:1 
>1 
~ 
~ 
~ 
~ 
0 
~ 
t:1 
~ 
~ 
~ 
Table B.3: Overview of the prevalence of hypertension in four categories by study and sex 
Study Men <140/90 
N 
Consulta- 9812 63.4 
tie bureaus 
together 
(1977-78) 
Til burg 1792 66.7 
Maastricht 1862 67.3 
Doetinchem 1176 62.7 
Amsterdam 1478 73.6 
Lei den 1469 60.4 
Rotterdam 2035 51.9 
COPIH ('74) 5803 53.4 
EPOZ 765 77.6 
(1975-78) 
Vlaardingen 201 64.2 
(1975-76) 
Vlagtwedde 314 51.6 
(1976) 
Bedum (1972) 
- -
1 this concerns first measurement 
N = population size 
Source: 200 
~140/90 ~160/95 
and and 
<160/95 <180/105 
20.4 12.2 
19.2 10.7 
16.7 11.9 
23.3 10.7 
14.3 9.3 
19.9 14.4 
27.9 15.1 
28.7 12.9 
15.8 5.2 
23.9 11.4 
36.3 9.2 
- -
Blood pressure in MmHg1 
~180/105 Women <140 ~140/90 ~160/95 
N and and 
<160/95 <180/105 
4.0 10675 78.4 13.3 6.3 
3.2 1805 78.3 14.4 5.8 
4.0 1944 84.9 9.0 4.6 
3.2 1271 73.8 16.4 7.8 
2.8 1876 80.7 10.3 7.1 
5.3 1670 78.4 12.8 6.3 
5.1 2109 73.1 17.3 6.8 
4.9 1622 65.0 20.7 11.0 
1.3 825 81.9 11.4 5.4 
0.5 184 72.8 15.8 6.0 
2.9 - - -
371 52.3 33.7 10.2 
~180/105 
2.0 
1.5 
1.4 
2.0 
1.9 
2.2 
2.7 
3.3 
1.2 
5.4 
-
3.8 
~ 
<:,..') 
(0 
Table B.4: Prevalence of obesity according to the Quetelet Index (QI) in the Netherlands 
Men 
Study Vlagtwedde COPIH 
N Q1>27 N Ql>27 
% % 
Age: 
20-24 209 12 
25-29 147 31 
30-34 147 27 
35-39 170 39 178 16 
40-44 205 36 1207 18 
45-49 163 35 1328 22 
50-54 1408 24 
55-59 1410 28 
60-64 923 25 
65-69 
70-75 
Women 
Study Utrecht (Overvecht, N=6000) 
Age: 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-75 
N: populationsize 
Source: 202 
Ql>26 
% 
±10 
±10-25 
±25-45 
±45-55 
Q1>29 
% 
±5 
±5-10 
±15 
±20-30 
Den Haag (N-139) Zeist Ede Zutphen 
Ql>27 N Q1>27 N Ql>27 N Ql>27 
% % % % 
648 5 
8 559 12 
558 14 
20 
101 20 
30 
131 35 816 11 
25 
198 38 
31 140 30 
41 
Den Haag (N=269) Zeist Ede 
Ql>26 N Ql>26 N Ql>26 
% % % 
729 6 
10 653 10 
710 12 
22 
33 
116 40 
42 
101 57 
57 104 56 
50 
. 
"" ~ 0 
> ~ ~ ~ 
~ 
~ 
~ 
~ 
0 
~ 
t:::l 
~ 
~ 
~ 
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In the following tables only published material was used. Sometimes the 
categories of hypertension did not agree. Since these tables are background 
material no adjustment was made but all available categories were reported. 
This may make tables somewhat cumbersome to read. Each time a survey 
was first introduced the sample size is given as well as the age groups on 
which the reported data are based. The population estimate given in the 
last column are the choice data on which prevalence data for mput in the 
Prevent model were based. The EPOZ data were later reconstructed for 
the purpose of testing the sensibility of the model for the initial input data 
(see chapter 8). 
Table B.5: Prevalence of hypertension, age group 35-44 
Bid pr. s CB COPIH EPOZ Vlaar. Vlach. Bed. Est.pop 
DBP<90 M 63.4 53.4 77.6 64.2 51.6 
- 58.4 
SBP<140 F 78.4 65.0 81.9 72.8 - 52.3 78.4 
DBP 90-94 M 20.4 28.7 15.8 23.9 36.3 - 24.6 
+SBP 140- F 13.3 20.7 11.4 15.8 - 33.7 13.3 
159 
DBP 95 M 12.2 12.9 5.2 11.4 9.2 - 12.6 
-104 
+SBP 160 F 6.3 11.0 5.4 6.0 - 7.8 6.3 
-179 
DBP~105 M 4.0 4.9 1.3 .5 2.9 - 4.4 
+SBP~180 F 2.0 3.3 1.2 5.4 - 3.8 2.0 
DBP ~90 M 21.4 31.0 13.3 12.9 15.3 - 26.2 
F 12.3 22.9 12.6 13.6 - 11.0 13.3 
SBP ~140 M 32.0 38.9 17.6 32.8 45.5 - 35.5 
F 18.8 20.1 12 24.5 - 45.5 18.8 
N M 9812 5803 765 201 314 
-
F 10675 1622 825 184 - 371 
Period '77-'78 '74 '75-78 '75-76 '76 '72 
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Table B.6: Prevalence of hypertension, age group 45-49 
Bld.pr. s CB project Copih KRIS Est.pop. 
DBP<90 M 45 45 
+SBP<140 F 49 49 
DBP 90-94 M 27 27 
+SBP 140- F 26 26 
159 
DBP ~95 M 29 19 29 
+SBP ~160 F 25 25 
DBP<95 M 95.0 
F 92.1 
DBP 95- M 4.2 
104 F 6.7 
DBP ~105 M .9 
F 1.1 
SBP<140 M 68.6 
F 90.1 
SBP 140- M 25.2 
159 F 4.3 
SBP~l80 M 6.2 
F 5.5 
N M 338 3364 
F 416 
Table B.7: Prevalence of hypertension, age group 50-54 
Bld.Pr. s Copih EPOZ KRIS Est.pop. 
DBP<90 M 41 29.1 - 41 
+SBP<140 F 45 19.5 - 45 
DBP 90-94 M 26 48.4 - 26 
+SBP 140- F 26 49.9 - 26 
159 
DBP 95- M - 18.9 - -
i04 
+SBP 160- F - 24.0 - -
179 
DBP ~105 M - 3.6 - -
+SBP~180 F - 6.6 - -
DBP ~95 M 32 - 19 32 
+SBP >160 F 29 - - 29 
N 10355 3364 
based on based on 
agegroup age group 
50-64 45-59 
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Table B.S: Prevalence of hypertension, age group 55-59 
Bld.pr. s Copih EPOZ Boot Est.pop. 
DBP<90 M 34 29.1 - 34 
+SBP<140 F 35 19.5 - 35 
DBP 90-94 M 29 48.4 44 29 
+SBP 140- F 30 49.9 34 30 
159 
DBP 95- M - 18.9 - -
104 
+SBP 160- F - 24.0 - -
179 
DBP;:::1o5 M - 3.6 - -
+SBP;:::180 F - 6.6 - -
DBP>95 M 37 - 20 37 
+SBP>160 F 35 - 15 35 
N 10355 M=733 
based on F=910 
agegroup 
50-64 30-59 
Table B.9: Prevalence of hypertension, age group 60-64 
Bld.pr. s Copih EPOZ Boot Est.pop. 
DBP<90 M 28 29.1 - 28 
+SBP<140 F 25 19.5 - 25 
DBP 90-94 M 29 48.4 69 29 
+SBP 140- F 31 49.9 76 31 
159 
DBP 95- M - 18.9 - -
104 
+SBP 160- F - 24.0 - -
179 
DBP;:::105 M - 3.6 - -
+SBP;:::I80 F - 6.6 - -
DBP ;:::95 M 43 - 26 43 
+SBP>160 F 44 - 41 44 
N based on based on 
agegroup age group 
50-64 60-74 
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Appendix C 
Input data 
In this appendix the input data on prevalences and IDR's are presented as 
they have been used in the Prevent runs in this publication. 
Table C.l: Prevalence of cigarette smoking by age, sex, exposure category 
and exposure level, 1985 
Age 20-24 25-34 35-49 50-64 65+ 
Sex M F M F M F M F M F 
Smokers 
1-12 22 24 21 24 18 21 22 19 . 23 9 
13-22 14 14 19 15 17 11 16 8 12 3 
23+ 4 4 7 5 10 5 10 4 6 1 
Non-smokers 56 52 40 41 36 48 30 56 34 78 
ex-smokers 
<1 yr. 2 2 3 2 1 2 2 1 2 1 
1-2yr. 1 2 3 2 1 1 2 1 2 1 
3-4yr. .5 2 3 3 3 2 2 1 2 1 
5-9yr. .4 1 4 5 5 4 4 3 4 1 
10+yr. .1 .2 2 2 6 5 12 7 16 5 
Source: NIPO in opdracht van Stichting Volksgezondheid en Roken, Continu onderzoek, 
Rookgewoonten, periode 85 II t/m 86 I Oct 15, mei 1986. 
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Table C.2: Lung cancer IDR's for men and women by current number of 
cigarettes smoked 
Males Females 
1-12 cig 1 1 
13-22 cig 12 12 
23+ cig 20 20 
Table C.3: IHD IDR's for men and women by age and by current number 
of cigarettes smoked 
<35 35-49 50-64 65+ 
M F M F M F M F 
1-12 cig 
- - 3 3 1.1 1.1 1.5 1.5 
13-22 cig - - 4 4 2 2 1.5 1.5 
23+ cig - - 4 4 2.4 2.4 1.1 1.1 
Table C.4: COLD IDR's for men and women by amount smoked 
males females 
1-12 cig 12 12 
13-22 cig 25 25 
23+ cig 30 30 
Table C.5: Prevalence of hypertension by age, sex, exposure category, 1985 
age 35-44 45-49 50-54 55-59 60+ 
sex M F M F M F M F M F 
Hypertensive 
Mild 22 12 24 24 24 24 26 21 26 28 
Severe 15 8 26 23 29 26 33 32 39 40 
Normotensive 58 78 45 49 42 45 34 35 28 25 
Ex-hypertensive 
Mild 2 1 2 2 2 2 3 3 3 3 
Severe 2 1 3 2 3 3 4 3 4 4 
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Table C.6: IHD IDR's for men and women with mild and severe hyperten-
sion in the Netherlands, by age and sex 
<45 yrs 
Men Women 
Mild 1.9 1.7 
Severe 2.3 2.9 
~45 yrs 
Men Women 
1.6 1.6 
1.8 2.7 
Table C.7: CVA IDR's for men and women with mild and severe hyperten-
sion in the Netherlands, by age and sex 
<45 ~45 
Men Women Men Women 
Hypertension 
Mild 3.5 2 1.8 1.5 
Severe 5 3.5 3 3 
Table C.8: Prevalence of elevated serum cholesterol by age, sex, exposure 
category, 1985 
Age 35-39 40-40 45-49 50-54 55-59 60+ 
Sex M F M F M F M F M F M F 
Elevated 
Mild 20 16 24 19 25 24 27 31 28 29 27 34 
Severe 10 5 13 6 9 9 14 18 15 27 15 24 
Normal 66 76 59 72 62 64 54 46 52 38 53 35 
Ex-elevated 
Mild 2 2 3 2 3 2 3 3 3 3 3 4 
Severe 1 1 1 1 1 1 2 2 2 3 2 3 
Table C.9: IHD IDR's for men and women by serum cholesterol level 
<45 45-54 55+ 
M F M F M F 
mild 
elevated 3.5 3 2 1.7 1.3 -
serumchol 
severe 
elevated 5.5 5 3 2 1.9 -
serumchol 
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Table C.10: Prevalence of obesity1 in the Dutch population by age and sex, 
1985 
Men Women 
<30 2 3 
31-40 5 4 
41-50 5 10 
>50 10 15 
1 Obesity is defined as a QI of >30 for men and >30 for women. 
Table C.ll: Percentage of drinkers in the Dutch population by age,sex and 
number of glasses of alcoholic beverages per week 
21-40 yrs 40+ 
M F M F 
Ref.pop. 
(4-21 drinks/ 54 33 43 37 
week) 
Excessive drink-
ers 22+ drinks/ 17 4 15 1 
week 
Abstainers 
<4 drinks/week 30 64 37 62 
Table C.12: Alcohol IDR's for men and women, for abstainers and excessive 
drinkers 
IHD 
cirrhosis 
traffic accidents 
accidental fall 
abstainers excessive drinkers 
2 
1 
1 
1 
2 
9 
2 
2 
Table C.13: Prevalence of age mother at first birth, by age group in the 
Dutch population, 1985 
25-29 30-34 35-39 40-44 45-49 50+ 
Ref. pop. 
( <20 yrs) 7 11 12 10 8 8 
20-29 56 61 68 73 73 69 
30+ 32 17 9 6 8 9 
No children 11 11 11 11 12 14 
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Table C.l4: Breast cancer IDR's by age of mother at first birth 
IDR 
Ref.pop. 1 
20-29 1.20 
30+ 1.74 
No children 1.72 
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Summary 
Introduction 
In 1986 the Health 2000 Report, a long term health policy document, was 
presented to the Dutch parliament. This document is part of shift in interest 
in public health towards health rather than health services planning. There 
are two interesting features in this shift. The one is the tendency to measure 
the effectiveness of a policy, an intervention or a technology in terms of 
health, the outcome rather than the input, output or process. The other is 
the acceptance that political choices need to be made, since however large 
the budget for health is, it will always be limited. 
One of the choices to make will be whether or not to invest in preventive 
interventions. Preventive interventions can be defined as deliberate changes 
in the prevalence of risk factors in a population. To be able to weigh the 
costs and the benefits of such preventive interventions, an estimate will 
have to be made of their effect on the health of the population. Furthermore 
changes in risk factor prevalence may also occur autonomously. An estimate 
of the changes in the health status of the population as a result of these 
shifts in risk factor prevalence, will be important for the planning of health 
services and for the setting of realistic targets, as proposed by WHO. 
Prevent is a tool that will estimate the health effects of changes in risk 
factor prevalence in a population, as a result of trends or interventions. 
Its results can either be used directly in health policy making to formulate 
targets or quantify different scenario's on changes in risk factor prevalence 
in the future, or its results can be used as input for formal decision making 
processes such as for instance cost effectiveness studies. 
The Prevent model 
In epidemiology an analysis of the distribution of disease incidence and risk 
factor prevalence in different populations is used to confirm the hypothesis 
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of a causal relationship between risk factor and disease. The strength of 
the relationship is often expressed as the ratio of incidence between exposed 
and non exposed, the Incidence Density Ratio (IDR). The importance of a 
risk factor for the incidence of a certain disease in a population is usually 
expressed as the Etiologic Fraction (EF), the proportion of the total inci-
dence of the disease that can be attributed to the prevalence of that risk 
factor in the population. The EF is sometimes used as an indication of the 
proportion of incidence that could be prevented by the total elimination of 
that risk factor in the population. 
However, since most often prevention will not eliminate but merely re-
duce the prevalence of a risk factor, a measure was developed to estimate 
the impact of a change in prevalence of a risk factor on the incidence of 
a disease, the Potential Impact Fraction (PIF). It stands for the incidence 
that is avoided by a preventive intervention as a proportion of the incidence 
that would have occurred in that population without the intervention. 
Prevent estimates the effect of changes in risk factor prevalence in a 
population in terms of health benefit. It is based on the epidemiologic 
effect measure the Potential Impact Fraction. To achieve the objectives 
of the project it has incorporated the following three requirements in the 
methodology: 
• the possibility that one risk factor affects several diseases, and that 
one disease is affected by several risk factors, 
• a time dimension to simulate the reduction in excess risk after cessa-
tion of exposure to the risk factor, 
• the interaction between the effect of the intervention and the demo-
graphic evolution in the population. 
The model will simulate the development, over time, of two populations: 
one as a result of trends in risk factor prevalence and demography, and the 
other which incorporates both trends and interventions on risk factors and 
the demography. Differences between these two populations are the effect 
of the intervention. In the current version of Prevent all measures of health 
benefit are based on mortality. 
Results 
Since the results are primarily intended for policy making the choice of 
the disease categories to include in the project was determined by criteria, 
relevant to public health policies: 
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• the disease had to contribute significantly to the ill health of the 
Dutch population, 
• the disease should have known risk factors upon which interventions 
could reasonably be applied. 
The availability of reliable data both on the relationship between risk 
factor and disease incidence and on the prevalence of the risk factor in the 
Dutch population, determined which risk factors and diseases were included 
in the current version of the model. Sensitivity testing on the input data 
and a historical reconstruction of lung cancer mortality in the Netherlands 
were done to provide an indication of the robustness of the model. 
With the Prevent model a number of risk factor interventions were sim-
ulated and the results analyzed. The interventions show that there is a con-
siderable difference in the outcome measured as a proportional mortality 
reduction as with the Potential Impact Fraction and an outcome measure 
in absolute terms such as mortality reduction. Especially for a common 
cause of death such as Ischemic Heart Disease even a small proportional 
reduction may represent a large number of deaths prevented. 
Interventions on the prevalence of smoking in the population illustrate 
both the importance of a multifactorial approach and of the time dimension. 
If only one disease is considered much of the effect of the intervention is 
missed. In order to evaluate the effect of a risk factor intervention the total 
(aggregated) health benefit should be considered. This also includes the 
possible increase in causes of death not related to the risk factor considered, 
as a result of the intervention. 
The timelag between smoking cessation and the ultimate effect on lung 
cancer mortality illustrates the consequences of the introduction of a time 
dimension. Not only does a considerable period elapse before the full effect 
of a reduction in smoking prevalence can be appreciated, but it also means 
that the quite sizable reductions in smoking prevalence in the recent years 
will be noticeable in an initial reduction in lung cancer mortality in the 
near future in both the trend and the intervention population. With the 
introduction of a time dimension changes in risk factor prevalence in the 
past will continue to affect health in the future. 
In the Dutch population which can expect a large increase in the pro-
portion of elderly in the coming years, the absolute number of cases of 
diseases which occur mostly in old age, will increase sharply in the future. 
For some diseases even considerable reductions in risk factor prevalence will 
not be able to counteract this increase. This means that even with a suc-
cessful preventive policy the need for certain curative services will continue 
to increase. If demography is not taken into account reductions in mortal-
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ity rates as a result of a preventive intervention may create the erroneous 
impression that the absolute number of cases will also go down. 
When comparing the effect of different risk factor interventions it is 
important to keep the following items in mind: 
• Not only the total health benefit should be compared but also the 
distribution over sub groups in the population. 
• The simulation time over which interventions are compared should be 
sufficiently long to show the full effect of each intervention. 
• The choice of benefit measure will influence the priority setting. 
Of all the risk factors in the Prevent model, the greatest health benefits are 
to be expected from a reduction in smoking prevalence. Not only a new 
generation of non smokers will greatly improve the populations health, a 
program of smoking cessation will also result in sizable mortality reductions, 
although mostly for men. 
Finally the Prevent model was applied to a number of recent Dutch 
policy documents to show how it can provide useful quantitative informa-
tion for policy making. The alternative smoking scenario's of the Dutch 
Lifestyle Scenario project were simulated with different assumptions of the 
population groups affected by the intervention. It shows that the health 
benefits will greatly differ depending on the group in the population in-
tervened upon. A similar quantification of the hypothetical smoking inter-
vention analyzed in the Dutch Cancer Scenario, illustrates why it is useful 
to look at risk factor interventions in a multifactorial model since the ex-
pected benefits are much higher if other diseases affected are also taken into 
account. 
The alternative risk factor reductions necessary to achieve the targets 
as stated in the Health 2000 Report and the more recent policy document 
on the Prevention of Cardiovascular Disease, were calculated. For Ischemic 
Heart Disease it will be impossible to achieve the target with an interven-
tion on one risk factor only. Even in a multifactorial intervention large 
reductions in risk factor prevalence in the near future, will be necessary if 
the target is to be achieved before the year 2000. 
Prevent shows a positive aspect of the interrelationship of risk factors 
and diseases. Some interventions proposed to achieve one disease specific 
target may automatically achieve another disease target. This is the case 
in all interventions suggested for the reduction in Ischemic Heart Disease: 
the inherent reduction in smoking prevalence ensures that the lung cancer 
target is achieved without additional interventions. This illustrates the 
necessity to apply targets in a comprehensive health policy, and not only 
by disease category. 
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Conclusions 
The results of hypothetical interventions simulated by Prevent show that a 
multifactorial model with a time dimension will yield different estimates of 
the effects of risk factor intervention than the traditional epidemiological 
measures. The use of a dynamic population model makes it easier to visu-
alize the interaction between changes in age specific mortality (as a result 
of changes in risk factor prevalences) and demography. This is especially 
important for policy making since it helps to show that despite a possible 
increase in absolute disease specific mortality, the mortality reduction due 
to a preventive intervention can be quite large. 
Prevent only expresses health benefits in outcome measures based on 
mortality. In the future it would be useful to extend this to morbidity 
measures also. This will only be possible if curative care is not assumed 
static over time. The model should therefore be extended into a public 
health model which not only looks at preventive interventions but also at 
interventions on curative care. It will then be possible to also express effects 
in terms of changes in the utilization of services or even costs. 
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Samenvatting 
Inleiding 
In 1986 werd de Nota 2000 aangeboden aan de Tweede Kamer. De nota be-
vat een lange termijn visie op de ontwikkelingen van gezondheidsbeleid en 
illustreert de verschuivende belangstelling van gezondheidszorgbeleid naar 
gezondheidsbeleid. Deze verschuiving is om twee redenen interessant. Ten 
eerste omdat in gezondheidsbeleid de effectiviteit van een beleidsmaatregel, 
een interventie of een technologie beoordeeld wordt in termen van het ge-
zondheidseffect voor de gehele bevolking en ten tweede omdat met het stel-
len van prioriteiten voor een gezondheidsbeleid, impliciet aanvaard wordt 
dat er keuzes gemaakt zullen moeten worden, ongeacht het uiteindelijk te 
besteden budget voor Volksgezondheid. 
Een van de keuzes die gemaakt zal moeten worden is of er wei of niet 
in preventie moet worden ge!nvesteerd. Primaire preventie maatregelen 
kunnen interventies omvatten op het v66rkomen van risicofactoren in de 
bevolking. Om de kosten en de baten van dergelijke maatregelen tegen el-
kaar te kunnen afwegen, zal een schatting van de effecten op de gezondheid 
van de bevolking van groot belang zijn. Bovendien kunnen er ook autono-
me veranderingen in risicofactor prevalentie optreden die de gezondheids-
toestand van de bevolking zullen be1nvloeden. De daaruit voortvloeiende 
verandering in de vraag naar zorg zal van belang zijn voor het vaststellen 
van het benodigde voorzieningenniveau. Dus zowel voor het beleid ten aan-
zien van preventie als voor het voorzieningenbeleid is het schatten van de 
gezondheidseffecten van verschuivingen in risicofactor prevalentie nuttig. 
Prevent is een simulatie model waarmee dergelijke gezondheidseffecten 
geschat kunnen worden. De resultaten kunnen of rechtstreeks in het beleid 
gebruikt worden, bijv. om doelstellingen te kwantificeren, of om de effec-
ten van verschillende leefwijze scenario's te simuleren, of gebruikt worden 
als effect schatting in meer formele besluitvormingsprocessen zoals kosten 
effectiviteits analyses. 
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Het Prevent model 
In de epidemiologie staat de analyse van de incidentie van ziekten in relatie 
tot de prevalentie van risicofactoren in een bevolking centraal. De mate 
waarin een risicofactor de kans op het krijgen van een ziekte bei:nvloedt, 
wordt meestal uitgedrukt als de verhouding tussen de incidentie bij geex-
poseerden en bij niet-geexposeerden, het relatief risico. Het belang van 
de risicofactor voor de totale incidentie in een bevolking wordt meestal 
uitgedrukt als het attributieve risico, dat deel van de totale incidentie dat 
toegeschreven kan worden aan het voorkomen van de risicofactor in de 
bevolking. Dit attributieve risico wordt soms ook gebruikt om aan te geven 
welk deel van de incidentie voorkomen zou kunnen worden wanneer de 
risicofactor in de bevolking geheel geelimineerd werd. 
Over het algemeen is een preventieve maatregel niet in staat om een 
risicofactor geheel uit te schakelen. Om het effect op de incidentie te schat-
ten van een vermindering in het voorkomen van een risicofactor, werd de 
Potential Impact Fraction gei:ntroduceerd. Deze PIF geeft de proportio-
nele reductie in de toekomstige incidentie aan, die het gevolg is van een 
vermindering in de prevalentie van de risicofactor. 
Prevent schat de gezondheidseffecten van een verandering in de preva-
lentie van een risicofactor gebaseerd op de Potential Impact Fraction, maar 
heeft daar de volgende elementen aan toegevoegd: 
• de mogelijkheid dat een risicofactor meer dan een ziekte bei:nvloedt 
en dat de incidentie van een ziekte door meerdere risicofactoren wordt 
bepaald, 
• een tijdsdimensie waarmee de geleidelijke afname in relatief risico 
wordt gesimuleerd die optreedt na het beeindigen van expositie aan 
een risicofactor, 
• de interactie tussen de proportionele verandering in incidentie en de 
absolute sterfte en de demografie. 
Het model simuleert de ontwikkeling in de loop der jaren van twee popu-
laties: de referentie bevolking onder invloed van trends in risicofactor pre-
valentie en demografie, en de interventie populatie waarbij rekening wordt 
gehouden met zowel trends in, als de effecten van interventies op de preva-
lentie van risicofactoren en de demografie. Het verschil tussen deze beide 
populaties is het effect van de interventie. In de huidige versie van het 
Prevent model worden alle effectmaten op sterfte gebaseerd. 
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Resultaten 
Aangezien de resultaten van het model in eerste instantie voor beleidsdoel-
einden bedoeld zijn, is de keuze van de ziektecategorieen die in het model 
zijn opgenomen gebaseerd op de volgende overwegingen: 
• de mate waarin de ziektecategorie bijdraagt tot de algemene sterfte 
in de N ederlands bevolking, 
• de mate waarin risicofactoren voor de ziekte bekend zijn, waarop re-
delijkerwijs zou kunnen worden geintervenieerd. 
De beschikbaarheid van betrouwbare gegevens zowel voor de relatieve 
risico's als voor de prevalentie van de risicofactor in de Nederlandse bevol-
king bepaalde uiteindelijk welke risicofactoren en welke ziektecategorieen in 
de huidige versie van het model werden opgenomen. Het model werd ver-
volgens getoetst op het effect van de keuze van de invoer variabelen op de 
resultaten via gevoeligheidsanalyses. Er werd ook een historische toetsing 
uitgevoerd door de ontwikkeling van de sterfte aan longkanker in Nederland 
tussen 1970 en 1985 te schatten op grond van het aantal rokers. 
Met het Prevent model worden vervolgens een aantal hypothetische in-
terventies gesimuleerd waarvan de resultaten worden besproken. Zoals te 
verwachten verschilt de beoordeling van interventies soms aanzienlijk wan-
neer het proportionele effect, zoals de PIF, of het absolute effect, zoals 
bijv. het sterfteverschil, wordt vergeleken. Voor belangrijke doodsoorzaken 
zoals ischemische hartziekten, kan zelfs een kleine procentuele afname een 
belangrijke sterftereductiein absolute aantallen betekenen. 
Het effect van een vermindering van het aantal rokers in de bevolking 
illustreert zowel het belang van een multifactorieel model als van de tijdsdi-
mensie. Wanneer slechts naar de gezondheidswinst in termen van een ziekte 
gekeken wordt, wordt het potentiele effect sterk onderschat. Om het totale 
effect van een interventie te kunnen beoordelen client het verschil in sterfte 
geaggregeerd over aile ziektecategorieen beschouwd te worden inclusief die 
doodsoorzaken die ten gevolge van de verschuiving in ziekteincidentie zullen 
toenemen. 
De tijd die verstrijkt tussen het stoppen met roken en de uiteindelijke 
daling in risico op bijv. longkanker, illustreert de consequenties van het 
invoeren van een tijdsdimensie. Niet aileen zullen de uiteindelijk effecten 
van een interventie pas na vele jaren merkbaar zijn, maar bovendien zal de 
niet onaanzienlijke daling in het aantal rokers van de afgelopen tien jaar 
in de eerstkomende jaren, ongeacht het te voeren beleid, nog aanleiding 
zijn tot een daling in leeftijdspecifieke longkankersterfte bij mannen. Bij 
vrouwen zal eerst nog merkbaar zijn dat er een aantal geboortecohorten 
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aankomen die in tegenstelling tot de oudere cohorten, wel degelijk in het 
verleden veel gerookt bebben. Met bet invoeren van een tijdsdimensie wordt 
zichtbaar gemaakt hoe verscbuivingen in risicofactor prevalentie uit het 
verleden ook in de toekomst nog de gezondbeidstoestand van de bevolking 
blijven bepalen. 
In Nederland zal in de komende jaren bet percentage ouderen maar 
vooral ook het absolute aantal ouderen in de bevolking nog sterk blijven 
toenemen. Omdat de gezondheidsproblemen in onze bevolking vooral op 
oudere leeftijd optreden, zal bet absolute aantal gevallen (en ook sterfge-
vallen) voor de belangrijkste doodsoorzaken in de komende jaren scherp 
toenemen. Voor een aantal doodsoorzaken zullen zelfs heel drastische ver-
minderingen in de prevalentie van risicofactoren niet in staat zijn om die 
stijging te niet te doen. Dit beeft tot gevolg dat zelfs met een zeer suc-
cesvol preventie beleid, de behoefte aan sommige gezondheidszorg voor-
zieningen zal blijven toenemen. Dit betekent niet dat bet preventiebeleid 
niets uitricht, want zonder die preventie maatregelen zou de beboefte aan 
voorzieningen nog veel sterker toenemen. 
Het gebruik van de resultaten 
Wanneer de effecten van verschillende interventies met elkaar vergeleken 
worden moeten de volgende aspecten daarin meegenomen worden: 
• niet aileen de tot ale gezondheidswinst voor de bevolking moet vergele-
ken worden maar ook de verdeling over groepen binnen die populatie, 
• de tijdspanne waarop interventies met elkaar worden vergeleken moet 
lang genoeg zijn om voor aile risicofactoren het maximale effect te 
bereiken, 
• de keuze van de uitkomstmaat waarop vergeleken wordt zal mede de 
prioriteitensteiling bei:nvloeden. 
Van aile risicofactoren die in Prevent zijn opgenomen, is de grootste ge-
zondheidswinst te verwachten van een interventie op bet roken. Een nieu-
we generatie niet rokers zal de gezondbeidstoestand van de bevolking sterk 
verbeteren. Maar een beleid gericht op bet doen stoppen met roken zal op 
een veel kortere termijn, een aanzienlijke sterftereductie opleveren. 
Tot slot werd Prevent gebruikt om een aantal recente beleidsdocumenten 
te kwantificeren. De alternatieve rookscenario's zoals zij door de Scenario 
Commissie Leefwijzen werden gepubliceerd, en de hypothetische interventie 
op roken die werd voorgesteld door de Scenario Commissie Kanker werden 
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gekwantificeerd. Deze simulaties Iaten zien dat de geschatte gezondheids-
winst van dergelijke interventies sterk afuangt van de subgroepen in de 
populatie op wie de interventie betrekking heeft en dat het te verwachten 
effect toeneemt wanneer in een multifactorieel model de belangrijkste door 
roken be'invloedde ziektecategorieen worden meeberekend. 
De alternatieve risicofactor interventies die in staat zouden zijn om de 
Targets uit de Nota 2000 of de Beleidsnota Preventie Hart en Vaatziekten 
te bereiken geven aan dat het onmogelijk zal zijn om de beoogde reduc-
tie in sterfte ten gevolge van ischemische hartziekten te bereiken wanneer 
slechts op een risicofactor wordt ge'intervenieerd. Maatregelen zullen ge-
richt moeten zijn op het tegelijkertijd terugdringen van de prevalentie van 
de verschillende risicofactoren. 
Een multifactorieel model van risicofactoren en ziekten laat ook zien dat 
sommige interventies bedoeld om een van de ziektetargets te bewerkstelli-
gen, soms automatisch ook een target voor een andere ziekte bereiken. Dit 
is bijvoorbeeld het geval voor de interventies die worden voorgesteld om het 
target voor de ischemische hartziekte te bereiken die, vanwege de interventie 
op roken, automatisch ook de gewenste daling in longkankersterfte teweeg 
brengen. Dit illustreert het belang van een algeheel gezondheidsbeleid en 
niet aileen een ziektegerichte aanpak. 
Conclusies 
De resultaten van de simulaties die met Prevent zijn uitgevoerd tonen aan 
dat effectschattingen van veranderingen in risicofactor prevalentie, aanzien-
lijk anders zijn wanneer een multifactorieel model met een tijdsdimensie 
gebruikt wordt. Het gebruik van een dynamisch populatie model waarmee 
ook absolute verschuivingen in de gezondheidstoestand van de bevolking 
kunnen worden gesimuleerd, maakt het gemakkelijker om de interacties 
tussen veranderingen in leeftijdspecifieke sterfte (als gevolg van een daling 
in risicofactor prevalentie) en de demografie zichtbaar te maken. Dit is 
vooral van belang voor het beleid omdat het laat zien hoe groot de gezond-
heidswinst van een preventieve maatregel kan zijn zelfs wanneer de absolute 
sterfte toeneemt vergeleken met het huidige niveau. 
Prevent berekent uitsluitend gezondheidswinst gebaseerd op sterfte. In 
de toekomst zou een dergelijk model moeten worden uitgebouwd om ook 
morbiditeits maten te bevatten. Daarvoor moet echter de invloed van de 
curatieve zorg ook gemodelleerd worden. Een dergelijk volksgezondheids 
model zou het dan ook mogelijk maken om effecten uit te drukken in termen 
van het gebruik van voorzieningen en zelfs kosten. 
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Dankwoord 
Bij het maken van een proefschrift, ben je je meer dan met andere werk-
stukken, bewust van hen die je geholpen hebben. Het is dan ook een goede 
gewoonte om hen schriftelijk te bedanken. Toen ik naging welke mensen 
in ieder geval in zo'n dankwoord genoemd zouden moeten worden, viel mij 
op dat zij die mij gesteund hebben in deze periode in twee groepen uiteen 
vallen, twee groepen die denk ik beide onontbeerlijk zijn geweest. Allereerst 
zou ik hen willen danken die mij daadwerkelijk geholpen hebben. Als eerste 
wil ik daarbij Jan Barendregt noemen zonder wie Prevent niets meer dan 
een hersenspinsel zou zijn gebleven. Hij heeft wonderen van programmeer-
werk verricht om het model op een micro computer te houden. Hoewel hij 
bij elk nieuw verzinsel mijnerzijds begon met bedenkelijk te kijken vanwe-
ge de nog beschikbare geheugen ruimte, bleek na enige dagen toch telkens 
weer een nieuwe, voor mij geheel onbegrijpelijk true om de computer te 
misleiden, het plan mogelijk te maken. Ook de introductie en het gebruik 
van :U.TEJX zou zonder J ans enthousiasme nooit mogelijk geweest zijn. 
Zonder de inhoudelijke bijdragen van andere collegae van het Instituut 
Maatschappelijke Gezondheidszorg zou het schrijven van dit proefschrift 
heel wat moelijker geweest zijn. Met name wil ik hier aileen Johan Mac-
kenbach, Dik Habbema, Caspar Looman en Ed van Beeck noemen. Een 
bijzondere plaats neemt Gerrit van Oortmarssen in die veel van zijn heel 
kostbare tijd in het lezen en becommentarieren van eerdere versies van de 
tekst heeft gestoken. 
Ook andere medewerkers van het instituut hebben mij veel werk uit han-
den genomen o.a.: Arry de Bruyn met het documentatiemateriaal, Theresa 
v.d Starre-Bout voor het invoeren van de literatuur en Atie Vogelenzang de 
Jong voor alle secretariaatswerkzaamheden. 
De leden van de promotie commissie Prof. Dr. F. Surmans, Prof. Dr. 
F.H. Rutten en Prof. Dr. A. Hofman wil ik het bijzonder danken voor 
het feit dat ze ondanks de vakantieperiode zo snel en zo enthousiast in hun 
commentaar waren. 
Maar hulp voor een proefschrift komt niet aileen van collegae, ook thuis 
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moet zo nu en dan echt geholpen worden. Voor die hulp ben ik Adrie Coljee 
en Liesbeth Pleyster veel dank verschuldigd. 
De andere groep mensen die bij een promotieonderzoek belangrijk is, 
zijn zij die je de ruimte geven. In de eerste plaats wil ik op deze manier 
Prof. D. Deliege bedanken die mij indertijd, ondanks de afwezigheid van 
financiele middelen, de ruimte gaf om aan de UCL in Brussel ruimschoots 
onderzoekservaring op te doen. Zonder een dergelijke startruimte was dit 
onderzoek er nooit gekomen. Ik wil het Stafbureau Beleidsontwikkeling 
van het Ministerie van WVC bedanken voor de financiele ruimte die ze 
voor dit onderzoek geschapen hebben, en het Instituut Maatschappelijke 
Gezondheidszorg omdat ze mij de ruimte gegeven hebben om me uitsluitend 
met dit onderzoek bezig te houden. 
Paul van der Maas neemt in deze rij een bijzondere plaats in, niet aileen 
omdat hij mijn promotor is, maar vooral omdat zijn steun in de afgelopen 
jaren in beide categorieen viel. Allereerst wil ik hem bedanken omdat hij 
. me de ruimte heeft gegeven om eigenwijs mijn eigen gang te gaan, maar 
daarnaast ook omdat hij me desondanks door de opzet van de voortgangs-
besprekingen ook vele malen daadwerkelijk geholpen heeft. 




